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Obesity is an independent risk factor for several cardiac pathologies. Sustained 
exposure to nutrient overload in obesity overwhelms cellular homeostatic apparatus, 
leading to metabolic disorders and organelle dysfunction. The integrity of homeostatic 
machinery is crucial for the heart to meet its energy need and for cardiomyocytes to 
survive. Recently, autophagy has emerged as a major catabolic process in maintaining 
energy and organelle homeostasis. 
Growing evidence suggest a role for autophagy in obesity related cardiac 
pathologies. Yet, the regulation of cardiac autophagy in obesity is unclear. In this study, 
we explored mechanisms regulating cardiac autophagy in an invivo mouse model of diet-
induced obesity and an invitro cell culture model of lipid overload. 12 weeks of high-fat 
diet (HFD) (45% kcal fat) significantly increased the autophagy marker protein LC3-II 
and autophagosome number in the murine heart independently of canonical upstream 
signaling through mTORC1 and AMPK. Interestingly, high-fat fed mice displayed a 
defective autophagosome turnover that may have led to autophagosome accumulation. 
Alteration in Beclin1 expression had no effect on HFD-induced autophagy, ruling out a 
major contribution of autophagy initiation pathways in this process. In vitro, cultured 
H9C2 cardiomyocytes displayed a biphasic autophagic response to palmitate. To explore 
the mechanism of early autophagic response to lipid overload, we performed    
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most experiments after 4 h of treatment when features of ER stress and cell death were 
absent. Similar to HFD, palmitate increased autophagosome accumulation primarily via 
an impairment in autophagosome turnover. Oleate alone had no effect on autophagy but 
cotreatment normalized the palmitate-induced autophagosome accumulation. Moreover, 
palmitate treatment led to a massive accumulation of superoxide which correlated with 
impaired lysosomal acidification and pH-dependent lysosomal enzyme activity. Using 
specific inhibitors and siRNA mediated gene silencing, we identified Nox2 as the major 
source of superoxide production. The activation of Nox2 was dependent on the palmitate-
induced activation of classical PKCs. Together, our study has identified a novel 
mechanism wherein palmitate-induced activation of PKC-Nox2 pathway led to impaired 
lysosomal enzyme activity and diminished autophagic turnover in cardiomyocytes. The 
Nox2-mediated inhibition of autophagic flux might contribute to other known 
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1.1. Obesity: a major health risk factor 
Obesity is a complex metabolic condition that contributes to the development of type 
2 diabetes (T2DM), high blood pressure, cardiovascular disease (CVD), and heart failure. 
It is an independent risk factor for hypertension, dyslipidemia, osteoarthritis, sleep apnea, 
hypoxia, ischemic heart injury, and certain types of cancers (Kenchaiah et al., 2002; 
Wellman and Friedberg, 2002; Wilson et al., 2002). Environmental factors such as 
excessive caloric intake and sedentary lifestyles significantly contribute to obesity 
epidemic. In addition, the obesity is also influenced by social, economic, behavioral, 
cultural, and genetic factors (1998).  
The prevalence of obesity has dramatically increased in the United States and around 
the world over the past 30 years. Between 2009-2010, estimates indicate that in the US 
alone, about 35.7% of adults and 17% of children are obese, with a body mass index 
(BMI)  30 kg/m2 (Ogden et al., 2012). The rate of obesity tightly correlates with an 
increased incidence of T2DM and heart diseases nationwide. Moreover, obesity related 
diseases are among the leading causes of deaths in the US: heart disease (ranked 1) and 
diabetes (ranked 7) (Murphy et al., 2012). The medical costs associated with obesity were 
estimated $147 billion for 2008 (Finkelstein et al., 2009) and is expected to rise to 
approximately $860-$960 billion by 2030 (Wang et al., 2008). 
 The obesity is not limited to developed countries. Underdeveloped countries with 
limited food supply and consumption have increasing reports of obesity. Despite rising 
awareness and expanding medical research, obesity remains an incompletely understood 
metabolic condition due to its complex etiologies. 
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1.2. Energy substrate metabolism in the heart 
The heart is an metabolically active organ with a continuous need for energy to 
maintain its contractile function, basal metabolic processes, and ionic homeostasis 
(Lopaschuk et al., 2010). It shows remarkable metabolic flexibility and utilizes a variety 
of carbon substrates such as fatty acids, glucose, lactate, puruvate and amino acids based 
on their availability to generate adenosine-5'-triphosphate (ATP) and meet its energy 
demand even during periods of fasting and intense exercise (Abel et al., 2012; Gertz et 
al., 1988; Wisneski et al., 1990). Under basal conditions, the majority of ATP in the heart 
comes from mitochondrial oxidative phosphorylation (OXPHOS). The ATP production 
through OXPHOS is driven by high energy electrons generated from nicotinamide 
adenine dinucleotide reduced (NADH) and flavin adenine dinucleotide reduced (FADH2) 
produced in the glycolysis, the tricaboxylic acid (TCA) cycle, and -oxidation of fatty 
acids (Stanley et al., 2005).   
Metabolism of glucose via glycolysis and glucose oxidation accounts for about 20% 
of the myocardial energy content (Abel et al., 2012). Glucose uptake into the cardiac 
myocytes is facilitated by glucose transporters, primarily GLUT-4, which is translocated 
to the plasma membrane upon stimulation by insulin or AMP-activated protein kinase 
(AMPK) or by cardiac contractility (Abel et al., 2012; Stanley et al., 2005). Additionally, 
glucose is derived from glycogen stores during starvation and intense exercise. As an 
energy substrate, glucose is converted to pyruvate by glycolysis. Pyruvate is either 
reversibly converted to lactate in the cytosol or transported into the mitochondrial matrix 
and decarboxylated to acetyl-CoA by the pyruvate dehydrogenase (PDH) complex. 
Acetyl-CoA finally enters the TCA cycle and is broken down to CO2 and H2O to generate 
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ATP to complete the process of glucose oxidation (An and Rodrigues, 2006). The control 
of glucose metabolism in the heart is complex and occurs at various levels from the entry 
of glucose through glucose transporters to glycolysis and glucose oxidation. The key 
modes of regulation involve changes in hormonal action, nutritional status, transcriptional 
control, allosteric regulation, and posttranslation modification of pathway specific 
enzymes (Lopaschuk and Kelly, 2008). Although glucose is not the major energy 
substrate in the normal adult heart, the reliance on glycolysis and glucose utilization 
significantly increases during myocardial ischemia, hyperglycemia, and heart failure 
(Abel et al., 2012; Lopaschuk and Kelly, 2008; Stanley et al., 2005).   
Fatty acid -oxidation accounts for majority of ATP production (70%) in the 
normal adult heart. Free fatty acids (FFAs) enter the myocardium by either passive 
diffusion or via membrane-bound transporters such as fatty acid translocase 
(FAT)/CD36, plasma membrane fatty acid binding protein (FABPpm), and fatty acid 
transporter protein (FATP) (Lopaschuk et al., 2010).  FFAs are esterified to fatty acyl-
CoAs which are either converted to triglycerides (TGs) or transported to mitochondria to 
generate energy. Mitochondrial transport of fatty acyl-CoA is facilitated by carnitine 
palmitoyl transferase 1 (CPT1), a rate limiting enzyme in fatty acid oxidation (FAO), and 
CPT2. The -oxidation generates acetyl-CoA, which enters the TCA cycle to generate 
NADH and FADH2 and fuel OXPHOS to produce ATP (Abel et al., 2012). The rate of 
FA metabolism in the heart is controlled by the availability and uptake of fatty acids into 
cardiomyocytes (CMs), allosteric regulation of enzymes and transporters, and 
transcriptional control of FAO enzymes. Insulin has also been shown to regulate fatty 
acid uptake by facilitating membrane translocation of CD36 translocase (Luiken et al., 
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2002). Another key regulator of -oxidation at the level of mitochondria is malonyl-CoA. 
It is a potent inhibitor of CPT1 and limits the uptake of fatty acyl-CoA into the 
mitochondria, resulting in reduced mitochondrial FAO (Kerner and Hoppel, 2000). 
Malonyl-CoA has a very high turnover rate and its level is tightly regulated in the heart 
by the action of three enzymes: AMPK, acetyl-CoA carboxylase, and malonyl-CoA 
decarboxylase (Stanley et al., 2005).  
Glucose oxidation and FAO are interregulated in the myocardium by a process called 
“glucose-fatty acid cycle” or “The Randle cycle” (Randle et al., 1963). High rates of 
FAO increase  mitochondrial acetyl-CoA/free-CoA and NADH/NAD+ ratios which 
activate PDH kinase resulting in the inhibition of PDH activity and subsequent reduction 
in glucose oxidation (Hue and Taegtmeyer, 2009). Alternatively, an inhibtion of the FAO 
rates leads to an increase in glucose uptake and oxidation by (i) decreasing cytosolic 
citrate levels and releasing inhibition of phosphofructokinase 1 (PFK-1), a rate limiting 
enzyme of the glycolytic pathway,  and (ii) lowering acetyl-CoA and NADH levels in 
mitochondria and hence relieving inhibition on PDH activity . Such interregulation of 
FAO and glucose oxidation allows the myocardium to control fuel selection and  
appropriately adapt to changes in substrate availability and demand in the CMs in 
coordination with hormonal control of circulating myocardial substrates (Hue and 
Taegtmeyer, 2009; Stanley et al., 2005). 
 
 
1.3. Energy metabolism of the heart in obesity 
Obesity is the major cause of insulin resistance. Lack of insulin action in adipocytes 
promotes lipolysis and increases circulating FFA levels. Elevated plasma FFA drive 
  
6 
excessive FFA uptake into the myocardium, causing an imbalance between FFA uptake 
and oxidation and resulting in the accumulation of toxic lipid intermediates such as long-
chain acyl-CoA, diacylglycerol and ceramides. These lipid intermediates may lead to 
impairments in insulin-stimulated GLUT4 translocation, glucose uptake, glucose 
oxidation, and insulin signaling in the heart (Abel et al., 2012; Boden, 2011). Studies 
from our lab have shown that the metabolic switch to fatty acids as a preferred energy 
substrate at the expense of glucose occurs early in the course of high-fat feeding (HFF) 
(Wright et al., 2009). 2 weeks of HFF in mice increased FAO but reduced basal rates of 
glycolysis and glucose oxidation in hearts and blunted insulin-stimulated glucose uptake 
in CMs. GLUT4 protein levels and translocation were significantly reduced, but insulin 
signaling through protein kinase B (PKB or AKT) was preserved. AKT activation has 
been shown to facilitate the translocation of CD36 to the plasma membrane (Glatz et al., 
2010), which could further increase myocardial fatty acid uptake and the subsequent 
accumulation of toxic lipid intermediates.  The ectopic lipid deposition in the heart, 
termed “cardiac lipotoxicity,” is the hallmark of obesity and diabetes. Cardiac 
lipotoxicity contributes to insulin resistance, impairment of mitochondrial function, CM 
hypertrophy, and apoptosis, which may ultimately lead to left-ventricular remodeling of 
the heart, dilated cardiomyopathy and other obesity-related cardiac pathologies (Avelar et 








1.4. Quality control mechanisms in the heart 
The continuous pumping of the heart places enormous demands on its energetic 
need. The proper functioning of the heart requires that both contractile components and 
energy metabolic pathways work efficiently. CMs maintain homeostasis through adaptive 
mechanisms regulating contractile function, energy metabolism, cell viability and cell 
size. Nevertheless, being postmitotic cells with little regenerative capacity, CMs sustain 
various cellular and subcellular insults as a consequence of the rigorous cardiac 
contractility and various other mechanical, metabolic, and thermal  stresses over the life 
span of a human being (Willis et al., 2009). To overcome such damage and maintain 
heart function, CMs possess three major intracellular quality control mechanisms that 
repair or remove dysfunctional proteins/organelles and replace them with functional ones: 
(1) chaperone mediated refolding of misfolded proteins; (2) the ubiquitin proteasomal 
system (UPS) for the degradation of short-lived proteins; and (3) autophagy for the 
recycling of cytoplasmic materials including long-lived proteins, complex lipids, 
carbohydrates, and damaged organelles via a lysosomal pathway (Figure 1.1) (Wang and 
Terpstra, 2012; Willis et al., 2009).   
The protein synthesis and degradation in the heart are under constant surveillance, 
which ensures that a synthesized nascent protein is properly folded and functional. 
Despite an extensive protein folding machinery in the endoplasmic reticulum (ER) and 
other subcellular compartments, protein misfolding is inevitable. This protein misfolding 
is further elevated under various cellular stress. The initial attempt to deal with misfolded 
proteins is their refolding to native form: a function performed by a diverse family of 







Figure 1.1. Intracellular protein quality control mechanisms in CMs. Molecular 
chaperones assist proteins to fold into their native form. During various cellular stresses, 
protein misfolding is upregulated. Misfolded proteins are either degraded by the ubiquitin 
proteasomal system (UPS) or chaperone mediated autophagy (CMA).  Bulk protein 






coordinate a refolding event depending on subcellular localization and misfolding 
conditions of the protein (Patterson, 2006). The synthesis and assembly of the basic 
sarcomeric proteins such as actin and myosin depends heavily on chaperones to avoid 
misassembly and aggregation. Chaperones are abundant in CMs and are upregulated 
during a cardiac stress (Birnie et al., 2005; Pantos et al., 2006). Desmin-related 
cardiomyopathies, for example, are the consequence of loss-of-function mutations in 
either the molecular chaperone B-crystallin or in desmin resulting in disorganized 
sarcomere and disintegrated myofibrils (Bova et al., 1999; Dalakas et al., 2000; Wang et 
al., 2001).   
At times, the molecular chaperones are inefficient resulting in terminally misfolded 
proteins that can be cytotoxic. Removal of such proteins occurs via selective and non-
selective pathways. The selective pathway is called the ubiquitin-proteasomal system 
(UPS). The degradation of intracellular proteins via UPS involved two key steps: (1) 
ubiquitination, where proteins targeted for degradation are covalently tagged at lysine 
residues with small proteins called ubiquitin (Ub) in an ATP-dependent reaction 
involving E1, E2, and E3 ligases, and (2) the degradation, in which polyubiquitinated 
proteins are delivered to and degraded by the 26S proteasome in a highly regulatory 
process (Zolk et al., 2006). Posttranslational modifications (PTMs), such as acetylation, 
phosphorylation, and sumoylation, also influence ubiquitination and degradation of target 
proteins (Manente et al., 2011). The ubiquitinated proteins are recognized by proteasomes 
either directly or via specific ubiquitin receptors (Lee and Brown, 2012; Sowa et al., 
2009). Normally, proteins targeted for proteasomal degradation are tagged with at least 
four lysine 48 (K-48) or lysine 11 (K-11) linked ubiquitin chains (Clague and Urbe, 
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2010). Monoubiquitination and lysine 63 (K-63) linked polyubiquitination of proteins are 
involved in nonproteolytic signaling pathways (Chen and Sun, 2009). A number of 
muscle specific ubiquitin ligases are involved in UPS-mediated degradation of 
sacromeric proteins and thus play an important role in structural and functional integrity 
of the sarcomere (Bodine et al., 2001; Zhang et al., 2005).        
Under severe cellular stress and cardiac pathologies, both chaperones and the UPS 
are overwhelmed by significant accumulation of misfolded proteins. Under such 
conditions, misfolded proteins are either selectively degraded in the lysosomal lumen via 
chaperone mediated  autophagy or form large aggregates, which eventually leads to the 
formation of specialized structures called aggresomes at the microtubule organizing 
center (Garcia-Mata et al., 2002). Aggresome formation is thought to be a protective 
mechanism to sequester potentially toxic proteins into confined cytoplasmic 
compartments (Wang and Terpstra, 2012). However, accumulation of aggregosomes 
induces nonselective degradation of its content via macroautophagy (Garcia-Mata et al., 
2002). Detailed mechanism of mammalian autophagy is described in section 1.5. 
 
 
1.5. Autophagy: a key regulator of cardiac cellular homeostasis 
Autophagy (Greek; auto=self, phagy= to eat) is an evolutionarily conserved process 
of cellular self-digestion. It is a catabolic process whereby long-lived proteins, damaged 
organelles, intracellular pathogens, and other cytoplasmic materials are degraded in the 
lysosomes. Depending on the mode of substrate delivery to lysosomes, autophagy is 
broadly classified into three different forms: microautophagy, chaperone mediated 






Figure 1.2. Different forms of mammalian autophagy. Three different types of autophagy 
are identified in mammalian cells based on the method of substrate delivery to lysosomes. 
In macroautophagy, cytoplasmic constituents are sequestered by a double membrane 
vesicle, the autophagosome, and delivered to the lysosome by heterotypic fusion. In 
CMA, misfolded/unfolded proteins containing KEFRQ consensus motif are selectively 
recognized by molecular chaperone Hsc70 and cochaperones and targeted to the 
lysosome via interaction with the lysosomal membrane protein Lamp-2A. In 
microautophagy, substrates targeted for degradation are trapped and internalized into a 
single membrane vesicle by direct invagination of the lysosomal membrane. The vesicle 
then pinches off into the lysosomal lumen to deliver the substrates. See text for details.  






Autophagy is maintained at a low level under physiological conditions to clear proteins 
and organelles damaged by general wear and tear. However, it is significantly induced in 
response to a stress such as nutrient starvation, hypoxia, ischemia and reperfusion (I/R), 
mitochondrial dysfunction, ER stress, oxidative stress, and various infections (Bellot et 
al., 2009; Deretic, 2006; Elmore et al., 2001; Lee et al., 2012; Lum et al., 2005; Matsui et 
al., 2007). Autophagy is also regulated at the transcriptional and epigenetic levels (He 
and Klionsky, 2009). Autophagy is primarily considered as a prosurvival process 
providing nutrients to cells under starvation through the degradation of proteins 
dispensable for basic cellular function. It also protects cells by removing toxic proteins 
aggregates, damaged organelles, and invading pathogens via lysosomal degradation. 
However, uncontrolled autophagy can be detrimental and may promote cell death by 
excessive degradation of essential proteins and cellular organelles that are essential for 
survival (Bursch, 2004).  
 
 
1.5.1. Mechanisms of mammalian autophagy 
The activation of a particular form of autophagy depends on the nature of stimulus or 
stressor and types of substrates to be degraded. Of three different forms of autophagy, 
microautophagy is the least studied in mammals. In yeasts, both nonselective (NSM) and 
selective (SM) forms of microautophagy exist. In NSM, cytosolic constituents, mainly 
proteins, cause tubular invaginations of the lysosomal membrane from which small 
vesicles engulfing the target proteins are pinched off into the lysosomal lumen and 
degraded by lysosomal proteases and hydrolases (Mijaljica et al., 2011). In SM, specific 
organelles such mitochondria, peroxisomes, and part of the nucleus are targeted for 
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lysosomal degradation (Farre and Subramani, 2004; Kissova et al., 2007; Roberts et al., 
2003). Interestingly, no direct evidence of microautophagy under physiological 
conditions is reported to date (Mijaljica et al., 2011).   
CMA is the major form of selective autophagy for long-lived proteins in mammalian 
cells. In CMA, proteins containing a KFERQ or KFERQ-like pentapeptide motif are 
recognized by the cytosolic chaperone heat shock cognate 70 (Hsc70) and cochaperones. 
The substrate-chaperone complex interacts with lysosome-associated membrane protein 
2A (Lamp-2A), which results in unfolding and translocation of the substrate into the 
lysosome for degradation (Majeski and Dice, 2004). About 30% of cytosolic proteins 
contain a KFERQ-like sequence that remains buried in the native protein fold. Upon 
misfolding of proteins, the pentapeptide sequence becomes exposed and is recognized by 
Hsc70, which ultimately targets misfolded proteins to CMA (Kiffin et al., 2004). 
Impairment of CMA leads to accumulation of oxidized proteins and protein aggregates 
making cells easily vulnerable to a variety of stress. Interestingly, CMA is upregulated in 
cells with impaired macroautophagy, probably as a prosurvival pathway to get rid of 
toxic cytoplasmic proteins (Kaushik et al., 2008; Massey et al., 2006). 
Macroautophagy (hereafter referred to as autophagy) is the most extensively studied 
form of autophagy in mammalian systems. The entire process of autophagy involves five 
distinct steps: initiation, expansion, vesicle maturation, fusion, and cargo degradation.  
The initiation step starts with the formation of a small membranous structure called the 
isolation membrane or phagophore. The precise origin of phagophore formation in 
mammalian cells is still unclear and may originate from the ER, mitochondria, the Golgi 
or the plasma membrane depending on the nature and degree of autophagic induction 
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(Mari et al., 2011). The phagophore expands with the acquisition of extra lipids to 
enclose the intracellular material targeted for degradation. Subsequent maturation of the 
phagophore resulted into a double-membrane vesicle called autophagosome. Mature 
autophagosomes were suggested to fuse first with late endosomes to form amphisomes 
and then with lysosomes to form autophagolysosomes or autolysosomes. Finally, the 
inner autophgosomal membrane and enclosed cargo are degraded by the lysosomal 
proteases and hydrolases into simple metabolites that are transported back into the 
cytosol to fuel essential cellular function (He and Klionsky, 2009; Mari et al., 2011).  
Autophagy is tightly regulated at every step of the process to ensure that cellular 
homeostasis is maintained during its evolution.  Autophagosome formation alone requires 
18 different core autophagy (Atg) proteins in addition to an increasing number of 
upstream signaling molecules that fine tune autophagy in response to various stimuli 
(Weidberg et al., 2011) . In a prototypic case, mammalian target of rapamycin complex 1 
(mTORC1) acts as a master regulator of autophagy (Figure 1.3). Under normal 
conditions, growth factor signaling activates mTORC1. Activated mTORC1 directly 
interacts with the Ulk1/2-Atg13-FIP200 complex and inhibits Ulk1/2 kinase activity and 
autophagy by phosphorylating Ulk1/2 and Atg13. Inactivation of mTORC1 such as 
during nutrient deprivation dissociates it from the Ulk1/2-Atg13 complex, resulting in the 
dephosphorylation and activation of Ulk1/2. This leads to phosphorylation of Atg13, FIP-
200, and Ulk1/2, and induction of autophagy. An active Ulk1/2-Atg13-FIP200 complex 
provides the initial signal for autophagy induction (Chan, 2009). Initiation of autophagy 















Figure 1.3. Molecular mechanism of mammalian autophagy. Multiple signaling 
molecules coordinate different steps in autophagy:  initiation, expansion, vesicle 
maturation, fusion, and cargo degradation. An inducer such as starvation relieves 
inhibitory phosphorylation of mTORC1 on the Ulk1/2 complex to initiate autophagy 
(step 1). The activated Ulk1/2 complex in turn activates Beclin1-Vps34 (PI3KC3) 
complex either through Ambra1 or other factors. The kinase activity of Vps34 is 
regulated by Beclin1, which in turn is controlled by an inhibitory interaction with Bcl-2. 
The catalytic activity of Vps34 results in the formation of PI3P: a key lipid molecule 
involved in interaction with various factors that supply membrane and protein 
components to the growing isolation membrane (phagophore) of unknown origin (step 2). 
In addition to these initiating regulatory complexes, autophagosome expansion and 
maturation requires two ubiquitin-like conjugation systems: Atg5-Atg12 and LC3 
(mammalian Atg8) (step 3). The LC3 (Atg8) conjugation is also required for the selection 
of autophagic cargo (substrate), determining autophagosome size and membrane 
curvature, and, in association with microtubule proteins, for the bidirectional movement 
of autophagosomes towards lysosomes for fusion. Mature autophagosomes either fuse 
with late endosomes to form amphisomes or with lysosomes to form autolysosomes (step 
4). The autophagic cargo is degraded in autolysosomes by lysosomal proteases and 
hydrolases into simple substrates which are effluxed back into the cytosol to be utilized 
for energy production and biomolecule synthesis that are vital for cellular homeostasis 













Recently, mTOR independent pathways of autophagy induction have also been 
documented in mammalian system (Sarkar et al., 2009; Williams et al., 2008). 
Uponautophagic stimulation, a Beclin1-class III phosphatidylinositol 3-kinase (PI3KC3 
or Vps34) complex consisting of Beclin1, Vps34, Vps15, Atg14L (Barkor), and Ambra1, 
is formed at the phagophore by an unclear mechanism. Beclin1 plays a crucial role in 
Vps34 activation and the Beclin1-Vps34 interaction is required for autopahgic induction. 
Beclin1 constitutively binds to its antiapoptotic partner Bcl2, which prevents Beclin1-
Vps34 interaction. However, in amino acid depleted condition, Beclin1 dissociates from 
Bcl2: a process mediated by multiple factors including Bcl2 degradation, competitive 
binding of Bcl2 with other proteins, and JNK1 phosphorylation of Bcl2 (Lavallard et al., 
2012). The dissociated Beclin1 binds to Vps34 and enhances its lipid kinase activity 
resulting in the formation of phospatidyl inositol-3 phosphate (PI3P). In autophagy, PIP3 
mediates the localization of several regulatory Atg proteins to the phagophore which is 
essential for the expansion of the autophagosome (Weidberg et al., 2011).The expansion 
of autophagosome also requires two ubiquitin-like (UBL) systems: Atg12-Atg5 and 
myosin light chain3 or  LC3 (mammalian Atg 8) conjugation systems. In the Atg12-Atg5 
system, Atg12 is initially activated by Atg7, an E1-like ubiqutin enzyme, and then 
transferred to Atg10, an E2-like ligase, which covalently attaches Atg12 to Atg5. Finally, 
the Atg12-Atg5 complex noncovalently attaches to Atg16L (mammalian Atg16-like 
protein) to form a larger Atg12-Atg5-Atg16L complex (Mizushima et al., 2003; 
Weidberg et al., 2011). The recruitment of this complex to the autophagosomal 
membrane may depend on PI3P formation (Weidberg et al., 2011). Interestingly, the 
complex dissociates from the membrane upon autophagosome formation and thus serves 
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as a specific marker of the phagophore (Mizushima et al., 2003). In the LC3 (Atg 8) 
conjugation system, a larger precursor form of LC3 is first cleaved by the cysteine  
by an E1-like enzyme, Atg7, and transferred to an E2-like ligase, Atg3, which lapidates 
LC3-I by covalent attachment of phosphatidyl ethanol amine (PE) to the glycine residue 
resulting into the formation of LC3-II (or LC3-PE) (Kim et al., 2001; Kirisako et al., 
2000). LC3-II is recruited to the growing autophagosome by Atg5-At12-Atg16L complex 
(Mizushima et al., 2001). Translocation of LC3-II to the membrane helps membrane 
expansion and closure of the double membrane structure to form the mature 
autophagosome (Lavallard et al., 2012). Among Atg proteins, only LC3-II remains 
attached to autophagosomes during their fusion with lysosomes and gets degraded in 
autolysosomes. Hence, LC3-II is used as a reliable biomarker for monitoring autophagy 
(Klionsky et al., 2007). Fusion of autophagosomes with lysosomes and degradation of the 
autophagosomal content is the final step of autophagy. Several motor proteins of the 
cytoskeleton such as Dynein and FYCO1 promote bidirectional movements of mature 
autophagosomes to microtubule organizing centers where they fuse with lysosomes 
(Pankiv et al., 2010; Ravikumar et al., 2005). The fusion is mediated by classical 
endocytotic pathway proteins such as Rab7, which interacts with autophagosomes and 
facilitates their fusion with lysosomes in a Lamp1/Lamp2 dependent manner (Jager et al., 
2004).  
Autophagy is also regulated at the transcriptional level. The forkhead box O family 
of transcription factors (FoxO) and transcription factor EB (TFEB) are implicated in the 
transcriptional control of autophagy genes. Constitutively active FoxO1 has been shown 
to prevent insulin dependent reduction in autophagy gene expression in hepatocytes 
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(Lavallard et al., 2012). Recently, TFEB has been identified as a master transcriptional 
regulator of a network of genes involved in autophagy and lysosomal biogenesis 
(Palmieri et al., 2011; Sardiello et al., 2009).           
Although bulk autophagy is largely considered a nonselective process, several 
studies showed autophagy to be highly selective for the targeting of cytoplasmic proteins 
and specific organelles for lysosomal degradation (Figure 1.4). Most cytosolic proteins 
targeted for selective autophagy are ubiquitinated and bound to ubiquitin-binding adapter 
protein p62/SQSTM1 (hereafter called p62) through its ubiquitin binding domain (UBD) 
(Figure 1.1). The self-oligomerization of p62 facilitates incorporation of more 
ubiquitinated proteins. The p62-target protein complexes are delivered to autophagosome 
through a direct interaction of LC3-interacting region (LIR motif) of p62 with specific 
residues within LC3 (Ichimura et al., 2008; Pankiv et al., 2007). Consistent with these 
observations, several in vivo studies showed the accumulation of p62-positive aggregates 
of ubiquitinated proteins when autophagic turnover was impaired (Bjorkoy et al., 2005; 
Gal et al., 2007; Settembre et al., 2008). 
Like proteins, various intracellular organelles and macromolecules also undergo 
selective autophagy. In mitophagy, mitochondria are selectively targeted for autophagic 
degradation. In vitro studies demonstrate that uncoupled mitochondria with diminished 
mitochondrial membrane potential are specifically recognized by the PTEN-induced 
kinase 1 (PINK1) which recruits the E3-ubiquitin ligase Parkin to the damaged 
mitochondria. Parkin ubiquitinates mitochondrial substrates which are recognized by p62 




Figure 1.4. Two major types of organelle specific autophagy. (A) In mitophagy, 
damaged mitochondria with diminished membrane potential () are selectively 
recognized by PINK1 which recruits the E3-ubiquitin ligase Parkin to mitochondria. 
Parkin ubiquitinates mitochondrial proteins, which are recognized by p62 to facilitate 
autophagic degradation of damaged mitochondria. Selective removal of normal 
mitochondria in maturing reticulocytes occurs via binding of Nix4 to mitochondria. Nix4 
directly interacts with LC3-II to direct mitochondria for autophagic degradation. (B) In 
lipophagy, small LDs or a portion of a large LD are sequestered by a growing 
autophagosomal membrane. The lipid droplets in mature autophagosomes are then 
degraded by lysosomal hydrolases to generate FFAs, which are utilized for ATP 













(Youle and Narendra, 2011). Mitophagy is also involved in the clearance of normal 
mitochondria in reticulocytes, which mature into mitochondria-deficient red blood cells. 
This form of mitophagy involves a different mechanism in which the outer mitochondrial 
membrane protein NIP3-like protein X (NIX) directly interacts with LC3 through its 
WXXL-like motif facing the cytosol to target mitochondria for autophagic degradation 
(Novak et al., 2010). Like mitochondria, defective ER, peroxisomes, and ribosomes are 
also selectively degraded by reticulophagy, pexophagy and ribophagy, respectively 
(Weidberg et al., 2011). 
Lipid droplets (LDs) are the other important organelles that are degraded by 
lipophagy (autophagy of LDs) to provide FFAs as substrates for ATP production. Recent 
reports suggest that lipophagy is an important process in the mobilization of esterified 
lipids in LDs in addition to previously known intracellular lipolysis (Singh and Cuervo, 
2012; Singh et al., 2009a). The mechanism of lipophagy is not well established. LC3 is 
found to be associated with LDs, however, if it directly interacts with LDs or remains 
associated with classical autophagosomes wrapping LDs is unclear (Shibata et al., 2009).  
The evidence for the involvement of autophagy in LDs catabolism came from 
knockdown of Atg5 in cultured hepatocytes. Normal hepatocytes responded to acute oleic 
acid challenge by increasing lipolysis which would prevent enlargement of LDs, whereas 
hepatocytes with Atg5 knockdown displayed increasing number and size of LDs upon 
acute oleic acid challenge. Likewise, in vivo, liver specific deletion of another Atg gene 
(Atg7) in mice resulted in the development of liver steatosis (Singh et al., 2009a). These 
studies also showed that lipophagy is involved in LDs metabolism both under basal and 
starvation conditions. Given the epidemic of fat-related diseases such as obesity and 
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T2DM, the role of autophagy in lipid metabolism and homeostasis in normal and disease 
states and in other organ systems requires further study. 
 
 
1.5.2. Regulation of lysosomal function  
Lysosomes are the final destination for macromolecules and cytoplasmic organelles 
bound for degradation through autophagy. Lysosomes contain about 50 different 
hydrolytic enzymes that perform their maximal activity at low pH. The acidic pH of 
lysosomes (pH5) is largely maintained by a vacuolar ATPase that pumps protons into 
the lysosomal lumen (Saftig and Klumperman, 2009). The acidic pH of the lysosome is 
critical for the degradation of the autophagic substrates. However, the mechanism of 
lysosomal acidification is complex and not entirely clear (Mindell, 2012). The proton 
pumping of the vATPase separates electric charge (greater positive charge in the 
lysosomal lumen than in the cytoplasm), which generates a transmembrane voltage. 
Therefore, a counter ion must move to dissipate this voltage for net proton pumping to 
occur. Although the molecular identity of such counterion channel remains elusive, it is 
generally agreed that both ClC-7, a Cl-/H+ antiporter, and a putative cation transporter 
(primarily a K+-channel) may contribute to the acidification of lysosomes (Graves et al., 
2008; Kornak et al., 2001; Mindell, 2012). The relative contribution of different channels 
may be context dependent and could vary in different cell types. More importantly, the 
assembly of the vATPase subunits, namely membrane-bound V0 and cytosolic V1, are 
also affected by various conditions which could, in turn, impair lysosomal acidification 





1.5.3. Autophagy in the heart 
Autophagy in the heart plays a critical role in cellular homeostasis and a defect in 
autophagy can be deleterious to the heart as evidenced by the deregulation of autophagy 
in many cardiomyopathies such as ischemic heart disease, Danon disease, myocardial 
infarction (MI), and heart failure (Gustafsson and Gottlieb, 2008; Martinet et al., 2007). 
Under baseline conditions, autophagy seems to maintain normal cardiac function and 
structure. For example, upregulation of autophagy in the murine heart in response to 
fasting suggests an important prosurvival role of autophagy in starvation (Mizushima et 
al., 2004). In contrast, disruption of basal autophagy by conditional deletion of cardiac-
specific Atg5 leads to accumulation of abnormal mitochondria, disruption of sarcomeric 
structure, and development of cardiac dysfunction (Nakai et al., 2007). Likewise, in 
Danon’s cardiomyopathy, defective autophagic clearance due to a deficiency in the 
lysosomal protein Lamp-2 results in a massive accumulation of autophagosomes (Nishino 
et al., 2000; Tanaka et al., 2000). Conversely, studies indicate that excessive autophagy 
may impair cardiac function. CMs from patients with cardiovascular diseases such as 
aortic stenosis, hypertensive heart disease, chronic ischemia, and dilated cardiomyopathy 
have increased numbers of autophagosomes in dying cells (Hein et al., 2003; Kostin et 
al., 2003; Yan et al., 2005). Whether autophagy plays a causal role in cell death or is 
upregulated in an attempt to rescue dying cells is not clear.  
 
 
1.5.3.1. Autophagy in cardiac hypertrophy and heart failure 
In response to hemodynamic stress, such as pressure overload, CMs increase in size 
resulting in cardiac hypertrophy. Autophagy was suppressed during cardiac hypertrophy 
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in the heart induced by 1 week of transverse aortic constriction (TAC) with no cardiac 
dysfunction (Nakai et al., 2007; Yamaguchi et al., 2003). Studies suggest that autophagy 
might play a protective role in compensatory cardiac hypertrophy. For example, cardiac 
hypertrophy induced by -adrenergic stimulation by isoproterenol infusion leads to left 
ventricular dilation and cardiac dysfunction in conditional Atg5-deficient mice but not in 
wildtype controls (Nakai et al., 2007). In contrast, activation of autophagy by rapamycin 
treatment not only prevents cardiac hypertrophy induced by thyroid hormone treatment or 
aortic banding but also regresses existing hypertrophy in parallel with improved cardiac 
function (Ha et al., 2005; Kuzman et al., 2007; McMullen et al., 2004).  Together, these 
data suggest that autophagy facilitates hypertrophic response in the heart. Interestingly, 
conditional Atg5-deficient mice undergo same degree of hypertrophy as wildtype mice in 
response to TAC, disputing the role of autophagy in TAC-induced cardiac hypertrophy or 
suggesting that an alternative hypertrophic response exists to compensate for autophagy 
(Nakai et al., 2007).   
Contrary to compensatory cardiac hypertrophy, autophagy was upregulated in heart 
failure in both patients and animal models (Nishida et al., 2009). In failing hearts, 
increased autophagy has been observed in dead or dying CMs together with apoptosis 
and necrosis (Kostin et al., 2003). However, it is unclear if CM death is caused by 
autophagy or is the consequence of impaired autophagic turnover in failing myocardium.  
Zhu et al. study suggested that in mice subjected to severe thoracic aortic banding 
(sTAB), autophagy plays a role in transition from cardiac hypertrophy to heart failure 
(2007). Compared to conventional TAC, sTAB mice showed rapid onset of clinical heart 
failure accompanied by a significant increase in autophagosome number. Suppression of 
25 
 
autophagy in Beclin1+/- mice decreased pathological remodeling of the heart following 
sTAB. In contrast, enhancement of autophagy by Beclin1 overexpression exacerbates 
cardiac remodeling. The conclusion from these data conflicts with an earlier study by 
Nakai et al. on Atg5-deficient mice which suggests that autophagy is an adaptive 
response to hemodynamic stress (2007). This discrepancy may be due to different genetic 
models used to suppress autophagy: while Atg5-deletion completely blocks basal 
autophagy, Beclin1+/- brings about only 50% reduction. Data from a recent study suggest 
that the improved cardiac function observed in sTAB-operated Beclin1+/- mice could be 
due to disinhibition of autophagic flux and consequential decrease in autophagosome 
number, implying that autophagy could be adaptive in the setting of sTAB-induced 
cardiac remodeling (Ma et al., 2012). Overall, an emerging consensus is that autophagic 




1.5.3.2. Autophagy in oxidative stress 
Oxidative stress is a common feature of several systemic and cardiac abnormalities 
such as obesity, dyslipidemia, insulin resistance, diabetes, I/R, heart failure, cancer, 
neurodegeneration, and aging. Oxidative stress occurs excessive reactive oxygen species 
(ROS) production overwhelms cellular antioxidant defense system. The mitochondrial 
electron transport chain (mETC) and the membrane-bound NADPH oxidase (Nox) are 
the major producers of ROS. The accumulated ROS indiscriminately oxidizes and 
damages various cellular constituents such as proteins, DNA, and lipids. Superoxide 
anion (O2●-) and hydrogen peroxide (H2O2) are two major forms of ROS in the heart.  
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As a prosurvival pathway, autophagy has long been envisioned as playing a key role 
in oxidative stress and associated pathologies. Studies have shown that both O2●- and 
H2O2 induce autophagy which, in turn, serves as an adaptive response to minimize further 
oxidative damage (Scherz-Shouval and Elazar, 2011). Since ROS are short lived and 
interconvertible, it is likely that multiple ROS coordinately mediate oxidative stress-
induced autophagy. For example, mitophagy is triggered by the generation of ROS, both 
O2●- and H2O2, which impairs mETC leading to the loss of mitochondrial membrane 
potential (m) and enhanced mitochondrial fragmentation. Consequently, the damaged 
mitochondria are eliminated by autophagy to prevent further ROS-induced damage (Lee 
et al., 2012; Scherz-Shouval and Elazar, 2011).   
Depending upon the site of ROS generation and the nature of stress, a specific ROS 
could regulate autophagic induction. For instance, superoxide is the major mitochondrial 
ROS regulating autophagy. In HeLa cells, O2●- has been shown to mediate glucose-
deprivation induced autophagy which is inhibited by overexpression of mitochondrial 
manganese superoxide dismutase (SOD2) and induced by siRNA mediated depletion of 
SOD2 (Chen et al., 2009). However, the mechanism inducing mitochondrial O2●- 
production in starvation is unclear (Chen et al., 2009). A separate study showed that H2O2 
also mediates starvation induced autophagy partially through PI3KC3 (Scherz-Shouval et 
al., 2007). H2O2 acts as a direct modifier of the cysteine-protease Atg4 by oxidizing the 
protein and enhancing its ability to convert LC3-I into LC3-II. Similarly, a number of 
autophagy genes have been identified as the direct target of redox modifications which 
lead to deregulation of autophagy under oxidative stress (Lee et al., 2012). It is important 
to emphasize that ROS usually react or cross-talk with reactive nitrogen species (RNS) 
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and other reactive molecules that may modulate their effect on autophagy. Therefore, in 
several pathologies oxidative and nitrosative stresses often coexist with altered 
autophagy.    
The role of NOX-borne ROS in autophagy is less known. The ROS produced by the 
NOX isoform 2 (Nox2) was recently shown to induce antibacterial autophagy in 
phagoycytes (Huang et al., 2009).  Upon induction, NOX2 translocates to the phagosomal 
membrane and generates superoxide by transferring electrons from cytosolic NOX to 
oxygen in the phagosomal lumen. The generation of ROS was necessary to target LC3 to 
phagosomes and subsequent degradation of phagosomes within lysosomes. A recent 
study linked NOX2 activation to toll-like receptor (TLR)-mediated induction of 
autophagy in inflammatory bowel diseases (Huang et al., 2009).  
The ROS/RNS also regulates autophagy at the transcriptional level by modifying key 
transcription factors and altering their activity. One such target is the Nrf2 /Keap1 
pathway (Itoh et al., 1997). Nrf2 not only induces the transcription of antioxidant and 
cellular detoxification genes but also induces autophagy by increasing p62 expression 
(Jain et al., 2010). A second major transcription factor activated by ROS is p53. The 
activation of p53 leads to the induction of both pro- and antiautophagic gene expression. 
The TIGAR (TP53-induced glycolysis and apoptosis regulator) is the direct target of p53 
and its overexpression has been shown to attenuate starvation or glucose/hypoxia induced 
autophagy (Bensaad et al., 2009). Another p53 target DRAM (damage-regulated 
autophagy modulator), on the other hand, promotes autophagy (Crighton et al., 2006).   
Oxidative stress also affects lysosomal integrity and function (Kurz et al., 2008). The 
lysosomal compartment is rich in iron released from macromolecules and damaged 
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mitochondria during autophagic degradation. The labile pool of iron reacts with H2O2 
generated during oxidative stress to form extremely reactive hydroxyl radical (OH●). The 
OH● causes oxidative damage to lysosomal membrane proteins and lipids, which 
subsequently leads to lysosomal membrane destabilization and enzyme leakage. 
Additionally, diffusion of H2O2 into lysosomes results in oxidative accumulation of 
undegradable intralysosomal material, called lipofuscin, which over time occupies most 
of the lysosomal volume especially in long-lived postmitotic cells including CMs. 
Lipofuscin accumulation redirects lysosomal enzymes away from lysosomes. 
Collectively, the dysfunctional lysosomes in oxidative stress result in the inhibition of 
autophagic turnover and accumulation of large autophagosomes as often observed in 
oxidative-stress associated pathologies such as aging and neurodegeneration.   
 
 
1.5.3.3. Cardiac autophagy in obesity and diabetes 
Obesity contributes to various metabolic disorders including dyslipidemia, 
hypertension, reduced high-density lipoprotein (HDL) cholesterol, and glucose 
intolerance which greatly increase the risk for several diseases including CVD and T2DM 
(Malnick and Knobler, 2006). Insulin resistance, characterized by reduced insulin action, 
is central to the pathogenesis of CVD and T2DM. In obesity, excessive expansion of 
visceral adipose tissue causes adipose tissue dysfunction resulting in the increased 
production of FFA due to uncontrolled lipolysis and release of inflammatory cytokines 
release from adipose tissue. High levels of circulating FFAs and inflammatory cytokines 
suppress insulin signaling in many tissues including liver, skeletal muscles and the heart 
(Abel et al., 2012; Chess and Stanley, 2008). In the heart, increased delivery of FFA leads 
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to the accumulation of toxic lipid intermediates which inhibit local insulin action via 
protein kinase C- dependent inhibitory phosphorylation of insulin receptor substrate 
proteins. Accumulation of toxic lipid metabolites also invokes diverse pathological 
responses including oxidative stress, ER stress, mitochondrial dysfunction, and apoptosis 
(Abel et al., 2012). The effect of lipotoxicity is multifactorial and could result from 
alterations in various homeostatic cellular pathways.  
Autophagy is an important cellular homeostatic pathway and has been shown to play 
critical roles in the regulation of metabolism in many organ systems (Rabinowitz and 
White, 2010). Derangement of metabolic pathways in obesity is well documented. Recent 
studies suggest a link between autophagy and obesity; however, the precise role of 
autophagy in the development of obesity is unclear (Lavallard et al., 2012; Xu and Ren, 
2012). Most studies on autophagy in relation to obesity are focused on insulin sensitive 
tissues and reveal opposing and tissue specific effects of autophagy.  
The role of basal autophagy in pancreatic islet homeostasis is demonstrated by the 
studies on -cell specific Atg7 knockout (Atg7-KO) mice (Ebato et al., 2008). 
Morphologically, loss of autophagy in Atg7-KO -cells displayed increased 
accumulation of ubiquitinated proteins, deformed and branched mitochondria, distended 
ER, decreased -cell mass, and reduced numbers of insulin vesicles accompanied by an 
increase in apoptosis and the loss of -cell proliferation. Functionally, Atg7-KO -cells 
exhibited impaired glucose-stimulated insulin secretion. Consequently, the KO mice 
became hypoinsulinemic and hyperglycemic suggesting a protective role of autophagy in 
-cell function. More importantly, when mice were challenged with a high-fat diet, 
autophagy was significantly upregulated in wildtype -cells, whereas lack of autophagy 
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Atg7-KO -cells resulted in accumulation of ubiqutinated proteins, lower -cell mass, 
increased apoptosis, degeneration of islets  and more severe glucose intolerance. 
Furthermore, autophagy was also upregulated in type 2 diabetic (db/db) mouse model 
compared to nondiabetic controls (Ebato et al., 2008; Fujitani et al., 2009). These data 
suggest that induction of autophagy in diet-induced obesity and T2DM is an adaptive 
response and protects pancreatic islets from deleterious effects underlying these 
metabolic diseases (Hur et al., 2010).  
Obesity is the direct consequence of the expansion of white adipose tissue (WAT) 
mass due to increased number and size of adipocytes. Adipocytes are the primary storage 
site of body fat and are generated from fibroblast-like preadiopocytes through a 
differentiation process called adipogenesis. Several studies have shown that the 
lysosomal-degradation pathway is an important regulator of cellular differentiation 
(Taniguchi et al., 2010; Zhang et al., 1995). Since autophagy is involved in the lysosomal 
degradation pathway, its role in adipogenesis in obesity has been studied extensively in 
recent years (Singh et al., 2009b; Zhang et al., 2009). Inhibition of autophagy by 
knocking down Atg7 or Atg5 gene blocked the differentiation of 3T3-L1 preadiopcytes 
and impaired adipogenesis or lipid accumulation. In congruence, adipose-tissue specific 
deletion of Atg7 resulted in leaner mice with reduced WAT mass and differentiation.  
(Singh et al., 2009b). In obese people, the degree of induction of autophagy is correlated 
with the degree of obesity and the size of white adipocytes (Kovsan et al., 2011). This 
induction of autophagy in adipose tissue has been found to be deleterious leading to the 
development of obesity. For instance, adipose tissue specific Atg7-KO mice were 
resistant to diet-induced obesity (DIO) with improved insulin sensitivity. Inhibition of 
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autophagy by ablation of the Atg5 gene impaired adipogenesis suggesting that induction 
of autophagy contributes to adipogenesis and development of obesity (Baerga et al., 
2009).  
Under baseline conditions, hepatic autophagy is involved in the maintenance of 
blood glucose and amino acid levels, and the regulation of Insulin response (Ezaki et al., 
2011; Yang et al., 2010). Upon starvation, hepatic autophagy increases the production of 
gluconeogenic amino acids, some of which are fed into hepatic gluconeogensis to 
produce glucose and maintain blood-glucose level (Yang et al., 2010). In contrast to 
autophagy in pancreas and adipose tissue, hepatic autophagy was significantly suppressed 
in obesity (Codogno and Meijer, 2010; Czaja, 2010). In parallel, obesity markedly 
induced the calcium-dependent protease calpain 2 which presumably resulted in the 
degradation of autophagy proteins and subsequent inhibition of the autophagic pathway 
(Yang et al., 2010). Obesity-induced defective hepatic autophagy contributes to elevated 
ER stress and possibly to insulin resistance in the liver. In fact, restoration of autophagy 
by Atg7 overexpression reduced ER stress and improved hepatic insulin sensitivity (Yang 
et al., 2010). Hepatic autophagy has also been shown to regulate intracellular lipid 
metabolism by lipophagy (Singh et al., 2009a). While a moderate increase in lipid supply 
induces lipophagy to provide FFAs for ATP production, sustained availability of lipids 
such as in ob/ob or high-fat fed mice, inhibits hepatic autophagic turnover (Codogno and 
Meijer, 2010; Yang et al., 2010). 
In the heart, the regulation of autophagy in obesity is one of the least understood 
processes in insulin sensitive tissues. While some studies suggest that autophagy in the 
heart is upregulated in obesity, there are conflicting data indicating that cardiac 
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autophagy is suppressed in obesity resulting in obesity-related cardiac dysfunction. For 
instance, in two different mouse models of T2DM, namely db/db and recombinant 
congenic strain (RCS)-10, markers of autophagy such as LC3-II, Beclin1, and Atg5-12 
conjugate were significantly upregulated. Notably, the RSC10 mice exhibited increased 
left ventricular (LV) mass while fractional shortening and LV end systolic (ESD) and end 
diastolic (EDD) diameters largely remained unchanged. Conversely, db/db mice 
exhibited both diastolic and systolic dysfunction in the absence of cardiac hypertrophy 
(Wellnitz, 2009). These results suggest that autophagy is activated in the diabetic heart 
irrespective of the functional status of the myocardium. Similarly, a recent study on a 
mouse model of DIO showed that 20 weeks of HFF significantly increased cardiac 
autophagy as measured by an increase in LC3-II and p62 levels (Xu et al., 2012).  
Surprisingly, the AKT-mTORC1 signaling which is known to suppress autophagy is also 
activated upon HFF. Although the increase in autophagy was suggested to be due to 
AKT2-mediated suppression of lysosomal biogenesis, how AKT2 impairs lysosomal 
biogenesis is not entirely clear. Importantly, the role of activated AKT-mTORC1 
signaling was not investigated. Functionally, HFF resulted in cardiac dysfunction 
manifested by increased LV mass, increased LV-ESD and LV-EDD, and decreased 
fractional shortening. The study concluded the inhibition of autophagy upon HFF as 
maladaptive since the restoration of autophagic turnover by AKT2 ablation partially 
preserved the cardiac function in HFF mice. However, the study did not address if the 
improvement in cardiac function is solely due to autophagy or due to other AKT2 
isoform specific functions.   
33 
 
The studies which contradict the idea of induced cardiac autophagy in obesity are 
based on the notion that under nutrient rich conditions such as obesity, the AKT-mTOR 
signaling is activated which in turn suppresses autophagy. Recently, the mTOR signaling 
and autophagy was examined in Ossabaw pigs with metabolic syndrome (MetS), 
characterized by obesity, dyslipidemia and insulin resistance. In MetS pig hearts, the 
mTOR signaling was markedly activated while autophagy was significantly regressed as 
assessed by lower Beclin1, Ulk1 and LC3-II levels (Li et al., 2012). Similarly, cardiac 
autophagy was inhibited in type I diabetic (T1DM) mouse model. The hearts from T1DM 
mice, induced by streptozotocin (STZ) injection or -cell calmodulin overexpression 
(OVE26), showed significant reduction in autophagy evidenced by reduced LC3II level 
(Xie et al., 2011a; Xie et al., 2011b). Restoration of autophagy by chronic activation of 
AMPK with metformin prevented diabetic cardiomyopathy in T1DM mice. These data 
suggest a beneficial effect of metformin in preventing the onset and development of 
diabetic cardiomyopathy via activation of AMPK and subsequently of autophagy. 
However, the involvement of mechanisms independent of autophagy in the beneficial 
effect of metformin cannot be ruled out in these studies. 
The available data on the regulation of cardiac autophagy in obesity provide an 
unclear picture of how the rate of autophagic turnover is affected in the obese heart and if 
the altered autophagy is beneficial or detrimental to heart function. Moreover, most of the 
studies based their conclusion on the static observation of molecular markers of a very 
dynamic process of autophagy, which could explain the inconsistency in the available 
data. A dynamic observation of the regulation of autophagy is crucial to understand the 
precise role of cardiac autophagy in obesity. In fact, studies have shown that the 
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autophagic process is highly dynamic based on the duration and severity of the stimulus 
with different functional consequences (Menon et al., 2011; Papackova et al., 2012; 
Patschan et al., 2008). Therefore, further studies are needed to reconcile the conflicting 




1.6. Summary and rationale 
Basal autophagy functions primarily as a quality control process by constantly removing 
damaged proteins and organelles. Under low nutrient conditions, the process acts as a life 
support by providing substrates essential for energy production and maintenance of vital 
cellular functions. Studies showed that autophagic activity must be maintained within a 
narrow range to have a beneficial effect. Both diminished and excessive autophagy can 
cause cell death. Likewise, defective autophagic turnover at the level of lysosomes is 
detrimental to cell survival. The heart is a metabolically demanding organ that requires a 
constant supply of energy to maintain its contractility. With no apparent regenerative 
capacity, CMs rely heavily on quality control mechanisms such as autophagy to maintain 
their healthy status. Autophagy plays a role in most of the cardiac pathologies namely I/R 
injury, hypertension and heart failure, presumably as an attempt to rescue CMs from 
injury. However, the role of autophagy in cardiac metabolism is largely underappreciated. 
The detrimental effect of nutrient excess in the heart is well documented in obesity-
related pathologies. Yet, there is no comprehensive study on what role autophagy plays in 
the cardiac adaptations to obesity. Furthermore, it is unclear whether altered cardiac 
autophagy in obesity is an adaptive or maladaptive response of the heart. Clearly, more 
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studies are required to understand the precise mechanism and role of cardiac autophagy 
in obesity. Such studies may identify molecular mediators that could be potential 
therapeutic targets to attenuate the pathological outcomes of obesity related cardiac 
diseases.  
The objective of this study is to understand the mechanisms that regulate autophagy 
in response to lipid overload both in vivo in a mouse model of DIO and in vitro in 
cultured embryonic CMs. The autophagic fluxdefined as the rate of progression of  
autophagycan vary temporally based on the severity and duration of a stress. Current 
data on the regulation of autophagy in obesity have been based on static observations of 
autophagy at single time points. Higher autophagosome abundance may result from either 
increased formation of autophagosomes or their decreased turnover or both, and static 
observations fail to account for such changes (Figure 1.5). In this study, we will monitor 
autophagy flux both in vivo and in vitro by using pharmacological inhibitors of the 
degradation steps of autophagy. Furthermore, this study examines the regulation of 
autophagy in the murine heart in response to short-term HFF and in cultured CMs 
following acute lipid overload. Such acute treatments allow us understand the mechanism 
of initial autophagic response in the absence of such cytotoxic response as apoptosis and 
necrosis, which normally occurs following more protracted lipotoxic stimuli. Finally, 
lysosomal activity is an essential component of autophagic flux. However, lysosomal 
functions have been relatively understudied in obesity and associated diseases. Therefore, 
this study also evaluates lysosomal function in vitro in response to fatty acid treatment to 
better understand the role of lysosomal activity in the regulation of autophagy. 


















Figure 1.5. Measurement of autophagic flux. (a) At a basal steady-state level [C], 
autophagosomes (AVs) are constantly formed and turned over in autolysosomes (ALs) 
upon fusion with lysosomes (LVs). AV abundance increases due to either increased flux 
or reduced turnover.  (b) If a treatment [T] stimulates autophagic initiation, the rate of 
AV formation is increased. The inhibition [I] of turnover leads to a proportionally higher 
accumulation of AVs in treated samples [T+I] than in control [C+I], i.e., [T+I]/[T] > 
[C+I]/[C]. (c) If a treatment inhibits AV turnover, the additional inhibition of AV 
turnover [T+I] results in either no additional or less than a proportional increase in AV 








Together, this is the first study which specifically investigates the mechanism(s) by 
which the initial autophagic response is altered in the presence of lipid overload both in 
vivo and in vitro. The outcome of this study will provide novel understanding of the 
regulation of autophagy flux including an evaluation of the role of lysosomal activity and 
expands our knowledge of potential mechanisms for autophagic alterations in obesity, 

















HIGH-FAT FEEDING INCREASES AUTOPHAGOSOMAL  
ABUNDANCE IN THE MOUSE HEART BY  















Elevated levels of FFA in obesity are believed to be one of the major contributing 
factors in the pathogenesis of T2DM and CVD. Studies from our lab have shown that 
mice fed with a high-fat, high-sucrose diet (HFD) for 10 weeks became hyperinsulinemic 
and glucose intolerant (Wright et al., 2009). The insulin signaling through AKT remained 
intact in high-fat fed mouse hearts. However, glucose utilization was significantly altered 
in the heart as early as 2 weeks of HFF leading to reduced glycolysis and glucose 
oxidation with a concomitant increase in FAO. Notably, these changes in cardiac 
substrate utilization occurred in the absence of any obesity phenotype or cardiac 
dysfunction. Chronic HFF leads to obesity phenotype in mice with the development of 
cardiac insulin resistance, cardiac hypertrophy, contractile dysfunction, and impaired 
intracellular Ca2+ handling and mitochondrial function (Dong et al., 2007; Turdi et al., 
2011). However, the pathogenesis of cardiac hypertrophy and cardiac dysfunction and the 
factors involved in transition to impaired myocardial function following HFF still remain 
elusive.  
Autophagy is highly regulated in various tissues such as liver, adipocytes, skeletal 
muscles, and pancreatic -cells, and plays an important role in preserving their normal 
function and architecture in the face of nutrient excess (Ebato et al., 2008; Sandri, 2010; 
Singh et al., 2009b; Yang et al., 2010). Although autophagy is regulated in various 
cardiac pathologies, its role in cardiac metabolism and function in the setting of obesity is 
unclear (Xu and Ren, 2012). While some data suggest an increase in cardiac autophagy 
following HFF, others suggest a decrease or no change (He et al., 2012; Xu et al., 2012). 
These studies did not assess autophagic flux or lysosomal function.  Therefore, it is 
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difficult to interpret which step in autophagy was affected by HFF. Preliminary studies 
from our lab have shown that in the left ventricles of insulin resistant pigs and in the left 
atrial appendages of diabetic and nondiabetic human subjects, autophagy was markedly 
increased (Zhang, Q.J.; unpublished data).  The characteristics of the pig model and 
human subjects used in these studies have been published (Anderson et al., 2009; 
Edwards et al., 2010). Surprisingly, AKT phosphorylation was significantly increased 
despite an increase in autophagy. Moreover, the increase in autophagosomes was 
independent of changes in mTOR and AMPK signaling.  
Based on available data, we hypothesize that lipid overload by HFF in mice 
increases autophagosome abundance in the heart primarily by suppressing 
autophagosome degradation and not by increasing autophagic flux. To test this 
hypothesis, we placed wild type mice on a HFD regimen and examine upstream signals 
of autophagy, core autophagic proteins, and lysosomal proteins. We also 
pharmacologically inhibited autophagosomal-lysosomal fusion to identify the step(s) in 
the autophagic pathway are altered in response to HFF.  
    
 
                                              2.2. Methods 
2.2.1. Animals  
The study was approved by the Institute of Animal Care and Use Committee of the 
University of Utah. Control (WT) and transgenic mice expressing mCherry-LC3 in CMs 
(MHC-mCherryLC3 or MCLC3) on C57BL/6 background were housed in our animal 
facility at 22 oC and on a 12-h light/dark cycle (6AM, light on) with free access to water 
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and a normal-chow (NCD, 13% kcal fat, 53% kcal carbohydrate, and 34% kcal protein, 
Teklad 8656, Madison, WI).  
 
 
2.2.2. High-fat diet regimen  
Eight-week old male WT or MCLC3 mice were fed with either a HFD (45% kcal fat, 
35% kcal carbohydrate, and 20% kcal protein, Research Diets Inc. D12451, New 
Brunswick, NJ) or the NCD (Teklad 8656) for 12 weeks. The gain in body weight was 
calculated as the difference in body weight measured before placing the animals on a diet 
regimen and at the time of harvest. For all studies, mice were fasted for 6 h (from 6 AM 
to 12 PM) and blood glucose levels were measured by a standard glucometer (Bayer, IN) 
before sacrifice.  
 
 
2.2.3. Measurement of hormones and metabolites in the heart and serum  
The heart was excised from anaesthetized mice and kept frozen in -80 oC until use. 
To measure TG content in the heart, 50 mg of tissue was homogenized in 1 ml of 
chloroform/methanol in TissueLyser II (Qiagen, Valencia, CA). The TGs were extracted 
by rocking the samples at room temperature for 3 h. Eight hundred µl of H2SO4 was 
added to each sample and centrifuged at 218xg for 10 min. Fifty µl of organic (bottom) 
layer was dried in a speedvac for 15 min. Three hundred µl of triglyceride assay buffer 
(Sigma-Aldrich, St. Louis, MO) was added to each sample and incubated at 37 oC for 15 
min with occasional mixing. Samples were loaded in 250 µl onto a 96-well plate and 
absorbance was measured at 562 nm. Glycerol standard was used to generate the standard 
curve (Sigma-Aldrich, St. Louis, MO).        
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Blood was collected from the submendibular vein of the mouse in a microfuge tube 
containing a small piece of Teflon. The serum was removed from the clotted blood by 
centrifugation and preserved in -80 oC until use. Circulating levels of insulin, glucagon 
and leptin were measured using the MEGPIXTM  (Luminex, Austin, TX), a multiplex 
enzyme-linked immunosorbent assay (ELISA), using a specific antibody-coated magnetic 
microsphere kit (Milliplex Map Kit; Millipore, Billerica, MA). Circulating levels of FFAs 
and TGs were measured in serum samples using kits from Wako Diagnostics (Richmond, 
VA).   
 
 
2.2.4. Metabolomics analysis of the heart and serum  
Hearts from NCD- or HFD- fed mice (heretofore NCD or HFD mice) were flash-
frozen in liquid nitrogen. Metabolomics analysis was performed by using gas 
chromatography-mass spectrometry (GC-MS) at the University of Utah Metabolomics 
Core Facility. The identity of the metabolites was verified by comparing with GC-MS 
profiles of known metabolites in the library. The amount of a metabolite in a sample was 
reported as the area under the peak for the corresponding metabolite in the chromatogram 
and was normalized to the starting tissue weight.       
Serum samples were prepared as described in section 2.2.3. GC-MS analysis was 
performed as above for heart samples, and the metabolite content in each sample was 







2.2.5. Histology and stereology 
The apical half of the heart was fixed in 10% zinc formalin (Thermo Fisher 
Scientific, Waltham, MA) for 1 h, embedded in paraplast, and sliced into 5 µM transverse 
sections (T.S). The T.S. was stained with hematoxylin-eosin and Masson’s trichrome 
stains. Images were acquired with an Olympus LX81 inverted light microscope equipped 
with an Olympus Microfire Digital Camera (New York, NY), and volume density was 




2.2.6. Cryosectioning and fluorescence microscopy 
The apical half of the heart from MCLC3 mice fed with NCD or HFD were 
embedded in Optimal Cutting Temperature (OCT) compound (Sakura Finetek, Torrence, 
CA) on dry ice for 25 min and sliced in 5 µM T.S. on a cryostat (Leica, Buffalo Grove, 
IL) at -20 oC. Tissue fixation/staining and confocal imaging were performed essentially 
as described previously (Perry et al., 2009). Briefly, the T.S. was fixed in 4% 
paraformaldehyde for 15 min, stained with Hoechst 33342 for 30 min, and mounted with 
ProLong Gold antifade reagent (Invitrogen, Grand Island, NY) for 2 h in the dark. 
Fluorescent images were taken using an Olympus IX81 FV1000 confocal microscope 
equipped with x40 dry objective (NA 0.80) and 488 nM (for Hoechst 33342) and 633 nM 
(for mCherry) lasers. The images representing different Z-sections were merged using 





2.2.7. Insulin stimulation of the heart  
Mice were anaesthetized by intraperitoneal (ip) injections of chloral hydrate (0.7 
mg/g body weight) before harvesting the tissues or prior to insulin injections. 
Anaesthetized mice were injected with 0.01 unit of human regular insulin (Novolin R) or 
an equal volume of saline via the inferior vena cava (ivc) as described previously (Kim et 
al., 2008). Five minutes following insulin injection, the heart was removed and kept 
frozen until further analysis.   
 
 
2.2.8. Activation of mTOR and inhibition of autophagic turnover 
For mTOR activation, mice were injected ip with a branch-chain amino acid 
(BCAA) solution (46 mM isoleucine, 91 mM, leucine, 61 mM, and 35 mM arginine, pH 
7.4) at a daily of dose of 100 µl/g body weight for 2 weeks prior to harvest.  
For the inhibition of autophagic turnover, mice were injected ip with three doses of 
the autophagosome-lysosome fusion inhibitor chloroquine (CQ) at 48 h (30 mg/kg body 
weight), 24 h (30 mg/kg), and 2 h (50 mg/kg) prior to harvest. Control animals were 
injected with an equal volume of saline. 
 
 
2.2.9. RNA isolation and quantitative RT-PCR 
Total RNA was extracted from hearts with TRIzol reagent (Invitrogen, Carlsbad, 
CA) and purified using RNAeasy kit (Qiagen, Valencia, CA). Total mRNA was reverse 
transcribed and individual gene expression was determined indirectly by quantitative 
real-time polymerase chain reaction (qRT-PCR) using an ABI Prism 7900 HT instrument 
(Applied Biosystems, Foster City, CA) as described previously (Riehle et al., 2011).  
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Each reaction was performed in triplicate in a 384-well plate using SYBR Green I 
chemistry and ROX internal reference dye (Invitrogen, Carlsbad, CA). Data were 
normalized to Cyclophilin mRNA level. The sequence of primers used was described 
previously (Liu et al., 2009).    
       
 
2.2.10. Immunoblotting 
Total proteins were extracted by homogenizing frozen tissues in a lysis buffer 
containing 50 mM HEPES (pH 7.5), 150 mM NaCl, 10% Glycerol, 1% Triton X-100, 1.5 
mM MgCl2, 1 mM EGTA, 10 mM Na4P2O7, 100 mM NaF, and 1X Halt protease and 
phosphatase inhibitor cocktail (Thermo Scientific), and analyzed by western blotting as 
previously described (Riehle et al., 2011). Antibodies against LC3 (Sigma, St. Louis, 
MO); Beclin1, GAPDH, phospho and total mTOR, AKT, AMPK and S6 (Cell Signaling, 
Danvers, MA); phospho FOXO1/3 and Ulk1 (Cell Signaling); total FOXO, total Ulk1, 
and Cathepsin D (Santa Cruz, Santa Cruz, CA) were used for immunodetection. IRDye 
800CW anti-Mouse (LICOR, Lincoln, NE) and Alexa Fluor anti-Rabbit (Invitrogen, 
Carlsbad, CA) were used as secondary antibodies. Fluorescence intensity of a protein 
band was detected and quantified by using the LICOR Odyssey Imager.  
 
 
2.2.11. Statistical analysis 
All data are presented as mean ± SEM. Unpaired Student’s t-test was performed to 
determine p-values when comparing between two groups. 1-way Analysis of variance 
(ANOVA) was used to compare data across multiple groups with one independent 
variable. Multiple groups with two or more independent variables were analyzed by 2-
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way ANOVA. Statistical significance was determined by Bonferroni’s post-hoc analysis 
using the GraphPad Prism 5 software (La Jolla, CA). For all analyses, p<0.05 was 




2.3.1. Body weight and systemic metabolic variables  
Mice on HFD for 12 weeks gained about 15 g of body weight compared to 5 g in 
NCD-fed littermate controls (Table 2.1). The fasting blood glucose levels were 
significantly increased in HFD mice compared to NCD mice. However, the fasting blood 
glucose levels in HFD mice (188.6 mg/dL) were below the diabetic level (>300 mg/dL) 
(von Herrath et al., 1995). The HFD mice had a significant rise in serum insulin and 
leptin levels compared NCD controls. In addition, circulating levels of FFAs and TGs 
were significantly elevated in HFD mice compared to NCD controls.  Although, body 
composition (fat mass and lean mass) was not measured in this study, mice on HFD 
showed marked accumulation of both visceral and subcutaneous adipose tissue. 
Supporting this observation, a previous study from our group have shown a significant 
increase in both gonadal fat pad mass and total fat mass in mice following 14 weeks of 
HFF compared NCD controls (Tanner et al., 2010). Taken together, 12 weeks of HFF 
manifested the basic hallmarks of diet induced obesity and the metabolic syndrome.   
 
 
2.3.2. Cardiac phenotype in HFD and NCD fed mice 
Consistent with a gain in body weight, 12 weeks of HFF led to an increase in heart 
weight (~8.8%) and biventricular weight (~10%) compared to NCD controls (Table 2.2). 
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Table 2.1. Phenotypic and metabolic characteristics of mice fed HFD or NCD for 12 
weeks. *p<0.05 vs. NCD (n=10-12). 
 
Parameters NCD HFD 
Age 21 ± 0.5 21 ± 0.5 
Body weight (g) 28 ± 0.5 39.9 ± 1.1 
Body weight/tibia length (g/mm) 1.6 ± 0.03 2.3 ± 0.57 
Blood glucose (mg/dL) 142.5 ± 8.1 188.6 ± 11.5 
Insulin (pg/ml) 92.82 ± 27.2 641.6 ± 176.4 
Leptin (pg/ml) 363.8 ± 147.3 19441 ± 3782.7 
Serum free fatty acids (mM) 0.33 ± 0.01 0.85 ± 0.04 




Table 2.2. Cardiac parameters of mice fed with HFD or NCD for 12 weeks. p<0.05 vs. 
NCD (n=10-12). 
 
Parameters NCD HFD 
Heart weight (mg) 130.0 ± 2.2 142.5 ± 3.3 
Heart weight/tibia length (mg/mm)   7.5 ± 0.2 8.1 ± 2.0 
Biventricular weight/tibia length (mg/mm)   7.1 ± 0.12 7.8 ± 1.9 










The increase in heart weight is usually accompanied by CM hypertrophy or increased 
fibrosis in the heart. CM size, examined by H&E staining, was similar in high-fat fed and 
normal-chow fed animals (Figure 2.1). Moreover, Masson’s trichrome staining of the 
T.S. of the heart showed no fibrosis in HFD mice. The histology data suggest that mice 
on HFD had normal cardiac growth. However, the HFF significantly increased TG 
content (~1.6 fold) in the heart (Table 2.2). The ectopic deposition of fat in TG might 
contribute to an increase in the heart and biventricular weight.      
 
 
2.3.3. Profiles of circulating metabolites from NCD and  
HFD fed mice 
To identify the obesity-related changes in the levels of circulating small metabolites, 
serum samples from 13-week NCD or HFD mice were analyzed by GS-MS analysis 
(Table 2.3). The initial goal of this analysis was to determine the changes in the 
circulating levels of amino acids. However, a generic extraction and analysis protocol 
allowed us to analyze several other metabolites including FFAs, carbohydrates, TCA 
cycle and glycolytic intermediates. Most surprisingly, the level of serum glucose was 
significantly low in HFD animals. Although most of the TCA cycle and glycolytic 
intermediates tended to be reduced the in HFD groups, no significant difference was 
observed compared to NCD controls. Notably, the circulating levels of most of the 
common nonesterified free fatty acids including palmitic acid and linoleic acid were 
significantly reduced in the HFD group which is in contrast with well-known observation 
of high circulating levels of glucose and free fatty acids in obesity and T2DM. Since the 

















Figure 2.1. No cardiac hypertrophy and fibrosis in mice following 12 weeks of high-fat 
feeding. Mice fed with HFD or NCD for 12 weeks were examined for CM size by H&E 
staining (upper panel). The presence of fibrotic tissue in the heart was assessed by 
Masson’s trichrome staining (lower panel). The fibrotic tissues stain blue on Masson’s 









Table 2.3. Levels of circulating metabolites in the serum from NCD or HFD  mice. 
 
Glycolysis and TCA Cycle  
Metabolite NCD HFD HFD-fold change p-value 
lactic acid 777.2 769.3 1.0 0.881 
pyruvic acid 585.9 519.4 0.9 0.682 
glycerol 8.8 4.3 0.5 0.039 
glyceric acid 59.8 42.1 0.7 0.252 
citric acid 574.3 584.3 1.0 0.869 
aconitic acid 17.9 16.0 0.9 0.423 
isocitric acid 67.7 34.6 0.5 0.135 
2-ketoglutaric acid 52.1 63.2 1.2 0.244 
succinic acid 118.6 64.1 0.5 0.311 
fumaric acid 131.4 93.6 0.7 0.164 
malic acid 221.7 164.1 0.7 0.191 
2-hydroxyglutarate 14.4 16.5 1.1 0.365 
DHAP 8.89 1.70 0.2 0.117 
galactose or isomer 2785.82 2379.16 0.9 0.217 
glucose 23092.73 16993.45 0.7 0.021 
glucose-1-phosphate 5.81 3.58 0.6 0.120 
glucose-6-phosphate 59.25 35.52 0.6 0.080 
Amino Acids 
2-aminoadipic acid 23.9 27.8 1.2 0.286 
lysine 93.7 182.9 2.0 0.045 
valine 658.7 490.3 0.7 0.028 
leucine 2013.1 1383.5 0.7 0.008 
isoleucine 1379.4 922.0 0.7 0.001 
threonine 250.9 265.0 1.1 0.642 
glycine 125.4 91.4 0.7 0.014 
serine 76.4 76.7 1.0 0.978 
alanine 227.7 233.7 1.0 0.821 
glutamic acid 25.2 15.6 0.6 0.075 
glutamine 1128.4 1111.5 1.0 0.910 
proline 649.8 669.5 1.0 0.808 
aspartic acid 120.0 74.1 0.6 0.011 
asparagine 16.0 13.6 0.8 0.140 
methionine 251.0 224.0 0.9 0.393 
cysteine 18.7 27.6 1.5 0.142 
homocysteine 0.9 0.7 0.8 0.337 
phenylalanine 271.5 238.8 0.9 0.197 
tyrosine 55.3 44.1 0.8 0.186 
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Table 2.3. (continued) 
 
Amino Acids     
Metabolite NCD HFD   HFD-fold change p-value 
tryptophan 706.6 964.7 1.4 0.094 
histidineND 4.6 7.7 1.7 0.049 
ornithine 15.2 19.9 1.3 0.066 
Triglyceride and Cholesterol       
phosphate 7829.8 5758.2 0.7 0.088 
diphosphate 631.9 885.2 1.4 0.031 
phosphoglycerol 260.6 255.5 1.0 0.935 
3-phosphoglycerate 9.6 2.7 0.3 0.058 
1-monooleoylglycerol 43.6 40.3 0.9 0.582 
1-monostearylglycerol 154.9 187.0 1.2 0.199 
1-monopalmitoylglycerol 260.9 207.9 0.8 0.090 
1-monopalmitolylglycerol 2.7 1.3 0.5 0.001 
cholesterol 1107.1 1054.6 1.0 0.710 
Carbohydrate         
fructose 660.7 690.9 1.0 0.869 
ribose 45.6 23.0 0.5 0.003 
sorbitol 27.8 21.7 0.8 0.662 
galacitol 70.7 73.4 1.0 0.829 
inositol 3117.2 1378.9 0.4 0.0001 
myo-inositol phosphate 136.3 159.5 1.2 0.414 
disaccharide 192.6 98.1 0.5 0.176 
Fatty Acids (nonesterified)  
lauric acid 54.0 48.9 0.9 0.359 
myristic acid 149.1 137.1 0.9 0.542 
palmitiladic acid 151.9 108.3 0.7 0.246 
palmitic acid 3127.2 3211.5 1.0 0.842 
linoleic acid 500.4 508.5 1.0 0.917 
oleic acid 649.1 1114.5 1.7 0.014 
elaidic acid 45.5 60.8 1.3 0.074 
stearic acid 1738.9 2131.8 1.2 0.039 










Table 2.3. (continued) 
 
Purine, Pyrimidine Metabolism and Other Metabolites   
Metabolite NCD HFD   HFD-fold change p-value 
xanthine 112.7 28.6 0.3 0.018 
adenosine 2.2 2.8 1.3 0.506 
adenine 2.4 2.0 0.8 0.423 
uracil 55.1 40.0 0.7 0.374 
phosphoenolpyruvate 9.9 1.0 0.1 0.136 
3-indoleacetic acid 5.0 5.1 1.0 0.891 
inosine 23.1 14.0 0.6 0.117 
rhamnose 0.5 0.3 0.6 0.048 
tyramine 1.4 1.1 0.8 0.316 



















could affect other analyses. Therefore, the levels of other metabolites in this study may 
not reflect their true levels in the serum. The GC-MS results contradict our own finding 
of increased fatty acid and triglycerides levels in the serum HFD animals (Table 2.1). 
Nevertheless, the GC-MS data clearly showed that circulating levels BCAAs such as 
valine (0.7 fold, p=0.043), isoleucine (0.6 fold, p=0.011), and leucine (0.3 fold, p=0.099) 
were significantly or near significantly low in HFD mice compared to NCD controls.  
 
 
2.3.4. Metabolomics profile of the heart from NCD and  
HFD mice 
Obesity has been known to increase fatty acid flux into the heart, which could alter 
various metabolic pathways. A previous study from our lab has shown that 5 weeks of 
HFF suppressed glycolysis, glucose oxidation rate, expression and membrane 
translocation of Glut4, and impaired insulin stimulated glucose uptake (Wright et al., 
2009). Accordingly, in the present study, the analysis of small metabolites and pathway 
intermediates by GC-MS showed that 12 weeks of HFD markedly reduced the abundance 
of key glycolytic intermediates in the heart (Table 2.4). For example, glucose-6-
phosphate was reduced by 80% and glucose-1-phosphate by 70% in HFD hearts 
compared to NCD controls. Interestingly, lactate and pyruvate levels were not changed 
between the two groups. Furthermore, free glucose levels in the heart was similar in both 
groups. In contrast to glycolytic intermediates, the levels of most TCA cycle 
intermediates remained fairly unchanged. The most notable changes observed between 
the two groups were in the level of amino acids. Most importantly and consistent with 
serum metabolomics data, the levels of BCAAs were significantly reduced in HFD hearts  
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Table 2.4.  Levels of small molecule metabolites in the heart from NCD or HFD mice. 
 
TCA Cycle  
Metabolite NCD HFD HFD-fold change p-value 
citrate 22394.2 25006.4 1.1 0.576 
aconitate 47.9 51.0 1.1 0.791 
isocitrate 316.1 295.3 0.9 0.793 
2-ketoglutarate 145.6 166.4 1.1 0.865 
succinate 1774.6 881.8 0.5 0.213 
fumarate 1217.6 821.2 0.7 0.293 
malate 1736.0 1602.7 0.9 0.798 
2-hydroxyglutarate 78.7 66.8 0.8 0.244 
Glycolysis  
glucose-6-phosphate 627.2 95.8 0.2 0.142 
glucose-1-phosphate 148.8 40.3 0.3 0.155 
DHAP (Di-OH-acetone-P) 8.0 5.7 0.7 0.344 
3-phosphoglycerate 179.0 81.6 0.5 0.145 
2-phosphoglycerate 19.1 10.2 0.5 0.102 
lactate 1324.5 1146.1 0.9 0.334 
pyruvate 372.6 320.0 0.9 0.775 
Amino Acids         
alanine 1480.9 1883.4 1.3 0.212 
glycine 1736.9 1067.5 0.6 0.081 
serine 7575.8 9526.0 1.3 0.250 
lysine 97.3 65.9 0.7 0.352 
valine 4385.8 2927.1 0.7 0.043 
leucine 1615.2 561.2 0.3 0.099 
isoleucine 1722.6 976.2 0.6 0.011 
threonine 2800.2 2803.6 1.0 0.993 
glutamate 11672.1 8418.7 0.7 0.011 
glutamine 4544.9 2449.5 0.5 0.128 
proline 227.8 179.6 0.8 0.289 
2-hydroxyyproline 4.6 2.6 0.6 0.138 
aspartate 5407.4 6138.3 1.1 0.596 
methionine 763.8 707.2 0.9 0.742 
phenylalanine 2026.6 954.7 0.5 0.025 
tryptophan 9.2 0.6 0.1 0.195 
tyrosine 31.9 31.5 1.0 0.956 
ornithine 19.0 8.2 0.4 0.036 
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Table 2.4. (continued) 
 
Fatty Acids (nonesterified) 
Metabolite NCD HFD HFD-fold change p-value 
phosphoethanolamine 1096.7 681.0 0.6 0.016 
decanoic acid 44.8 26.0 0.6 0.048 
lauric acid 92.5 60.8 0.7 0.063 
myristic acid 53.4 39.5 0.7 0.028 
palmitiladic acid 195.0 64.2 0.3 0.009 
palmitate 10610.1 6250.1 0.6 0.045 
linoleic acid 988.1 657.6 0.7 0.036 
oleic acid 636.1 565.3 0.9 0.493 
elaidic acid 106.7 99.1 0.9 0.789 
stearate 6492.4 4800.5 0.7 0.165 
arachidonic acid 24.1 9.1 0.4 0.313 
arachidic acid 53.0 34.3 0.6 0.021 
pantothenoic acid 496.0 321.5 0.6 0.031 
Cabohydrates         
glucose 26897.0 23031.1 0.9 0.337 
fructose 59.9 50.9 0.8 0.339 
galactose or isomer 5.3 3.5 0.7 0.047 
gluconic acid 27.9 12.1 0.4 0.0005 
inositol 12634.3 5948.0 0.5 0.001 
Cholesterol, Purine-Pyrimidine,and Small Metabolites   
Cholesterol 1802.4 1799.8 1.0 0.996 
monostearin 2525.3 1928.9 0.8 0.219 
creatinine 1637.0 1428.9 0.9 0.447 
adenosine 1134.3 494.3 0.4 0.122 
uracil 59.6 38.0 0.6 0.102 
cytosine 172.9 135.8 0.8 0.076 









compared to NCD controls: valine (0.7 fold, p=0.043), isoleucine (0.6 fold, p=0.011), and 
leucine (0.3 fold, p=0.099). The GC-MS analysis of the metabolites did not show any 
anticipated increase in the level of free fatty acids in the hearts of HFD animals.  
 
 
2.3.5. Insulin-stimulated AKT signaling was preserved  
in the hearts of HFD mice 
To examine if 12 weeks of HFF alters insulin signaling in the mouse heart, insulin-
stimulated AKT phosphorylation was assessed by western blot in the heart of HFD 
animals injected via IVC with insulin or saline and compared to NCD controls (Figure 
2.2). Insulin significantly increased AKT phosphorylation both in NCD and HFD groups 
relative to respective saline controls as  assessed by pAKT-S473/AKT fold change 
(NCD-saline: 1.0  ± 0.061, NCD-insulin: 27.27 ± 2.157, HFD-saline: 0.82 ± 0.079, and  
HFD-insulin: 22.59 ± 1.438). However, no significant difference was observed in insulin-
stimulated AKT phosphorylation between NCD and HFD groups, meaning that HFF did 
not alter insulin signaling through AKT in the mouse heart. Furthermore, basal AKT 
phosphorylaton was also similar between the two groups.   
 
 
2.3.6. High-fat feeding regulates cardiac autophagy in mice 
In the heart, the role of autophagy and its mechanistic regulation following HFF are 
unclear from previous studies (Xu and Ren, 2012). To understand the mechanism of 
regulation of cardiac autophagy upon HFF, changes in autophagy markers and pathway 

















Figure 2.2. Basal and insulin stimulated AKT signaling in the heart are not altered by 
high-fat feeding. Mice fed with either NCD or HFD for 12 weeks were administered 
saline or 0.01 U insulin via IVC injection. (A) Insulin signaling through AKT was 
assessed in the heart by immunoblotting. (B) Graph represents the data quantified from 









2.3.6.1. High-fat feeding alters autophagy markers in the heart 
12 weeks of HFD in mice significantly increased autophagy in the heart compared 
NCD controls. The western blot showed that LC3-II level, measured by LC3-II/GAPDH 
fold change, was increased by 40% in HFD hearts compared to NCD hearts (Figure 
2.3.A) (NCD: 1.0 ± 0.082, HFD: 1.4 ± 0.025). Consistent with western blot data, HFF 
increased cardiac autophagosome abundance as evidenced by a 2.5-fold increase in the 
number of mCherry-LC3-positive puncta in the heart sections of HFD- MCLC3 mice 
compared to NCD-MCLC3 mice (Figure 2.3.B).  
 
 
2.3.6.2. High-fat feeding-induced changes in autophagy is  
independent of canonical autophagy-induction pathways  
Insulin signaling through AKT is known to suppress autophagy through mTORC1 
activation (Kanazawa et al., 2004). To determine if an increase in autophagy upon HFF is 
due to an impairment in insulin signaling through AKT, and its downstream targets in 
autophagy FoxO1 and FoxO3 were assessed by western blotting. The data show that 
phosphorylation of AKT (at T-308 and S-473) was normal in the heart of HFD mice, 
suggesting normal AKT kinase activity (Figure 2.4.A). Downstream of AKT, FoxO1 
(T24) and FoxO3 (T32) phosphorylation was also intact in HFD hearts. These data 
suggest that canonical Insulin-AKT-FoxO1 signaling regulating autophagy remains 
normal in HFD hearts and is unlikely to regulate HFD-induced autophagy. Autophagy is 
also induced by AMPK in the heart under various conditions including glucose 
deprivation. Since glucose uptake in the heart was impaired by 10 weeks of HFF in our 






Figure 2.3. Increased autophagic abundance in the heart of HFD mice. (A) 
Representative western blots of the autophagy proteins LC3-I, LC3-II, Beclin1, and p62, 
and lysosomal hydrolase Cathepsin D (CatD) from the total heart homogenates of NCD 
or HFD mice. GAPDH was used as a normalizer. Graphs represent mean ± SEM. 
*p=0.0042 vs. NCD, n=9-11. (B) Representative confocal microscopic images of 
transverse sections of the heart from NCD or HFD mice expressing cardiac specific 
mCherry-LC3. The red puncta represent mCherry-LC3 positive autophagosomes and 
autolysosomes. The nuclei were counterstained blue with Hoechst 33342. Scale bar is 50 












Figure 2.4. High-fat diet-induced autophagy is not regulated by canonical autophagy 
signaling pathways. (A) Representative western blots of key signaling molecules 
regulating initiation of autophagy. Posttranslational modifications by phosphorylation of 
proteins regulating autophagic initiation were analyzed in the whole heart homogenate of 
mice fed with NCD or HFD for 12 weeks (n=7-9). GAPDH was used as a normalizer. (B) 
The mRNA level of autophagic genes in the heart from NCD and HFD mice (n=4-5). The 












phosphorylation of AMPK in HFD hearts was similar to that in NCD hearts, suggesting 
an AMPK-independent autophagic regulation by HFF (Figure 2.4.A).  
Transcriptional regulation of autophagic genes by FoxO is also known to induce 
autophagy in the heart (Sengupta et al., 2009). To examine if HFD induced autophagy is 
regulated at the transcriptional level, mRNA levels of autophagic genes under direct 
control of FoxO transcriptional activity were examined by qRT-PCR (Figure 2.4.B). The 
data indicate that the expression level of all the autophagic genes examined remained 
unchanged in HFD hearts compared NCD hearts. These data suggest that FoxO does not 
regulate autophagic gene expression in the heart of HFD mice. This is consistent with a 
lack of change in FoxO1 and FoxO3 phosphorylation as assessed by western blot.  
 
 
2.3.6.3. High-fat diet-induced autophagy is independent of  
changes in mTOR signaling  
As described earlier, mTORC1 forms a critical node converging multiple upstream 
signaling to regulate autophagy in response to various stimuli. The mTORC1 activation 
inhibits autophagy, whereas its suppression enhances the process. The regulation of 
mTOR signaling was examined in the heart of NCD or HFD animals. Consistent with 
increased autophagy, phosphorylation of mTOR was repressed in HFD hearts by ~ 34% 
compared to controls (NCD: 1.0 ± 0.116, HFD: 0.66 ± 0.036) (Figure 2.5.A).  The 
decrease in mTOR phosphorylation was accompanied by the reduced phosphorylation of 
mTOR targets. The phsophorylation of Ulk1 at S757 was decreased by ~ 40% (NCD: 1.0 
± 0.123, HFD: 0.6 ± 0.059) and of ribosomal protein S6 was reduced by ~ 69% (NCD: 











Figure 2.5.  Regulation of cardiac autophagy by high-fat feeding is independent of 
changes in mTOR signaling. (A) Mice fed with either NCD or HFD for 12 weeks were 
analyzed for mTOR signaling in the heart by western blotting. Representative blots of 
total and phosphorylated proteins are shown. *p<0.05 vs. NCD, n=4-5. (B) Mice fed with 
NCD or HFD for 12 weeks were injected daily with BCAA solution for the last 2 weeks 
and analyzed for indicated proteins by western blotting. *p<0.05 vs. NCD-PBS, n=4-5. 








The downregulation of mTOR signaling was consistent with decreased levels of 
BCAA in the heart (Table 2.3 and section 2.3.4) and in the serum (Table 2.4 and section 
2.3.5) of HFD mice. The lower level of BCAA could contribute to the suppression of 
mTOR activity, which in turn induces autophagy. To determine if HFD-induced 
autophagy is regulated by mTOR, mTOR signaling was stimulated by injecting mice with 
a BCAA solution. Western blot analysis showed that mTOR signaling was induced in 
hearts of both NCD and HFD fed mice upon BCAA injection compared to phosphate 
buffered saline (PBS)-injected controls (Figure 2.5.B). The phosphorylation of mTOR 
target S6 was significantly increased in BCCA injected NCD or HFD mouse hearts 
compared to controls (NCD-PBS: 1.0 ± 0.231, HFD-PBS: 0.4 ± 0.067, NCD-AA: 3.9 ± 
0.698, HFD-AA: 2.8 ± 0.260). However, despite activation of mTOR signaling, 
autophagy assessed by LC3-II levels in HFD mice remained significantly induced even 
after mTOR signaling was induced by BCAA (NCD-PBS: 1.0 ± 0.058, HFD-PBS: 1.6 ± 
0.058, NCD-AA: 2.8 ± 0.548, HFD-AA: 2.8 ± 0.200). Unexpectedly, BCAA treatment 
was associated with higher LC3-II despite induced mTOR phosphorylation in NCD mice. 
 
 
2.3.6.4. High-fat diet-induced autophagosomal abundance is  
secondary to impaired autophagosome turnover 
The major signaling pathways known to induce autophagic initiation either remained 
intact or were altered independently of any changes in HFD-induced autophagy. Since 
autophagic abundance is also increased by the reduced rate of autophagosome 
degradation independently of changes in autophagic initiation, we examined if 
autophagosome turnover is impaired in the heart by HFF. Autophagosome degradation in 
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the lysosome was blocked by increasing lysosomal pH (lysosomal basification) with CQ. 
Lysosomal basification blocks the activity of lysosomal hydrolases/proteases which work 
optimally at an acidic pH. CQ injection led to a significant increase in the level of the 
autophagy marker LC3-II in NCD hearts compared to control NCD hearts (NCD-cont:  
1.0 ± 0.309, NCD-CQ: 2.04 ± 0.091) (Figure 2.6). However, CQ treatment did not cause 
any additional increase in LC3-II levels in HFD mice compared to control HFD mice 
(HFD:  1.95 ± 0.391, HFD-CQ: 2.15 ± 0.027). These results suggest that the increased 
autophagic abundance in the heart upon HFF was primarily due to impaired degradation 
of autophagosomes and that CQ treatment could not further impair the turnover process 
so that no further accumulation of autophagosomes occured.  
 
 
                                               2.4. Discussion 
Obesity is a common risk factor in various cardiac pathologies such as ischemic 
heart disease, hypertension, CVD, heart failure, and diabetic cardiomyopathy. Autophagy 
is highly-regulated under these pathological conditions (Mellor et al., 2013a; Nemchenko 
et al., 2011). Yet, the mechanism by which obesity regulates autophagy is not clearly 
defined. Our preliminary studies in insulin resistant porcine model and on diabetic human 
subjects showed increased autophagosomes independent of changes in insulin and mTOR 
signaling. Other studies also observed a dissociation between autophagy and mTOR 
signaling in the heart (Li et al., 2012; Xu et al., 2013). In this study we tested the 
hypothesis that autophagic abundance in the hearts of HFD mice is primarily due to the 





















Figure 2.6. Impairment of autophagic turnover in the HFD murine heart. Mice fed either 
HFD or NCD were injected with or without chloroquine (CQ) for 3 days prior to harvest. 
Representative western blots for LC3-I, LC3-II and GAPDH in total heart homogenates 








Twelve weeks of HFD significantly increased body weight in mice in parallel with 
elevated circulating levels of TGs, FFAs, fasting blood glucose, insulin, and leptin. 
Metabolomics analyses of serum showed a trend towards an increase in both saturated 
and unsaturated fatty acid levels in HFD mice. Additionally, HFD mice exhibited marked 
ectopic deposition of fat in various tissues including liver, kidney, and intestinal linings 
together with increased deposition of both visceral and subcutaneous fat (data not 
shown). In the heart, the HFF significantly increased heart weight and TG levels without 
increasing CM size and fibrosis.  Furthermore, we observed a marked decrease in several 
key glycolytic pathway intermediates in the metabolomics analyses of HFD hearts, which 
is consistent with our previous finding of reduced glucose uptake and utilization in the 
heart of HFD mice (Wright et al., 2009). However, insulin signaling through AKT 
remained intact in HFD hearts. This implies that myocardial insulin signaling may remain 
preserved despite a systemic impairment in insulin action. In summary, our HFD mice 
displayed all the major hallmarks of the metabolic syndrome.  
 HFD also led to a significant increase in levels of the autophagy protein LC3-II and 
accumulation of mCherry-LC3 positive autophagosomes in the heart. The abundance of 
autophagy markers is influenced by the rate of autophagosome formation and their 
turnover in lysosomes. Analysis of major metabolic signaling pathways regulating 
autophagosome formation revealed that signaling through upstream molecules such as 
AKT, FoxO1and FoxO3, and AMPK remained normal in the HFD heart. Recent studies 
suggest transcriptional activation of autophagic genes as a mechanism of inducing 
autophagy. The analysis of autophagic gene expression by qRT-PCR showed no 
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difference in the transcript level of core autophagic genes. These data imply that 
autophagosome formation might not be perturbed in HFD hearts.    
Since mTOR can be directly regulated by nutrients such as amino acids independent 
of AKT, we examined mTOR signaling in the heart in response to HFF. Western blot 
analyses showed blunted mTOR signaling upon HFF as evidenced by reduced 
phosphorylation of mTOR and its downstream targets. Likewise, the levels of BCAAs 
activating mTOR were also reduced in serum and the heart of HFD-mice. However, 
administration of BCAAs, despite inducing mTOR signaling, failed to suppress 
autophagy, indicating an mTOR independent autophagic induction by HFF. Complete 
blockade of autophagic turnover by CQ did not increase autophagic abundance above that 
caused by HFF. Together, this study showed that accumulation of autophagosomes in 
HFD mouse hearts was primarily due to impairment in the degradation of 















PALMITATE INCREASES AUTOPHAGOSOME  
ABUNDANCE BY IMPAIRING 














Obesity has long been known as an independent risk factor for the development of 
CVD (Hubert et al., 1983; Lavie et al., 2009). Excessive caloric intake and a sedentary 
lifestyle contributes to obesity and insulin resistance, and elevate circulating levels of 
TGs and FFAs. Chronic exposure to high levels of energy substrates can have a 
deleterious effect (“ lipotoxicity” ) on the myocardium due to the formation toxic lipid 
intermediates such as ceramide, DAG, and ROS (Wende and Abel, 2010). Studies in 
transgenic mice overexpressing the cardiac-specific fatty-acid transporter showed that 
ectopic lipid accumulation itself could induce lipotoxic cardiomyopathy and premature 
cell death independently of any systemic metabolic effects of obesity (Chiu et al., 2001). 
The heart initially attempts to minimize lipotoxicity by inducing FAO and channeling 
excess lipids towards relatively inert TG droplets (Goldberg et al., 2012). Recent studies 
in mouse models uncovered that autophagy represents a novel mechanism important in 
regulating lipid metabolism in multiple tissues such as liver, adipocytes, neurons, and 
pancreatic beta cells (Ebato et al., 2008; Kaushik et al., 2011; Shibata et al., 2009; Singh 
et al., 2009a; Singh et al., 2009b). However, the role of autophagy in cardiac lipid 
metabolism and its regulation in a lipid-overloaded heart is poorly understood.  
High circulating levels of fatty acids have been shown to regulate autophagy in 
animal models of diabetes and DIO in a tissue dependent manner. In pancreatic beta cells, 
autophagy is induced in both diabetic (db/db) and nondiabetic high-fat fed mice and is 
essential for maintaining islet homeostasis (Ebato et al., 2008). In contrast, hepatic 
autophagy is suppressed in high-fat fed, insulin-resistant mice (Liu et al., 2009). In the 
heart, autophagy is differentially regulated under numerous pathological conditions 
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including ischemic injury, hypertensive heart disease, and heart failure, with both 
beneficial and detrimental outcomes (Gustafsson and Gottlieb, 2009; Wang et al., 2010b). 
However, the regulation of cardiac autophagy and its role in obesity and diabetes is 
controversial. A previous study revealed an inhibition of cardiac autophagy by the 
activated mTOR complex1 (mTORC1) in HFD mice (Sciarretta et al., 2012b). In 
contrast, studies on two mouse models of type-2 diabetes (db/db and RCS10) reported an 
increase in markers and mediators of autophagy  (Wellnitz, 2009). Induction of 
autophagy markers was also observed in HFD murine hearts despite mTORC1 activation 
(Xu et al., 2013). While the basis for these discrepant results is not clear, accumulating 
evidence suggest that the magnitude and direction of autophagic regulation are highly 
dependent on the duration of HFF, composition of fatty acids in the diet and to 
differences in genetic background strain (Mei et al., 2011; Papackova et al., 2012). 
Moreover, many of these studies based their conclusion on a static observation of the 
dynamic process of autophagy. In fact, in vitro studies in pancreatic beta cells suggest 
that saturated fatty acids invoke a highly fluctuating biphasic autophagy response 
(Komiya et al., 2010; Las et al., 2011). In the present study, we examined the dynamic 
regulation of autophagy by lipid overload in CMs. Our study identified a novel 
mechanism whereby lipid overload impairs the lysosomes’ ability to degrade 







                                              3.2. Methods 
3.2.1. Cell culture and reagents 
H9C2 (rat embryonic cardiomyoblasts, ATCC) and Ad-293 (Agilent) cells were 
maintained in Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen) with 25 mM 
glucose and 10% fetal bovine serum (FBS) (Thermo Scientific). H9C2 cardiomyoblasts 
were differentiated in DMEM with 5 mM glucose and 1% FBS for 5 days. Lysosomal 
acidification was inhibited with 80 M chloroquine (Sigma), de-novo ceramide synthesis 
with 50 µM myriocin (Sigma), and CPT1 with 50 µm etomoxir (Sigma). NADPH 
oxidase isoform 2 (Nox2) activity was inhibited with 10 mM apocynin (4′-hydroxy-
3′methoxyacetophenone), total PKC activity with 2 µM GF109203x, and classical and 
novel PKC-isoform specific activities with 2 µM Gö6976 and 10 µM rottlerin, 
respectively. Cellular superoxide was scavenged by treating cells with 10 mM tiron.   
 
 
3.2.2. Free fatty acid (FFA)-bovine serum albumin (BSA)  
complex solution 
Solutions of FFA complexed with BSA were prepared essentially as previously 
described (Cousin et al., 2001). Briefly, a 100 mM stock solution of FFA was prepared in 
0.1 M NaOH at 70oC. The stock solution was mixed with a 20% (w/v) solution of FFA-
free BSA (Sigma) at 50oC to prepare a 10 mM FFA-20% BSA complex solution. The 
solution was added to a desired concentration in DMEM with 5 mM glucose and 10% 
FBS and used immediately after filtration. For vehicle control, cells were incubated with 




3.2.3. Viral transductions 
Adenovirus expressing GFP-LC3 and a retroviral expression vector for mCherry-
GFP-LC3 were kindly provided by Dr. Roberta Gottlieb and Dr. Eric Adler, (University 
of California, San Diego), respectively. Viruses were generated and amplified in Ad-293 
cells. Adenoviruses were partially purified by repeated freeze-thaw in a 10% glycerol 
solution in PBS followed by centrifugation at 5000 rpm for 5 min. Viral supernatant was 
titered and used to transduce cells as described (Huang et al., 2010). All subsequent 
treatments were performed 18 h posttransduction. For retroviral transduction, viral 
supernatant of Ad-293 cells was filtered through 0.45-M-pore filter and added to H9C2 
cell culture medium supplemented with 4 g/ml polybrene (Millipore). Stably transduced 
cells were obtained by selection against puromycin (5 g/ml; Invitrogen). 
 
 
3.2.4. Western blot analyses 
Total proteins were extracted from cells in a lysis buffer containing 50 mM HEPES 
(pH 7.5), 150 mM NaCl, 10% Glycerol, 1% Triton X-100, 1.5 mM MgCl2, 1 mM EGTA, 
10 mM Sodium Pyrophosphate, 100 mM Sodium Fluroride, and 1X Halt protease and 
phosphatase inhibitor cocktail (Thermo Scientific), and analyzed by western blotting as 
described previously (Riehle et al., 2011). Antibodies against LC3 and alpha-Tubulin 
(Sigma); phospho and total mTOR, AKT, and S6 (Cell Signaling); phospho-Ulk1 and 
GAPDH (Cell Signaling); Ulk1, p62 (SQSTM1), and Cathepsin D (Santa Cruz); Lamp1 





3.2.5. Measurement of apoptosis 
Apoptosis was assessed in H9C2 cardiomyocytes (CMs) using FITC Annexin V 
Apoptosis Detection Kit with PI (BioLegend) following supplier’s protocol. Briefly, 
following each treatment, cells were washed and resuspended in a staining buffer, stained 
with FITC-Annexin V and propidium iodide (PI) for 15 min at room temperature, and 
subsequently analyzed by flow cytometry using appropriate filters.  
 
 
3.2.6. Fluorescence microscopy 
For live cell imaging, cells were plated on an 8-chamber coverglass (Lab-Tek, 
Nunc). Lysosomes were stained with 75 nM LysoTracker Red for 30 min or with 1 M 
LysoSensor Yellow/Blue (Invitrogen) for 10 min and placed in an on-stage humidified 
incubator at 37oC for image acquisition.  For GFP-LC3 and mCherry-GFP-LC3 
fluorescence, cells were fixed in 4% PFA. For other immunofluorescence, cells were 
blocked/permeabilized in 5% goat serum/5% horse serum/0.2% TritonX-100 following 
fixation. Fixed cells were stained with anti-Lamp1, anti-Tom20 (Santa Cruz), or anti-
Ceramide (Enzo Life Sciences) primary antibody (1:250 dilution) for 1 h at 37oC and 
with Alexa Fluor-conjugated secondary antibodies (1:500 dilution; Invitrogen) for 1 h at 
room temperature. Cell nuclei were counterstained with DAPI (Invitrogen). Images were 
obtained using an Olympus IX80 FV 1000 confocal microscope equipped with 
appropriate lasers. Quantification of GFP-positive puncta and other fluorescent intensity 
was performed from a minimum of three randomly selected sections per sample with 50 




3.2.7. ATP measurement 
Total ATP content in cells was measured by a bioluminescence assay based on the 
luciferase/luciferin reaction using the ATP assay system kit (Thermolabsystems) 
following supplier’s protocol.  
 
 
3.2.8. Lysosomal enzyme activity 
Cathepsin L activity was examined by staining live CMs with Magic Red Cathepsin 
L substrate (Immunochemistry Technologies) for 1 h at 37oC following supplier’s 
protocol. Fluorescent images were acquired as described earlier. Crude lysosomal 
fractions, prepared as described (Parent et al., 2009), were used to measure beta- 
galactosidase activity using mammalian beta-galactosidase assay kit (Thermoscietific) 
and beta-hexosaminidase activity as described previously (Vaidyanathan et al., 2001). 
 
 
3.2.9. Superoxide measurement by ESR spectroscopy 
Following each treatment, cells were washed and incubated for 30 min at 37oC with 
1M HEPES buffer (pH 7.4) containing 25 M deferoxamine mesylate and 0.2 mM 1-
Hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine, HCl (CMH; Alexis Corp, 
USA) to trap superoxide as CMH-free radical adduct. The cell sample was homogenized 
and aspirated into a capillary tube for the detection of the adduct by electron spin 
resonance (ESR) spectroscopy. ESR spectra were recorded using a Brüker EMX micro 
EPR spectrometer with the following settings: center field, 3511G; field sweep, 70 G; 
microwave frequency, 9.85 GHz; microwave power, 20 milliwatts; modulation 
77 
 
amplitude, 0.5G; conversion time, 5.0 ms; time constant, 1.28 ms; resolution, 1400 
points; and receiver gain, 50dB. 
 
 
3.2.10. Statistical analyses 
All data are presented as mean ± SEM. Unpaired Student’s t-test was performed to 
determine p-values when comparing between two groups. 1-way Analysis of variance 
(ANOVA) was used to compare data across multiple groups with one independent 
variable. Multiple groups with two or more independent variables were analyzed by 2-
way ANOVA. Statistical significance was determined by Bonferroni’s post-hoc analysis 
using the GraphPad Prism 5 software (La Jolla, CA). For all analyses, p<0.05 was 




3.3.1. Acute palmitate treatment regulates autophagy with  
no cytotoxic effect 
To study the regulation of autophagy in lipid overload, H9C2 CMs were first 
incubated with 250 to 1000 M of palmitate, the most abundant saturated circulating 
FFA, for 2-8 h. Treatment with 500 M palmitate for 4 h resulted in the maximal 
increase in the autophagy marker protein LC3-II in the absence of ER stress and cell 
death (data not shown). Next, we examined if palmitate treatment exhibits time-
dependent autophagic response as recently reported in pancreatic beta cells (Komiya et 
al., 2010; Las et al., 2011). As shown in Figure 3.1.A, palmitate induced a biphasic 









Figure 3.1. Short-term palmitate treatment regulates autophagy in H9C2 CMs without 
cytotoxicity. (A) H9C2 CMs were incubated with vehicle or 500 µM palmitate at 
indicated time points and autophagy was monitored by analyzing the levels of LC3-II 
normalized to GAPDH in total cell lysates. Graph represents mean ± SEM. *p<0.05 vs. 
vehicle (n=3). (B-C) H9C2 CMs were incubated with either vehicle or 500 µM palmitate 
for 4 h. Following vehicle or palmitate treatment, CMs were either stained with Annexin-
V/FITC and propidium iodide (PI) and analyzed by flow cytometry (B), or examined for 
DNA fragmentation (C). CMs treated with 10 mM H2O2 for 1 h were used as positive 
controls. (D) Total ATP content in CMs treated with vehicle or palmitate (n=6). (E) 
Representative LC3-I and II immunoblots from CMs incubated with vehicle or palmitate 
for 4 h (a and b, respectively) and subsequently replaced with normal growth medium for 







dropping to baseline before being increased rapidly after 8 h. As such, we chose to 
perform all subsequent experiments with 500 µM palmitate and 4-h incubation to study 
the mechanism of initial, preclinical regulation of autophagy in response to lipid overload 
without the confounding effect of cytotoxicity.  
To verify that our treatment caused no cytotoxicity, we examined markers of 
apoptosis and necrosis in H9C2 CMs following palmitate treatment. Flow cytometric 
analysis of CMs stained with FITC-Annexin V and propidium iodide (PI) showed no 
difference in staining between vehicle and palmitate treated CMs. In contrast, CMs 
incubated with exogenous H2O2 as positive control showed a clear increase in Annexin V 
binding and PI positivity (Figure 3.1.B). Accordingly, examination of genomic DNA in 
vehicle and palmitate treated CMs exhibited no DNA laddering, a characteristic of 
apoptotic cell death, whereas H2O2 treatment significantly increased genomic DNA 
laddering in CMs (Figure 3.1.C). Moreover, we measured ATP level in H9C2 CMs since 
changes in cellular ATP level have been shown to induce apoptotic and necrotic cell 
death (Eguchi et al., 1997; Tsujimoto, 1997). As shown in Figure 3.1.D, we did not 
observe any change in total ATP content by palmitate treatment. Together, these data 
indicate that 4 h of palmitate treatment alters autophagy in H9C2 CMs without inducing a 
cytotoxic effect. Finally, when CMs pretreated with palmitate were returned to normal 
growth medium, autophagy was restored to basal levels by 8 h (Figure 3.1.E), and total 
cellular protein content was comparable with CMs pretreated with vehicle (data not 
shown), suggesting that palmitate-dependent autophagy is a transient, reversible process 




3.3.2. Palmitate impairs autophagosome turnover  
The metabolic status of a cell is a critical factor in the regulation of autophagy. In the 
normal fed state, insulin signaling pathway suppresses autophagy in the heart (Mellor et 
al., 2013b); however, insulin action in the heart progressively declines under conditions 
of lipid overload as in genetic and dietary mouse models of obesity (Abel et al., 2012). 
To explore the potential mechanisms whereby lipid overload by palmitate alters cardiac 
autophagy, we examined upstream metabolic signals known to regulate the autophagic 
initiation process. As shown in Figure 3.2, insulin signaling through Akt-phosphorylation 
(at S473) remained intact in palmitate-treated CMs compared with vehicle controls. Since 
mTOR can be regulated by both Akt dependent and independent pathways, we assessed 
mTOR signaling in palmitate-treated CMs. Interestingly, phosphorylation of mTOR (at 
S2448) and its downstream target in autophagy, Ulk1 (at S757), were unaffected by 
palmitate. The classical mTOR target ribosomal protein S6 phosphorylation also 
remained preserved in palmitate-treated CMs. Additionally, AMPK, an important kinase 
sensing cellular energy status, is also known to upregulate autophagy by activating Ulk1 
and inhibiting mTOR. Like AKT and mTOR signaling, we did not observe any change in 
AMPK signaling in palmitate-treated CMs as assessed by phosphorylation of AMPK (at 
T172) and its target Ulk1 (at S555). These data indicate that canonical upstream signaling 
pathways regulating autophagy in insulin sensitive tissues remained normal following 
short-term palmitate treatment. Therefore, the observed increase in autophagic markers in 
response to palmitate might not be primarily due to an induction of the autophagic 







Figure 3.2.  Palmitate-induced autophagy is independent of the canonical signaling 
pathways initiating autophagy.  H9C2 CMs were incubated with either vehicle or 500 µM 
palmitate for 4 h. Proteins involved in autophagy initiation signaling were analyzed by 
immunoblotting. Graphs represent mean ± SEM (n=3-6).  
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The accumulation of autophagic markers is consistent with either increased 
autophagosome formation or reduced turnover. In the absence of changes in major 
signaling pathways initiating autophagy, we explored autophogosome turnover as a 
potential step impacted by palmitate that leads to autophagosome accumulation.  
Autophagosome turnover in vehicle or palmitate treated CMs was completely blocked by 
chloroquine (CQ) treatment for the last 1 h of incubation. While palmitate alone 
significantly increased LC3-II level, CQ treatment further increased accumulation of 
LC3-II under both conditions (vehicle: 1.0 ± 0.146, palmitate: 2.5 ± 0.113, vehicle+CQ: 
3.4 ± 0.037, palmitate+CQ: 4.5 ± 0.176) (Figure 3.3.A). Interestingly, upon CQ addition, 
the fold increase in vehicle-treated CMs was much higher (~3.5 fold) than in palmitate-
treated CMs (~1.8 fold) compared with respective non-CQ treatments. These data suggest 
that the palmitate-induced increase in LC3-II may primarily be due to partial impairment 
in autophagosome turnover. Supporting this notion, the adapter protein p62 (SQSTM1), 
which is degraded by autophagy, remained higher in palmitate-treated CMs, and, 
expectedly, in CQ-treated CMs under both conditions. To validate our observation, we 
repeated palmitate and CQ treatment in H9C2 CMs expressing adenoviral GFP-LC3, and 
scored GFP-positive autophagosomes using fluorescence microscopy (Figure 3.3.B). 
Consistent with immunoblot data, palmitate treatment led to significantly higher numbers 
of GFP-positive puncta than vehicle treatment (vehicle: 4 ± 1.364, palmitate: 16 ± 2.273). 
However, CQ addition increased the number of puncta more robustly in vehicle-treated 
CMs than in palmitate-treated ones (vehicle+CQ: 47 ± 5.455, palmitate+CQ: 37 ± 3.636). 
Finally, we examined autophagosome abundance in H9C2 CMs stably expressing dual 



















Figure 3.3. Palmitate impairs autophagosome turnover in H9C2 CMs. (A-B) H9C2 CMs 
incubated with either vehicle (1% BSA) or 500 µM palmitate for 4 h in presence or 
absence of  80 µM Chloroquine (CQ) for the last 1 h were analyzed for LC3-I, LC3-II 
and p62 levels by immunoblotting. Data represent mean ± SEM. (n=6). (B and C) H9C2 
cells transiently expressing adenoviral GFP-LC3 (Ad GFP-LC3) (B), or stably expressing 
mCherry-GFP-LC3 (C) were incubated with vehicle or palmitate in presence or absence 
of CQ as described in panel A. (B) Confocal images showing distribution of Ad-GFP-
LC3 (green). Graph represents average number of GFP-positive puncta/cell ± SEM 
(n=6). (C) Confocal images showing GFP (green) and mCherry (red) fluorescence of 
mCherry-GFP-LC3. DAPI (blue) stains the nuclei. Scale bars represent 10 µm. p<0.05 






fluoresce in autophagosomes, but GFP fluorescence is quenched when autophagosomes 
fuse with lysosomes because of the acidic pH of the lysosomal lumen. As shown in 
Figure 3.3.C, vehicle treated CMs mostly exhibited mCherry punctae with no apparent 
GFP puncta, suggesting a rapid autophagosome turnover. In contrast, palmitate-treated 
CMs predominantly exhibited dual-fluorescent positive puncta, suggesting either 
increased formation of autophagosomes or defective nonacidic autolysomes. Inhibition of 
lysosomal acidification with CQ resulted in even greater accumulation dual-fluorescent 
puncta in both vehicle and palmitate treated CMs similar to one observed with palmitate 
alone. Together, our data support an impairment in autophagosome turnover as a 
potential mechanism for autophagosomal abundance in palmitate-treated H9C2 CMs.  
 
 
3.3.3. Palmitate induces autophagy in the absence of ER stress 
ER stress is a classical hallmark of obesity and diabetes in both humans and animal 
models (Boden et al., 2008; Cnop et al., 2012). Several experimental models of ER stress 
have been shown to induce autophagy in multiple cell types (Madaro et al., 2013; Nijholt 
et al., 2011; Ogata et al., 2006). Therefore, we tested if ER stress mediates or precedes 
palmitate-induced autophagy. Immunoblot analyses showed that proteins in two different 
unfolding protein response (UPR) pathways (IRE1-XBP1 and PERK-eIF2) involved 
in ER stress and autophagy were not altered following 4 h of palmitate treatment (Figure 
3.4). Changes in the UPR pathway were observed only after 8 h of palmitate treatment 
when phosphorylation of IRE1 and the active form of XBP1 (generated from alternative 






Figure 3.4. Autophagic response to palmitate is independent of ER stress. H9C2 CMs 
incubated with either vehicle or 500 µM palmitate for 4 h and 8 h were analyzed for 
proteins involved in UPR-mediated ER stress. Data represent mean ± SEM. p<0.05 vs. 









autophagy precedes ER stress in palmitate-treated H9C2 CMs. 
 
 
3.3.4. Palmitate-induced autophagy is independent of ceramide  
Ceramide is an important byproduct of palmitate metabolism and is known to 
mediate cytotoxic effects of palmitate in multiple cell types (Summers, 2006). Several 
studies have shown that ceramide promotes autophagy (Daido et al., 2004; Pattingre et 
al., 2009a; Scarlatti et al., 2004). To determine if ceramide plays a role in palmitate-
dependent autophagy, we first examined the level of ceramide in palmitate-treated H9C2 
CMs by indirect immunofluorescence using an anticeramide antibody. Consistent with 
previous findings, ceramide levels were significantly elevated (~2 fold) following 
palmitate treatment (Figure 3.5.A).  We then blocked de novo ceramide synthesis by 
inhibiting serine-palmitoyl transferase 1 (SPT1), an enzyme involved in ceramide 
biosynthesis with myriocin. While myriocin completely prevented palmitate-induced 
ceramide accumulation, it did not prevent palmitate-induced accumulation of the 
autophagy marker protein LC3-II (Figure 3.5.B). These data suggest that palmitate-
induced ceramide synthesis and autophagosome accumulation are independent processes, 
and ceramide does not mediate palmitate’s effect on autophagosomal abundance.  
 
 
3.3.5. Palmitate-induced autophagosome accumulation is  
dependent on superoxide 
Oxidative stress caused by high levels of reactive oxygen species (ROS) plays an 






Figure 3.5. Palmitate induced autophagosome accumulation is not mediated by ceramide. 
(A) CMs incubated with either vehicle or palmitate for 4 h in the presence or absence of 
50 µM myriocin were immunostained with anticeramide antibody and visualized by 
indirect immunofluorescence. p<0.0001 vs. vehicle, n=6. Number of CMs/n=50. Scale 
bar is 50 µm. (B) CMs treated identically as described in panel A were analyzed for LC3-









and diabetes (Marchi et al., 2013). In vitro studies have linked palmitate-induced 
accumulation of ROS to various lipotoxic effects of palmitate including apoptosis and 
insulin resistance (Kim et al., 2010; Yuzefovych et al., 2010). Recently, both 
palmitateand ROS have been shown to regulate autophagy in various cell types (Azad et 
al., 2009; Choi et al., 2009; Scherz-Shouval and Elazar, 2011; Tan et al., 2012; Wen et 
al., 2011). However, it is not entirely clear from these studies if ROS mediates palmitate-
dependent autophagy. To investigate the role of ROS in palmitate-dependent autophagy, 
we first determined the level and the identity of ROS generated by palmitate treatment in 
H9C2 CMs. Measurement of cellular ROS by flow-cytometry following DCFDA (2’,7’–
dichlorofluorescein diacetate) staining showed no difference between vehicle and 
palmitate treated CMs. Subsequent measurement by ESR spectroscopy using a specific 
spin probe revealed a massive increase in superoxide level (~3.8 fold) in palmitate-treated 
CMs compared to vehicle controls (Figure 3.6.A). Treatment with the generic superoxide 
scavenger tiron significantly lowered LC3-II level in palmitate-treated CMs (~ 35%) 
compared with palmitate-treated controls (palm-control: 3.2 ± 0.176, palm-tiron: 2.1 ± 
0.058) (Figure 3.6.B). However, basal autophagy was not affected by tiron treatment 
(veh-control: 1.0 ± 0.116, veh-tiron: 1.1 ± 0.088). Moreover, tiron treatment completely 
blunted palmitate-induced accumulation of GFP-positive autophagosomes (punctae) in 
H9C2 CMs (Figure 3.6.C). These data provide clear evidence that palmitate-induced 










Figure 3.6. Palmitate regulates autophagy in a superoxide dependent manner. (A) 
Superoxide production in H9C2 CMs incubated with either vehicle or 500 µM palmitate 
for 4 h and was measured by ESR using CMH as a superoxide spin trap probe. 
p<0.0001 vs. vehicle (n=5). (B) CMs were incubated with vehicle or palmitate in the 
presence or absence of 10 mM tiron for 4 h and analyzed for LC3-I and LC3-II by 
western blot. Data represent normalized LC3-II levels (n=6). p<0.001 vs. vehicle-control 
and p<0.05 vs. palmitate-control. (C) Confocal images of GFP-LC3 in Ad GFP-LC3 
expressing H9C2 CMs incubated with vehicle or palmitate in the presence or absence of 








3.3.6. Oleate reverses palmitate-induced autophagy  
The elevated circulating fatty acids as in obesity and diabetes are a mixture of 
various FFAs and their complex derivatives. To understand if palmitate-induced 
autophagy is specific to palmitate or a general effect of fatty acid overload, we incubated 
H9C2 CMs for 4 h with 500 M oleate– the most abundant circulating fatty acid in the 
body. Interestingly, autophagy remained normal in oleate-treated CMs as assessed by 
LC3-II immunoblot (Figure 3.7.A). Furthermore, superoxide level in oleate-treated CMs 
remained similar to vehicle controls (Figure 3.7.B). These data further support a 
superoxide-mediated regulation of autophagy in palmitate-treated CMs. Next, we 
examined if oleate can normalize palmitate-induced autophagy in H9C2 CMs. 
Coincubation with oleate not only reversed autophagic abundance in palmitate-treated 
CMs in a dose dependent manner but also restored autophagy to the basal level at an 
equimolar concentration of palmitate and oleate (Figure 3.7.C). These data suggest that 
palmitate exerts specific effect on autophagy. These data, therefore, uncovered a novel 
effect of oleate in reversing palmitate induced autophagy which may play a beneficial 
role in protecting cells from toxic effects of palmitate as described in previous studies. 
 
 
3.3.7. Lysosomal content and autolysosome formation  
are not affected by palmitate 
Transcriptional activation of autophagy and lysosomal genes by transcriptional factor 
EB (TFEB) plays a central role in starvation induced autophagy (Settembre et al., 2011). 
We examined if palmitate-dependent autophagic abundance involves altered transcription 






Figure 3.7. Oleate normalizes autophagy in palmitate-treated H9C2 CMs. (A and C) 
Western blots of LC3-I and LC3-II in H9C2 CMs treated with either vehicle or 500 µM 
oleate (A), or cotreated with 500 µM palmitate and varying concentration of oleate (ole) 
(C) for 4 h. Data represent fold change in LC3-II levels normalized to GAPDH (n=6, 
panel A n=3, panel C). *p<0.001 vs. vehicle alone. (B) Production of superoxide in H9C2 
CMs treated with either vehicle or 500 µM oleate was measured by ESR using CMH as a 









of mature autophagosomes. mRNA levels of genes involved in lysosomal biogenesis, 
acidification and function were determined by quantitative real-time PCR (qRT-PCR). As 
shown in Figure 3.8.A, lysosomal gene expression largely remained intact in palmitate-
treated H9C2 CMs. Accordingly, lysosome content, assessed by lysosome-associated 
membrane protein 1 (Lamp1) levels, was similar between vehicle and palmitate treated 
CMs (Figure 3.8.B). Recent studies have attributed defective autophagosome-lysosome 
fusion to increased autophagosome accumulation in pancreatitis and diabetic 
cardiomyopathy (Fortunato and Kroemer, 2009; Zhao et al., 2012). We examined if 
palmitate-induced autophagosome accumulation is secondary to impaired 
autophagosome-lysosome fusion. H9C2 CMs expressing Ad-GFP-LC3 were stained with 
LysotrackerRed in live cells or immunostained with Lamp1 antibody in fixed cells 
following palmitate treatment. Fluorescent micrographs revealed that most 
autophagosomes (GFP-punctae) colocalized positively with lysosomes (red punctae) both 
in live and fixed CMs (Figure 3.8-C and D, respectively), suggesting autophagosome-
lysosome fusion to form autolysomes remained intact in palmitate-treated CMs. 
 
 
3.3.8. Palmitate impairs lysosomal acidification and enzyme  
activity in a superoxide dependent manner 
Lysosomal pH (~4.5-5.0) is a key determinant of lysosomal enzyme activity.  In 
vitro studies have observed impairment in lysosomal acidification and enzyme activities 
in response to fatty acid, lipoprotein, and cholesterol overload (Cox et al., 2007; Las et 
al., 2011). We examined if lysosomal acidification and function were impaired in 






Figure 3.8. Lysosomal content and autolysome formation are not affected by palmitate 
treatment. (A-B) H9C2 CMs incubated with vehicle or 500 µM palmitate for 4 h were 
analyzed by qRT-PCR for mRNA levels of lysosomal genes normalized to cyclophilin A 
(A, n=5), and by western blot for Lamp1 (B, n=5). (C) Confocal images of GFP-LC3 in 
CMs expressing Ad GFP-LC3 following vehicle or palmitate treatment. Lamp1 was 
detected by indirect immunofluorescence. DAPI (blue) stains the nuclei. White arrows 
indicate puncta colocalized with GFP-LC3 and Lamp1. (D) Ad GFP-LC3 expressing 
CMs were incubated with vehicle or palmitate for 4 h and stained for lysosomes with 50 
nM Lysotracker Red for 30 min. White arrows represent puncta colocalized with GFP-













with the vital dye LysoSensor yellow/blue. The yellow fluorescence is pH independent, 
whereas blue fluorescence intensifies as lysosomal pH rises. Fluorescent micrographs 
showed that palmitate significantly increased lysosomal pH as evidenced by increased 
blue staining (Figure 3.9.A). Interestingly, lowering of superoxide levels with tiron 
completely abolished palmitate-induced alkalization of lysosomes, suggesting a 
superoxide-dependent impairment in lysosomal acidification in palmitate-treated CMs. 
We next examined the activity of cathepsin L (CatL), a lysosomal endopeptidase, in live 
CMs using MagicRed (MR), a CatL substrate which is cleaved by the enzyme into a red-
fluorescent product. Consistent with impaired lysosomal acidification, CatL activity was 
blunted in palmitate-treated CMs but not in vehicle controls (Figure 3.9.B). Importantly, 
palmitate-induced inhibition of CatL activity was reversed by tiron treatment. We further 
examined if lysosomal enzyme function per se is diminished by palmitate treatment 
possibly through a superoxide- mediated oxidative damage. However, the activity of two 
crudely-purified lysosomal hydrolases, β-galactosidase and β-hexosaminidase, remained 
preserved in palmitate-treated CMs (Figure 3.9.C). Collectively, our data demonstrated 
that palmitate impairs lysosomal acidification possibly by a mechanism that is secondary 
to enhanced superoxide production which in turn impairs pH-dependent activity of 
lysosomal enzymes.  
 
 
3.3.9. Palmitate does not alter mitochondrial superoxide  
production and mitophagy 
Mitochondria are major producers of ROS. ROS production by mitochondria rises to 



















Figure 3.9. Palmitate-induced impairment in lysosomal acidification and enzyme activity 
is superoxide dependent. (A) CMs incubated with vehicle or 500M palmitate in the 
presence or absence of 10 mM tiron for 4 h were subsequently incubated with either 
LysoSensor Yellow/Blue dye during the last 10 min and visualized by confocal 
fluorescence microscopy. The graph represents the ratio of LysoSensor blue to yellow 
fluorescence. (B) CMs preincubated with vehicle or palmitate and with or without tiron 
were treated with MR CatL substrate during the last 1 h of incubation and visualized by 
confocal microscopy. The graph represents MR intensity (AU) per cell.  (A-B) Data are 
presented as mean ± SEM, n=6. Number of cells/n=25. Scale bar is 20 µm. (C) Activities 
of lysosomal hydrolases β-galactosidase and β-hexosaminidase in crudely-purified 











contribute to their poor outcomes (Bugger and Abel, 2010; Sivitz, 2010). Numerous 
studies have recapitulated many of these features of mitochondria in cells overloaded 
with palmitate (Jheng et al., 2012; Yang et al., 2012; Yuzefovych et al., 2010). Growing 
evidence suggests that dysfunctional mitochondria are selectively cleared by mitophagy 
(mitochondria targeting autophagy) to protect cells from mitochondria-dependent 
oxidative stress and cell death (Gottlieb and Carreira, 2010; Kubli and Gustafsson, 2012). 
Therefore, we examined if palmitate-induced autophagy is mediated by mitochondrial 
superoxide. Mitochondrial superoxide was scavenged by transiently overexpressing 
mitochondria-targeted superoxide dismutase 2 (SOD2) in H9C2 CMs. Despite SOD2 
overexpression, palmitate-induced autophagic abundance was not attenuated (Figure 
3.10.A), suggesting a nonmitochondrial origin of superoxide mediating autophagy. Since 
the superoxide production from mitochondrial OXPHOS complexes requires substrate 
delivery to mitochondria, we inhibited carnitine palmitoyl transferase 1 (CPT1) with 
etomoxir to block the transfer of long-chain fatty acid substrates into the mitochondria. 
Surprisingly, etomoxir accentuated the palmitate-induced increase in LC3-II level in 
H9C2 CMs (Figure 3.10.B), ruling out a contribution of mitochondrial FAO to 
superoxide generation and palmitate-induced autophagy in H9C2 CMs. Finally, we 
evaluated for evidence for increased mitophagy in palmitate-treated CMs. If palmitate 
results in dysfunctional and depolarized mitochondria, mitophagy should be induced by 
palmitate. The phosphatase and tensin homolog-induced putative kinase 1 (PINK1)-
Parkin interaction is required for stress-induced mitophagy. Both proteins are stabilized 
in depolarized mitochondria and their level is increased in mitophagy (Kubli and 


















Figure 3.10. No evidence for mitochondrial superoxide production and mitophagy in 
palmitate-treated H9C2 CMs. (A) H9C2 CMs transfected with empty vector (pEmpty) or 
mitochondria-targeted SOD2 (pSOD2) were treated with vehicle or 500 µM palmitate for 
4 h and were immunoblotted for SOD2 and LC3-I and II. (B) H9C2 CMs treated with 
vehicle or palmitate as described in (A) and with or without 50 M etomoxir for 4 h were 
blotted for LC3-I and II. (C-D) H9C2 CMs treated with vehicle or palmitate for 4 h were 
immunoblotted for indicated proteins in the mitochondrial fraction (C) or in total cell 
lysate (D). Graph represents mean ± SEM. p<0.05 vs. vehicle, n=3. (B). Confocal 
microscopy of Ad GFP-LC3 (green) expressing H9C2 cells treated with vehicle or 
palmitate and subsequently incubated with anti-Tom20 antibody (red)  and DAPI (blue). 










Parkin levels were similar between vehicle and palmitate treated samples although LC3-
II was significantly increased upon palmitate treatment (Figure 3.10.C). Moreover, the 
level of mitochondrial resident proteins Hsp60 and SOD2, which are degraded by 
mitophagy, remained unchanged in total cell lysates upon palmitate treatment (Figure 
3.10.D). Lastly, when we immunostained H9C2 CMs expressing Ad-GFP-LC3 with the 
outer mitochondrial protein Tom20, we could not observe colocalization of 
autophagosomes (green punctae) with Tom20-positive mitochondria (red) upon palmitate 
treatment (Figure 3.10.E). Of note, we did not observe any changes in mitochondrial 
morphology in palmitate-treated CMs. Together, our data clearly showed that palmitate-
induced autophagy is independent of mitochondria. Neither mitochondrial superoxide 
production nor mitophagy was altered by palmitate treatment. 
 
 
3.3.10. Palmitate-induced autophagy is dependent on Nox2  
Besides mitochondria, plasma membrane-bound NADPH oxidases (Noxs) are a 
major source of superoxide in cells. Nox2 and Nox4 are the major isoforms expressed in 
the heart (Zhang et al., 2013). Exposure to palmitate has been shown to induce Nox-
derived superoxide production in cultured cells (Lambertucci et al., 2008; Maloney et al., 
2009; Morgan et al., 2007). However, if Nox is involved autophagy induced by lipid-
overload is not clear. Although previous studies relate ROS production to activation of 
autophagy, it is not clear if ROS is also involved in suppression of autophagic turnover as 
seen in our study. Therefore, we examined if increased superoxide production in 
palmitate-treated CMs is generated from Nox isoforms which could potentially be 
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involved in superoxide production, and if inhibiting Nox activity reverses palmitate-
effect on autophagy. 
Treatment with the Nox inhibitor Apocynin significantly reduced the accumulation 
of LC3-II in H9C2 CMs incubated with palmitate compared with untreated CMs (Figure 
3.11.A). To test if apocynin reduces LC3-II levels by improving lysosomal function, we 
measured lysosomal enzyme CatL activity using MR substrate in live CMs. Supporting 
our hypothesis, apocynin significantly improved CatL activity in palmitate-treated cells 
(Figure 3.11.B). Surprisingly, in vehicle-treated CMs, we observed a slight increase in 
LC3-II level and a modest decrease in CatL activity. This effect could be due to 
inhibition of NOX activity below the physiological level required for acidification of 
endosomal vesicles that mature into lysosomes as suggested previously (Lamb et al., 
2009). Although apocynin is primarily known to inhibit Nox2, it may also work as an 
antioxidant. To examine if Nox2 is specifically regulating palmitate-induced autophagy, 
we silenced Nox2 activity by siRNA mediated knockdown of its regulatory subunit 
p47phox. Consistent with apocynin data, silencing of Nox2 activity significantly lowered 
LC3-II level in palmitate-treated CMs (~31%) (Figure 3.11.C). Furthermore, knockdown 
of p47phox completely normalized the superoxide level in palmitate-treated CMs (Figure 
3.3.D). Taken together, our data illustrate that palmitate-induced autophagosome 
accumulation is mediated by increased Nox2 activity which leads to increased superoxide 


























Figure 3.11. Palmitate-induced autophagy is dependent on Nox2 activity. (A) H9C2 CMs 
were incubated with vehicle or 500 M palmitate for 4 h in presence or absence of 10 
mM apocynin and immunoblotted for LC3-II. Graph represents mean ± SEM (n=3). (B) 
CMs treated as described in (A) were incubated with MR Cat L substrate during the last 1 
h of incubation and visualized by confocal microscopy. Graphs represent MR intensity 
(AU) per cell. Data represent mean ± SEM, n=4. Number of cells/n=25-30. Scale bar is 
20 µm. p<0.05 vs. vehicle-control #p<0.05 vs. palmitate-control. (C-D) CMs transfected 
with scramble (scr) or p47phox siRNA for 48 h were incubated with vehicle or palmitate 
for 4 h. (C) Immunoblot analyses of LC3-II and p47phox in total cell lysate, and (D) 
superoxide level in whole cell homogenate measured by ESR using CMH as a superoxide 









3.3.11. Classical PKC isoforms link palmitate treatment  
to Nox2 activity and autophagy 
To identify molecular signals that may link palmitate treatment to Nox2 activation, 
we examined different classes of protein kinase C (PKC). Justification for these 
experiments are based on a series of observations. First, palmitate has been shown to 
activate different PKC isoforms based on cell types (Alcazar et al., 1997; Kewalramani et 
al., 2011; Wang et al., 2010a). A similar activation of different PKCs have been reported 
in humans and animal models with obesity and diabetes (Farese and Sajan, 2012; 
Geraldes and King, 2010; Itani et al., 2000; Qu et al., 1999). Second, activation of PKCs 
was observed in parallel with activation of various Nox isoforms, and inhibition of PKCs 
led to inhibition of Nox activity (Gupte et al., 2009; Herrera et al., 2010; Raad et al., 
2009; Siow et al., 2006). We incubated H9C2 CMs with different PKC inhibitors. 
GF109203x is a pan PKC inhibitor, whereas Gö6976 and rottlerin inhibit classical and 
novel classes of PKCs (Bynagari-Settipalli et al., 2012; Kontny et al., 2000). Immunoblot 
data show that generic inhibition of PKC had no significant effect on palmitate-induced 
autophagy (palm-control: 2.7 ± 0.124, palm-GF109203X: 2.3 ± 0.095) but led to an 
increase in LC3-II level in vehicle-treated CMs (veh-control: 1.0 ± 0.122, veh-
GF109203X: 2.4 ± 0.199) (Figure 3.12.A). Interestingly, inhibition of novel PKCs 
resulted in a robust increase in LC3-II level in both vehicle and palmitate treated CMs 
(veh-rottlerin: 4.9 ± 0.811, palm-rottlerin: 4.1 ± 0.344). In contrast, inhibition of only 
classical PKCs significantly blunted palmitate-induced autophagic accumulation in CMs 
(palm- Gö6976: 1.7 ± 0.034). Consistent with a role of PKC in activating Nox-dependent 

















Figure 3.12. Classical PKC isoforms mediate palmitate-induced Nox2 activation and 
autophagy. (A) H9C2 CMs were incubated with vehicle or 500 µM palmitate for 4 h in 
the presence or absence of total (GF109203x), classical (Gö6976), and novel (rottlerin) 
PKC inhibitors and analyzed for LC3-II by immunoblotting. Graph represents mean ± 
SEM.p<0.05 vs. vehicle-control #p<0.05 vs. palmitate-control (n=6). (B) CMs 
transfected with or without scrambled siRNA for 48 h were incubated with vehicle or 
palmitate for 4 h in the presence or absence of Gö6976. Superoxide levels were measured 
by ESR using CMH as a spin probe. Graph represents normalized ESR peak intensity ± 
SEM (n=4-9). (C) CMs incubated with vehicle or palmitate and with or without Gö6976 







completely prevented palmitate-induced superoxide production in H9C2 CMs (Figure 
3.12.B). Finally, immunoblot analyses of subcellular fractions showed that palmitate 
remarkably increased the translocation of p47phox subunit of Nox2 to the plasma 
membrane which is required for Nox2 activation (Figure 3.12.B). Treatment with 
Gö6976 partially blunted the p47phox membrane localization. These data support the 
involvement of classical PKCs in mediating palmitate-induced autophagosomal 




In this study, we demonstrated that lipid overload by palmitate increases cardiac 
autophagosome abundance primarily due to a defect in lysosomal function to degrade 
autophagic substrates. Studies on the regulation of cardiac autophagy in genetic and 
dietary models of obesity are limited. Accumulation of autophagic markers have been 
observed in models of DIO in parallel with hyperactivation of mTOR (Birse et al., 2010; 
Xu et al., 2012). However, the role of mTOR in regulating autophagy is not clear in these 
studies. In contrast, studies on insulin resistant T2DM mice have observed downregulated 
mTOR signaling in the heart while autophagy was induced  (Mellor et al., 2013a). We 
explored the mechanisms whereby lipid overload regulates cardiac autophagy. Palmitate 
treatment for 4 h significantly increased both autophagy marker protein LC3-II and 
autophagosome number in H9C2 CMs confirming previous reports. However, signaling 
through Akt, AMPK, and mTOR was unaffected by palmitate treatment, indicating that 
pathways that activate autophagic initiation do not contribute to lipid-overload induced 
cardiac autophagy. Recent studies also observed an accumulation of autophagic markers 
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in palmitate-treated hepatocytes and pancreatic-β cells independently of pathways 
regulating autophagic initiation (Las et al., 2011; Tan et al., 2012). Autophagosome 
accumulation may also result from defective autophagic turnover as observed in Danon 
disease, Pompe disease, and several neurological disorders (Levine and Kroemer, 2008; 
Son et al., 2012). Upon blockade of autophagic turnover with CQ, we observed that the 
palmitate-induced increase in LC3-II level was secondary to impaired autophagosome 
degradation, which is supported by increased accumulation of the autophagic substrate 
p62 and of mCherry-GFP positive autophagosomes in palmitate-treated CMs. 
 In this study, we focused on the mechanism of palmitate-induced autophagy at the 
preclinical stage without the confounding effects of cell death. Several studies suggest a 
link between ER stress and autophagy in response to lipid overload (Choi et al., 2009; 
Yin et al., 2012). We found that acute palmitate treatment did not invoke ER-stress 
response at 4 h of treatment. The earliest evidence for ER stress was observed only at 8 h 
of treatment when the IRE1-XBP1 axis of the UPR-pathway was activated, suggesting 
an ER-stress independent mechanism of autophagic regulation. As a major byproduct of 
palmitate metabolism, ceramide mediates a host of cytotoxic effects of lipid overload 
including autophagy (Pattingre et al., 2009b). We also observed an elevated ceramide 
level in palmitate-treated CMs. While blocking de novo ceramide biosynthesis by an 
SPT1 inhibitor lowered ceramide production, autophagy induced by palmitate was not 
altered, ruling out the role for ceramide in the autophagic process. 
Elevated ROS production and ensuing oxidative stress are major hallmarks of 
obesity related pathologies. ROS induced cytotoxic effects have also been observed in 
palmitate-treated cells (Kim et al., 2010; Wen et al., 2011). Since ROS has been shown to 
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induce autophagy, we measured ROS production and explored its role in palmitate-
induced autophagy. Palmitate incubation led to massive superoxide generation in H9C2 
CMs and scavenging superoxide significantly lowered palmitate-induced autophagic 
accumulation. We also found that superoxide-dependent autophagy is specific to 
palmitate as monounsaturated FFA oleate failed to induce both superoxide production 
and autophagy. Oleate also reversed palmitate-induced autophagic accumulation. Our 
observations confirm previous reports suggesting that oleate induces different cellular 
response than palmitate and could antagonize various pathological effects of palmitate 
(Coll et al., 2008; Hu et al., 2011). Defective autophagic turnover results from various 
factors including reduced lysosomal content, impaired autolysosome formation, and 
defective lysosomal enzyme activity (Dehay et al., 2010; Koga et al., 2010; Las et al., 
2011). Palmitate-treatment did not affect lysosomal protein content or autophagosome-
lysosome fusion. However, we observed a defect in lysosomal enzyme activity in parallel 
with impaired lysosomal acidification in response to palmitate. Both lysosomal 
acidification and enzyme activity were normalized by scavenging superoxide, suggesting 
a pH-dependent defect in palmitate-treated CMs. 
Mitochondria as a major source of ROS including superoxide is well documented in 
animal models of diabetes and in cultured cells with lipid overload (Bugger and Abel, 
2008; Yang et al., 2012). We examined the role of mitochondria in palmitate-induced 
autophagy. Overexpression of mitochondrial superoxide dismutase (SOD2) had no effect 
on autophagy. Surprisingly, inhibition of CPT-1 to limit mitochondrial substrate delivery 
and superoxide production accentuated palmitate-induced autophagy. Moreover, features 
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of mitophagy were absent in palmitate-treated CMs. Therefore, our data excludes the 
possibility of mitochondrial involvement in palmitate-induced autophagy.  
Our study has identified Nox2 as the major source of superoxide that regulates 
palmitate-induced autophagic abundance. Pharmacological inhibition of Nox2 activity 
significantly lowered autophagic abundance and enhanced lysosomal enzyme activity in 
palmitate-treated CMs. Likewise, RNAi mediated depletion of the Nox2 subunit p47phox 
blunted autophagic abundance and dramatically lowered superoxide level induced by 
palmitate. The activation of Nox2 in response to palmitate is mediated by classical PKC 
isoform, primarily PKC. Inhibition of classical PKC attenuated palmitate-induced 
autophagy and prevented superoxide production in palmitate-treated CMs. More 
importantly, we observed increased membrane translocation of p47phox upon palmitate 
treatment. This translocation of p47phox, which is required for Nox2 activation, was 
partially blocked by inhibition of classical PKCs. In summary, our data support a model 
wherein palmitate activates classical PKCs which in turn promotes the formation and 
membrane localization of p47phox-bound Nox2 subcomplex potentially by 
phosphorylation of p47phox. The activated Nox2 increases superoxide production 
thereby impairing lysosomal acidification and pH-dependent lysosomal enzyme activity. 
Therefore, the increased autophagosome accumulation observed in palmitate-treated CMs 
could be secondary to an impairment in lysosomal function to degrade autophagic 
substrates.  
In a mitochondria-centric world of oxidative stress and associated pathologies, the 
role of Nox is underappreciated. However, several studies have recognized that Nox-
derived ROS contributes to numerous pathologic conditions including hypertension, I/R, 
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diabetes and CVD (Lassegue et al., 2012). Enhanced Nox activity and superoxide 
generation have been reported in experimental models of obesity and diabetes (Furukawa 
et al., 2004; Jiang et al., 2011), in patients with metabolic syndrome (Fortuno et al., 
2006), and in diet-induced T2DM murine heart (Matsushima et al., 2009). Here, we 
uncovered a novel role for Nox2 in regulating autophagosome turnover by directly 
impacting lysosomal acidification and activity in response to lipid overload. Our study 
has identified a molecular regulator of autophagy in a mechanism highly relevant to 
obesity and can be exploited for the reactivation of autophagy as a potential therapeutic 
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Obesity is often accompanied by hypertension (>60%) and is probably the most 
common cause of left-ventricular (LV) hypertrophy. Sustained high systolic blood 
pressure in obese individuals is associated with concentric LV hypertrophy (Abel et al., 
2008). Accumulating evidence indicates that autophagy is highly regulated in a variety of 
cardiac pathologies associated with obesity such as diabetes, I/R injury, hypertension and 
heart failure (discussed in section 1.5.2). However, the functional consequences of 
autophagy in obesity is unclear.  
Our study in DIO mouse models revealed that HFF significantly increased 
autophagosome abundance in the heart without affecting cardiac contractile and 
hemodynamic functions. Therefore, the functional implications of such impairment in 
autophagic degradation is unclear. Since hypertension worsens cardiac function in many 
obesity-related heart diseases, we investigated how autophagy is regulated and what role 
it plays in pressure-overload induced hypertensive heart in HFD mice. Additionally, the 
regulation of autophagy and the associated changes in cardiac function in the presence of 
an additional stress such as pressure-overload in HFD animals may provide an insight 
into the functional consequence of autophagy in DIO.  
     
 
4.2. Methods not described in Chapters 2 and 3 
4.2.1. Transverse aortic constriction  
After 8 weeks of NCD or HFD, cardiac pressure overload was introduced in a subset 
of WT mice by TAC by placing a 27-gauge (27-G) metal clip between the innominate 
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artery and the left common carotid artery. Control animals were subjected to sham 
surgery with no aortic constriction.  
 
 
4.2.2. Cardiac contractile and hemodynamic function 
Cardiac contractile function was assessed in TAC and sham operated animals every 
week for 4 weeks by transthoracic echocardiography using a 13 MHz linear probe (Vivid 
FiVe, GE Medical Systems, Milwaukee, WI). LV systolic and diastolic dimensions, wall 
thickness, fractional shortening, ejection fraction, and stroke volume were calculated as 
described previously (Riehle et al., 2011). 
LV hemodynamic function was measured in mice by terminal cardiac catheterization 
prior to sacrificing the mice at the end of the diet regiment. These functional 
measurements were performed essentially as previously described (Riehle et al., 2011). 
Data were obtained and analyzed using LabChart7 Pro software (ADInstruments, 
Colorado Springs, CO). 
 
 
                                               4.3. Results 
4.3.1. Body weight and heart weight measurements 
Mice fed HFD for 12 weeks gained significant body weight (~29-46%) compared to 
NCD controls (Table 4.1). 4 weeks of TAC did not influence body weight in animals on 
either diet. However, TAC resulted in significant cardiac hypertrophy in NCD mice as 
evidenced by an increase in normalized heart weight (HW) and biventricular weight 






Table 4.1. Body weight, heart weight, and biventricular weight of WT mice fed with NCD or HFD for 12 weeks and subjected to 
sham or TAC surgery for the last 4 weeks of diet. Effect of diet (p<0.005), effect of surgery (p<0.05), and $interaction of diet and 
surgery (p<0.05) (n=3-5).    
 
  NCD HFD 
Parameters  Sham TAC Sham TAC 
Body Weight (g) 27.8 ± 0.414 24.3 ± 1.716 35.9 ± 0.778 35.6 ± 3.14 
Body weight/tibia length (g/mm) 1.7 ± 0.029 1.5 ± 0.101 2.2 ± 0.044 2.2 ± 0.182 
Heart weight (mg)$ 134.2 ± 5.9 250.2 ± 40.3 133.4 ± 1.0 154.5 ± 17.4 
Heart weight/tibia length (mg/mm)$ 8.1 ± 0.337 15.2 ± 2.411 8.0 ± 0.064 9.4 ± 1.025 
Biventricular weight/tibia length (mg/mm)$ 7.3 ± 0.196 14.0 ± 2.208 7.1 ± 0.040 8.6 ± 0.985 
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hypertrophy was significantly blunted in HFD mice compared to TAC operated NCD 
mice (38% decrease in HW and BVW). These data indicate that HFF attenuates pressure 
overload-induced cardiac hypertrophy in mice. 
 
 
4.3.2. Cardiac pressure-overload suppresses both basal and  
HFD-induced autophagic abundance  
To understand how pressure overload by TAC may regulate cardiac autophagy in the 
setting of HFF, proteins involved in autophagy and its regulation were analyzed by 
immunoblotting in sham and TAC operated mice (Figure 4.1). Consistent with our earlier 
observation, HFF increased autophagic abundance in HFD mice compared with NCD 
controls. In contrast, TAC significantly reduced autophagy in both NCD (by 40%) and 
HFD (by 30%) animals as measured by LC3-II level (NCD-sham: 1.0 ± 0.082, NCD-
TAC: 0.6 ± 0.109, HFD-sham: 1.34 ± 0.046, HFD-TAC: 1.0 ± 0.090). The adapter 
protein p62 was markedly increased in TAC-hearts than in sham-hearts on both diets 
(NCD-sham: 1.0 ± 0.082, NCD-TAC: 1.2 ± 0.011, HFD-sham: 0.87 ± 0.048, HFD-TAC: 
0.98 ± 0.046), suggesting a suppression of autophagy upon TAC. Interestingly, Beclin1 
was induced in response to TAC in NCD mice but not in HFD mice (NCD-sham: 1.0 ± 
0.046, NCD-TAC: 1.4 ± 0.034, HFD-sham: 0.9 ± 0.022, HFD-TAC: 0.9 ± 0.014). 
However, the processing of lysosomal protein Cathepsin D (CSD) to its intermediate 
form (~46 kD) was significantly reduced in HFD animals and was not altered by TAC 
(NCD-sham: 1.0 ± 0.026, NCD-TAC: 1.0 ± 0.041, HFD-sham: 0.8 ± 0.015, HFD-TAC: 
0.8 ± 0.027). 




















Figure 4.1. Reduced cardiac autophagy in response to pressure overload. Wildtype mice 
were fed with either a NCD or HFD for 12 weeks and analyzed for proteins involved in 
autophagy and its regulation in the heart. Representative immunoblots of proteins 
involved in the regulation of autophagy initiation (AKT, AMPK and Beclin1), mTOR 
signaling (S6), autophagic substrate targeting and vesicle formation (p62 and LC3), and 
lysosomal substrate degradation (CatD). Effect of diet (p<0.005), effect of surgery 













regulatory pathways were assessed by immunoblotting. The data in Figure 4.1 show that 
TAC activates the AKT-mTOR signaling pathway in NCD and HFD hearts to different 
degrees. TAC resulted in a 2.2-fold increase in AKT-S473 phosphorylation in NCD 
hearts but only by 1.5-fold in HFD hearts (NCD-sham: 1.0 ± 0.137, NCD-TAC: 2.16 
±0.560, HFD-sham: 1.06 ± 0.367, HFD-TAC: 1.5 ± 0.232). Likewise, mTOR signaling 
measured by S6 phosphorylation was suppressed upon HFF, and TAC failed to induce S6 
phosphorylation in HFD-hearts to the same extent as in NCD-hearts (NCD-sham: 1.0 ± 
0.46, NCD-TAC: 3.52  ± 1.2, HFD-sham: 0.37 ± 0.18, HFD-TAC: 0.65 ± 0.25). The 
alternate upstream pathway regulating autophagy through AMPK was not altered at 
baseline or in response to TAC in both NCD and HFD mice. 
 
 
4.3.3. High-fat feeding improves cardiac contractile function  
in mice subjected to pressure-overload 
 To study the impact of altered autophagy on cardiac structure and function, mice on 
NCD or HFD were examined by echocardiography 1, 2, 3 and 4 weeks following sham or 
TAC surgery. The data presented in Table 4.2 suggest that HFF per se did not alter LV 
dimensions in sham operated animals. However, TAC led to significant LV hypertrophy 
in NCD and HFD mice compared to respective sham controls. The LV diastolic 
dimensions measured by IVSd, LVIDd, and LVPWd were significantly increased as early 
as 1 week following TAC and remained higher at later time points. The TAC-induced 
changes in LV systolic dimensions were relatively subtle until 4 weeks of banding. 
Interestingly, TAC-induced LV hypertrophy was more pronounced in NCD mice than in 






Table 4.2. Echocardiographic measurements in mice fed with NCD or HFD for 12 weeks and subjected to sham or TAC surgery for 
the last 4 weeks of diet. IVSd, interventricular septum thickness in diastole; IVSs, interventricular septum thickness in systole; LVIDd, 
left-ventricular internal diameter in diastole; LVIDs, left-ventricular internal diameter in systole; LVPWd, left-ventricular posterior 
wall thickness in diastole; LVPWs, left-ventricular posterior wall thickness in systole; EF, ejection fraction; FS, fractional shortening; 
HR, heart rate; SV, stroke volume. Effect of diet (p<0.005), effect of surgery (p<0.05), and $interaction of diet and surgery (p<0.05), 
same postsurgery time point (n=3-5).  
 
Diet NCD HFD NCD HFD 




IVSd (cm) 0.079 ± 0.004 0.084 ± 0.011 0.074 ± 0.001 0.090 ± 0.004 0.084 ± 0.002 0.108 ± 0.003
#
 0.082 ± 0.004 0.105 ± 0.009
#
 
IVSs (cm) 0.110 ± 0.002 0.117 ± 0.011 0.107 ± 0.003 0.13 ± 0.008 0.120 ± 0.007 0.136 ± 0.013
#
 0.116 ± 0.005 0.141 ± 0.012
#
 
LVIDd (cm) 0.395 ± 0.013 0.417 ± 0.018 0.403 ± 0.016 0.423 ± 0.015 0.386 ± 0.004 0.417 ± 0.024 0.394 ± 0.011 0.389 ± 0.008 
LVIDs (cm) 0.305 ± 0.014 0.331 ± 0.025 0.313 ± 0.015 0.331 ± 0.017 0.292 ± 0.010 0.336 ± 0.034 0.303 ± 0.009 0.301 ± 0.007 
LVPWd (cm) 0.062 ± 0.002 0.076 ± 0.004 0.062 ± 0.003* 0.058 ± 0.001 *$ 0.066 ± 0.002 0.070 ± 0.002# 0.062 ± 0.002 0.071 ± 0.003# 
LVPWs (cm) 0.081 ± 0.001 0.091 ± 0.003 0.074 ± 0.008* 0.072 ± 0.003* 0.080 ± 0.005 0.085 ± 0.005 0.075 ± 0.004 0.085 ± 0.003 
% EF 53.83 ± 2.248 49.94 ± 5.339 53.21 ± 1.795 52.13 ± 2.457 56.42 ± 3.327 47.47 ± 6.958 54.05 ± 1.394 53.48 ± 1.740 
% FS 22.77 ± 1.227 20.79 ± 2.747 22.42 ± 0.993 21.82 ±1.331 24.34 ± 2.000 19.66 ± 3.756 22.87 ± 0.791 22.54 ± 0.977 
HR (bpm) 520 ± 16 524 ± 21 543 ± 30 520 ± 40 534 ± 20 550 ± 60 532 ± 21 573 ± 56 






Table 4.2. (continued) 
 
Diet NCD HFD NCD HFD 




IVSd (cm) 0.087 ± 0.005 0.106 ± 0.009
#
 0.087 ± 0.005 0.103 ± 0.005
#
 0.089 ± 0.002 0.101 ± 0.001
#
 0.086 ± 0.004 0.097 ± 0.008
#
 
IVSs (cm) 0.123 ± 0.007 0.139 ± 0.015
#
 0.117 ± 0.007 0.144 ± 0.004
#
 0.127 ± 0.003 0.131 ± 0.005 0.124 ± 0.008 0.136 ± 0.012 
LVIDd (cm) 0.386 ± 0.007 0.439 ± 0.041 0.415 ± 0.011 0.407 ± 0.011 0.382 ± 0.003 0.465 ± 0.024
#
 0.407 ± 0.016 0.418 ± 0.023
#
 
LVIDs (cm) 0.291 ± 0.006 0.355 ± 0.045 0.327  ± 0.012 0.313 ± 0.011 0.283 ± 0.003 0.388 ± 0.027
#
 0.314 ± 0.018 0.325 ± 0.023
#$
 
LVPWd (cm) 0.074 ± 0.008 0.069 ± 0.005 0.064  ± 0.004 0.064 ± 0.006 0.077 ± 0.002 0.071 ± 0.003 0.065 ± 0.004* 0.061 ± 0.004* 
LVPWs (cm) 0.095 ± 0.007 0.086 ± 0.005 0.078  ± 0.004* 0.074 ± 0.004* 0.097 ± 0.005 0.083 ± 0.006 0.079 ± 0.003 0.078 ± 0.007 
% EF 57.31 ± 0.651 47.51 ± 5.666 51.04  ± 2.025 54.27 ± 1.886
$
 58.88 ± 1.842 42.29 ± 3.666
#
 54.49 ± 2.742 53.25 ± 2.435
#$
 
% FS 24.71 ± 0.382 19.56 ± 3.028 21.24  ± 1.098 22.98 ± 1.049
$
 25.69 ± 1.095 16.82 ± 1.784
#
 23.21 ± 1.553 22.44 ± 1.369
#$
 
HR (bpm) 519 ± 18 566 ± 33 546  ± 24 563 ± 43 555 ± 43 529 ± 33 539 ± 23 567 ± 62 






TAC mice than in HFD-TAC mice by 4 weeks of TAC. Correspondingly, TAC resulted 
in impaired contractile function in NCD mice compared to NCD-sham controls as 
evidenced by a significant reduction in % EF and % FS after 3 weeks of banding. 
However, TAC- induced impairment in contractile function was blunted in mice fed with 
HFD. These data suggest that HFF attenuates cardiac hypertrophy and improves 
contractile function in mice subjected to pressure overload. 
 
 
4.3.4. High-fat feeding does not alter pressure overload- 
induced changes in hemodynamic function 
To examine the effect of cardiac pressure-overload on mice fed with HFD, 
hemodynamic function was measured after 4 weeks of TAC by LV catherization. TAC 
significantly increased LV pressure in both NCD and HFD mice evidenced by increased 
systolic and diastolic arterial pressure (APsys and APdia) and  increased LV pressure 
(LVSP, LVEDP, and LVDevP) relative to sham controls (Table 4.3). More importantly, 
the HFD did not affect the hemodynamic profile of mice both at baseline (in sham 




Hypertension  is a common manifestation in obesity; it plays a causative role in 
hypertensive heart diseases commonly associated with obesity (Narkiewicz, 2006). 
Importantly, the risk for CVD is amplified only when obesity coexists with hypertension 






Table 4.3. Hemodynamic parameters obtained after LV catheterization of mice fed with NCD or HFD for 12 weeks and subjected to 
sham or TAC surgery for the last 4 weeks of diet. WT and Bec1-Tg mice fed with NCD or HFD. APsys, systolic arterial pressure; 
APdia, diastolic arterial pressure; LVSP, left-ventricular systolic pressure; LVDevP, left-ventricular developed pressure; HR, heart 
rate; +dP/dt, peak rate left-ventricular pressure increase; -dP/dt, peak rate of left-ventricular pressure decrease; LVEDP, left-
ventricular end diastolic pressure. Effect of diet (p<0.005), effect of surgery (p<0.05), and $interaction of diet and surgery (p<0.05), 
same postsurgery time point (n=5-6).  
 
Diet NCD HFD 
Surgery Sham Band Sham Band 
APsys (mmHg) 88.32 ± 3.15 155.246 ± 13.871# 88.567 ± 6.442 163.671 ± 17.524# 
APdia (mmHg) 52.11 ± 3.36 63.2128 ± 1.8882# 47.4658 ± 6.3555 59.2441 ± 6.3087# 
LVSP (mmHg) 89.49± 2.83 159.25 ± 15.359# 85.916 ± 6.146 169.162 ± 17.104# 
LVMP (mmHg) -2.593 ± 0.841 3.3914 ± 3.3003 -2.2412 ± 2.0046 2.6744 ± 3.3998 
LVDevP (mmHg) 92.08 ± 3.10 155.859 ± 18.462# 88.157 ± 4.847 166.488 ± 18.204# 
HR (min-1) 477.8 ± 26.16 561.1 ± 12.847# 478.5 ± 24.206 485.4 ± 12.378# 
+dP/dt  (mm Hg/sec) 7600.1 ± 630.8 7984.9 ± 2112.7 6547.9 ± 589.6 7895.1 ± 1089 
-dP/dt  (mm Hg/sec)   -7651.7 ± 697.8 -8945.7 ± 2014.7 -8907.1 ± 2977.7 -9389.7 ± 1330.8 
LVEDP (mm Hg) 3.35 ± 0.57 16.89 ± 5.33# 2.50 ± 2.19 10.3783 ± 2.96# 
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associated heart diseases.  
Data presented in earlier chapters revealed that HFD-induced obesity is accompanied 
by increased autophagosome abundance in the heart. However, it is unclear whether such 
an increase in autophagic abundance is detrimental to the heart or is an attempt to protect 
heart from HFD-induced cardiac abnormalities. To understand the functional role of 
HFD-induced autophagy in the heart, we subjected the mice on HFD to cardiac pressure 
overload as an additional stress that may mimic conditions experienced by the heart in 
obesity; namely high-levels of circulating fatty acids and hypertension. 
Both basal and HFD-induced cardiac autophagy were suppressed by TAC, albeit to 
different degrees. The suppression of autophagy paralleled with the activation of AKT 
and mTOR signaling, and accumulation of autophagic substrate protein p62, suggests that 
TAC inhibits the proximal arm of the autophagic induction pathway. Notably, the TAC-
dependent activation of AKT and mTOR was significantly greater in NCD hearts 
compared with HFD hearts. Likewise, TAC-induced inhibition of autophagy was less 
pronounced in HFD-hearts. Furthermore, accumulation of p62 and processing of 
lysosomal protein CSD (~46kD) were simultaneously lower in HFD-TAC mice than in 
NCD-TAC mice. These data suggest that HFF partially alleviated the suppression of 
autophagy primarily by TAC (higher LC3-II level) primarily through the attenuation of 
AKT-mTOR signaling, which was sufficient to induce autophagosome turnover (low p62 
level). However, the degree of autophagic turnover was still not enough to reduce 
autophagosomal abundance as p62 level in HFD-TAC mice was still higher than in HFD-
sham mice, which was probably due to reduced lysosomal activity (lower CSD-46kD 
level) associated with HFF. 
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Phenotypic and echocardiographic measurements revealed a surprisingly beneficial 
affect HFF in TAC-operated hearts. HFF attenuated TAC-induced cardiac hypertrophy as 
HW and BVW in HFD mice was similar to sham animals and much lower than in NCD-
TAC mice. Cardiac contractile function (% EF and % FS) remained preserved in TAC-
operated HFD mice but worsened in NCD-TAC mice. Intriguingly, HFF had no apparent 
effect on changes LV hemodynamic induced by TAC as hemodynamic parameters 
remains similar in NCD and HFD mice.   
  In this study we observed that HFF partially reversed cardiac hypertrophy and 
impairment in contractile function induced by TAC in parallel with relatively maintained 
autophagic induction. Such improvement in cardiac function in HFD could be due to 
restoration of autophagy to normal level (similar to NCD-sham controls) by TAC, or it 
could an effect of HFF on pathways independent of autophagy. Moreover, it is not 
entirely clear from this study if TAC improved lysosomal function affecting 
autophagosome turnover, which may have improved cardiac function in HFD mice. 
Additional experiments such as fasting that induces autophagosome formation followed 
by cardiac function measurement may allow us to determine the directionality of changes 
in cardiac function in HFD-TAC animals compared to NCD-TAC controls and if such 
changes correlate with autophagy. Together, these results open an opportunity for further 
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The role of autophagy as an adaptive or maladaptive response is context dependent 
(Nemchenko et al., 2011). For example, reduced autophagy in pressure overload-induced 
hypertrophy is considered an adaptive response since the excessive autophagy observed 
in chronic pressure-overload leads to heart failure. Furthermore, suppression of 
autophagy by genetic knockdown of Beclin1 delays the progression of pressure-overload 
induced heart failure (Zhu et al., 2007). In liver, 10 weeks of HFF has been shown to 
diminish autophagy in rat together with increased myocardial TG content. The authors 
suggest that reduced autophagy following 10-week HFF may be a cellular attempt to 
protect liver from the lipid-induced insulin resistance (Papackova et al., 2012). However, 
long-term HFF in mice for 20 weeks showed that defective autophagy contributes insulin 
resistance and restoration of autophagy improves hepatic insulin action (Yang et al., 
2010). These data present a complex role of autophagy in hepatic insulin action which 
varies with the duration of HFF. It is important to note that autophagic response to HFF is 
also highly tissue dependent.  The mechanism of HFD-induced autophagic regulation in 
the heart as observed in our study was different from hepatic autophagy as reported in 
previous studies. There is no data on whether the increased abundance of 
autophagosomes in HFD mice is protective or detrimental to the heart. In this study we 
tested our hypothesis that reduced autophagosomal turnover is an adaptive response of 
the heart to protect itself from lipid toxicity. We utilized Beclin1 heterozygous (Bec1+/-) 
and cardiac-specific Beclin1 overexpressing (Bec1-Tg) mice to suppress or induce 
autophagic initiation, respectively, in the heart in the setting of HFF and examined the 
effect of these genetic alterations on autophagy and cardiac function.       
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5.2. Methods not described in Chapters 2, 3 and 4 
5.2.1. Fasting animals 
For fasting studies, mice were kept in empty cages without food for 20 h (for 
Beclin1+/- study) or 24 h (Bec1-Tg study) with free access to water and were sacrificed 
immediately after fasting. 
 
 
5.2.2. Cardiac contractile and hemodynamic function 
Cardiac contractile function was measured in wildtype (WT), Beclin1+/-, and Bec1-
Tg mice prior to and 4, 8, and 12 weeks following NCD or HFD as described in section 
4.2.2. LV hemodynamic function was measured immediately prior to sacrificing the mice 
as described in section 4.2.2.  
 
 
5.2.3. Glucose and insulin tolerance tests  
Glucose tolerance test (GTT) was performed in mice following 10 weeks of NCD or 
HFD feeding. Mice were fasted for 6 h (6 AM -12 PM) before the test. A single bolus of 
glucose (1 mg/kg body weight in 0.9% saline) was administered by ip injection. Blood 
was drawn from tail vein and glucose levels were measured at 0, 5, 15, 30, 60, and 120 
min using a standard glucometer (Bayer, IN).  
Insulin tolerance test (ITT) was performed in mice following 11 weeks of NCD or 
HFD feeding. Random fed mice were given an ip injection of human regular insulin 
(Novolin R) (0.75 U/kg body weight in 0.9% saline) and blood glucose levels were 




                                               5.3. Results 
5.3.1. Morphometric and physiological data 
Twelve weeks of HFF significantly increased body weight (BW) and heart weight 
(HW) in WT and Bec1+/- mice compared to NCD littermate controls (Table 5.1). 
Likewise, HFF significantly increased BW both in WT and Bec1-Tg mice but HW 
remained normal compared to NCD controls (Table 5.2). Fasting blood glucose levels 
were significantly higher in HFD mice across all genotypes compared to NCD controls.  
 
 
5.3.2. Beclin1 regulates fasting induced cardiac autophagy 
The Bec1+/- and Bec1-Tg mouse models used in this study have previously been 
shown to display altered autophagic activity with functional consequences in response to 
sTAB (Zhu et al., 2007). To revalidate the use of these models to suppress autophagy, we 
fasted mice and examined autophagy signaling in the heart. 15-week old WT or Bec1+/- 
male mice were fasted for 20 h (2 PM-10 AM) before harvesting the tissue. Immunoblot 
analyses show that autophagy in the heart, assessed by LC3-II level, was significantly 
induced in WT mice upon fasting relative to WT-fed mice (WT-fed: 1.0 ± 0.151, WT-
fast: 1.5 ± 0.207) (Figure 5.1). The fasting-induced autophagy was blunted in Bec1+/- 
mice (Bec1+/--fed: 0.96 ± 0.048, Bec1+/--fast: 1.03 ± 0.091). Interestingly, Beclin1 level 
was unaltered by fasting in both WT and Bec1+/- mice (WT-fed: 1.0 ± 0.027, WT-fast: 
0.9 ± 0.063, Bec1+/--fed: 1.0 ± 0.030, Bec1+/--fast: 0.9 ± 0.106). These data suggest that 
haploinsufficiency of Beclin1 plays a role in the suppression of fasting-induced 
autophagy in the murine heart, and validate Bec1+/- mouse as a relevant model to study 
the effect of suppression of autophagic initiation in response to a stress. 
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Table 5.1. Body weight, heart weight, and blood glucose level of WT and Bec1+/- mice 
fed with NCD or HFD for 12 weeks. Effect of diet (p<0.005), effect of genotype 
(p<0.05), and $interaction of diet and genotype (p<0.05) (n=10-12). †Pre- and postdiet 
differences in body weight.  
 
  WT Bec1+/- 
Parameters NCD HFD NCD HFD 
Body weight (g) 29.5 ± 0.7 40.0 ± 1.8 28.8 ± 0.8 40.0 ± 1.4 
Body weight/tibia length 
(g/mm) 
1.7 ± 0.04 2.3 ± 0.09  1.7 ± 0.04 2.3 ± 0.08 
†Body weight gain (g) 5.9 ± 0.7 16.0 ± 1.6 5.9 ± 0.5 16.7 ± 1.0 
Heart weight/tibia length 
(mg/mm) 
7.8 ± 0.1 8.8 ± 0.3 8.0 ± 0.2 8.5 ± 0.2 




Table 5.2. Body weight, heart weight, and blood glucose level of WT and Bec1-Tg mice 
fed with NCD or HFD for 12 weeks. Effect of diet (p<0.005), effect of genotype 
(p<0.05), and $interaction of diet and genotype (p<0.05) (n=12-16). †Pre- and postdiet 
differences in body weight.  
 
  WT Bec1-Tg 
Parameters NCD HFD NCD HFD 
Body weight (g) 28.0 ± 0.5 36.5 ± 0.8 27.9 ± 0.5 35.6 ± 0.9 
Body weight/tibia length 
(g/mm) 
1.6 ± 0.03 2.1 ± 0.04 1.6 ± 0.03  2.1 ± 0.05 
†Body weight gain (g) 3.4 ± 0.4 11.9 ± 0.6 3.2 ± 0.2 10.5 ± 0.9 
Heart weight/tibia length 
(mg/mm) 
7.7 ± 0.2 7.9 ± 0.2 7.8 ± 0.2 7.9 ± 0.2 





















Figure 5.1. Effect of altered Beclin1 expression on fasting-induced autophagy. (A) 15-
week old WT and Bec1+/- mice were fasted for 20 h and immunblotted for indicated 
proteins in the heart. Densitometries of the indicated blots represent mean ± SEM (n=4-
6). (B) 10-week old WT and Bec1-Tg mice were fasted for 24 h and immunblotted for 
indicated proteins in the heart. Densitometries of the indicated blots represent mean ± 
SEM (n=3). Effect of fasting (p<0.005), #effect of genotype (p<0.05), and $interaction of 


































We next examined if the cardiac overexpression Beclin1 would induce basal and 
fasting-induced autophagy. 10-week old WT and Bec1-Tg mice were fasted for 24 h (9 
AM-9 AM) and analyzed for proteins involved in autophagy in the whole heart 
homogenate. The Beclin1 level was significantly higher in both fed and fasted Bec1-Tg 
mice compared to WT controls (WT-fed: 1.0 ± 0.02, Bec1-Tg-fed: 147.8 ± 17.40, WT-
fast: 1.2 ± 0.25, Bec1-Tg-fast: 44.0 ± 5.59 (Figure 5.1). Surprisingly, Beclin1 level was 
significantly reduced by ~70% upon fasting in Bec1-Tg mice compared to Bec1-Tg-fed 
animals, which is in contrast with the general notion that Beclin1 is upregulated by 
fasting. Nonetheless, fasting significantly induced autophagy in both genotypes as 
assessed by LC3-II level (WT-fed: 1.0 ± 0.06, Bec1-Tg-fed: 1.1 ± 0.20, WT-fast: 2.1 ± 
0.24, Bec1-Tg-fast: 1.7 ± 5.59). Additionally, there was a modest (~20%) decrease in 
LC3-II level in fasted Bec1-Tg hearts compared to fasted WT-hearts. Interestingly, 
phosphorylation of the mTOR target protein S6 was significantly upregulated upon 
fasting in mice in both genotypes (WT-fed: 1.0 ± 0.73, Bec1-Tg-fed: 4.0 ± 0.58, WT-fast: 
5.6 ± 2.88, Bec1-Tg-fast: 17.7 ± 1.91). The S6 phosphorylation was more pronounced in 
Bec1-Tg mice than in WT mice under both fed and fasted conditions. The induction of 
mTOR signaling in parallel with an induction in autophagy in fasted animals is currently 
unclear and requires further study.   
 
 
5.3.3. High-fat diet-induced autophagic abundance is  
unaffected by altered Beclin1 expression. 
Beclin1 is known to promote autophagic initiation as downregulation of Beclin1 
suppressed fasting-induced autophagy in our study as well as in others (Kang et al., 
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2011). To test if knockdown of Beclin1 attenuates HFD-induced autophagic abundance, 
core autophagic proteins and upstream regulators of autophagy were analyzed by western 
blot (Figure 5.2). Consistent with our previous data, 12 weeks of HFF significantly 
increased cardiac autophagosome abundance as evidenced by increased LC3-II level in 
HFD mice than in NCD controls (WT-NCD: 1.0 ± 0.112, WT-HFD: 1.23 ± 0.025). 
Contrary to the role of Beclin1, autophagy in Bec1+/--NCD mice was higher than in WT-
NCD mice. Furthermore, HFF did not cause any additional increase in autophagy in 
Bec1+/- mice above the basal level (Bec1+/--NCD: 1.3 ± 1.354, Bec1+/--HFD: 1.3 ± 0.110). 
Interestingly, Beclin1 protein level was not reduced in Bec1+/--mice compared WT 
controls (WT-NCD: 1.0 ± 0.056, Bec1+/--NCD: 1.2 ± 0.032). However, HFF led to a 
significant increase in Beclin1 level in either genotype (WT-HFD: 1.38 ± 0.149, Bec1+/--
HFD: 1.45 ± 0.134). To determine if heterozygosity of Beclin1 regulates autophagic 
initiation pathway independent of its protein level, we examine upstream signaling 
molecules and autophagy proteins involved in autophagic induction. Insulin signaling 
through AKT trended downward in HFD animals independently of genotypes. However, 
mTOR signaling assessed by S6 phosphorylation remained unchanged in HFD mice. 
Likewise, AMPK phosphorylation also remained preserved in WT and Bec1+/- mice on 
HFD. The autophagy protein Atg7, which is upregulated upon autophagic induction, was 
slightly higher following HFF in WT and Bec1+/- mice.  These data suggest that despite a 
trend towards an increase in some autophagic markers in HFD hearts, upstream signaling 
and autophagic initiation pathway essentially remained unchanged upon HFF and Beclin1 
heterozygosity.  





















Figure 5.2. Regulation of autophagy by high-fat feeding is unaffected by Beclin1 
heterozygosity. Wildtype and Bec1+/- mice were fed with NCD or HFD for 12 weeks and 
analyzed for proteins involved in autophagy and its regulation. (A) Representative 
western blots of proteins involved in mTOR signaling (S6), autophagic induction 
(Beclin1), and autophagosome formation (LC3). (B) Representative immunoblots of 
proteins regulating initiation of autophagy (AKT and AMPK) and formation of LC3-II 
(Atg7). Densitometries of the indicated immunoblots presented as mean ± SEM. Effect 
of diet (p<0.005), #effect of genotype (p<0.05), and $interaction of diet and genotype 








HFF, we examined if cardiac-specific Beclin1 overexpression regulates HFD-dependent 
autophagy. The Beclin1 level in the heart was 25-27 fold higher in transgenic animals 
compared to WT controls (WT-NCD: 1.0 ± 0.097, WT-HFD: 1.4 ± 0.083, Bec1-Tg-NCD 
(25.4 ± 2.259, Bec1-Tg-HFD: 27.5 ± 2.859) (Figure 5.3). 12 weeks of feeding 
significantly induced levels of the autophagy marker LC3-II in HFD mice in both 
genotypes compared to NCD controls (WT-NCD: 1.0 ± 0.089, WT-HFD: 1.8 ± 0.215, 
Bec1-Tg-NCD: 1.1 ± 0.589, Bec1-Tg-HFD: 1.9 ± 0.244), which supports our previous 
observation of HFD-induced autophagosomal abundance. However, the Beclin1 
overexpression could not alter autophagy in both NCD and HFD mice. Although insulin 
signaling through AKT and mTOR signaling through ribosomal protein S6 were partially 
reduced, the data were highly variable and no significant difference was observed 
between NCD and HFD mice across both genotypes. The hyperphosphorylated form of 
4E-BP1 (4E-BP1) has been shown to be a consequence of signaling via AKT and 
mTOR kinases (Gingras et al., 1998). Interestingly, the level of 4E-BP1 was slightly 
upregulated in HFD mice compared to NCD controls in both genotypes (WT-NCD: 1.0 ± 
0.102, WT-HFD: 1.5 ± 0.248, Bec1-Tg-NCD: 1.3 ± 0.234, Bec1-Tg-HFD: 1.5 ± 0.146, p-




5.3.4. HFD-induced changes in cardiac dimension and 
function are independent of Beclin1 expression 
To examine if genetic suppression of Beclin1 level alters cardiac function upon HFF, 






Figure 5.3. Cardiac-specific transgene expression of Beclin1 does not impact high-fat 
diet-induced autophagy. Wildtype and Bec1-Tg mice were fed with NCD or HFD for 12 
weeks and analyzed for proteins involved in autophagy and its regulation. Representative 
western blots of proteins involved in mTOR signaling (S6), in the regulation of 
autophagic initiation (AKT and Beclin1), and in autophagosome formation (LC3). 
Densitometries of the indicated immunoblots presented as mean ± SEM. Effect of diet 
(p<0.005), #effect of genotype (p<0.05), and $interaction of diet and genotype (p<0.05) 











mice prior to and 4, 8, and 12 weeks following HFD or NCD feeding. HFF resulted in 
mild LV hypertrophy as evidenced by a significant increase in LV- wall thickness as 
early as 4 weeks (Table 5.3). Both IVS and LVPW were significantly higher in HFD 
hearts compared to NCD hearts upon 4, 8, and 12 weeks of HFF. These changes in LV-
wall thickness remain preserved in Bec1+/- mice. More importantly, HFD mice had no 
impairment in cardiac contractile function. Both %EF and %FS were similar in HFD and 
NCD mice in both genotypes. 
In contrast to Bec1+/- mice, Bec1-Tg mice express high level of Beclin1 in the heart 
compared to WT mice which enhances autophagic activity (Zhu et al., 2007). We tested 
if the heart-specific overexpression of Beclin1 alters cardiac structure and function in 
NCD and HFD mice. Cardiac dimension and contractile function were assessed before 
and 4, 8, 12 weeks following NCD or HFD. The data presented in Table 5.4 show that 
HFF leads to mild cardiac hypertrophy in both WT and Bec1-Tg mice. The LV wall 
thickness (IVSd, IVSs, LVPWd, and LVPWs) and systolic internal diameter (IVIDs) 
were slightly increased in HFD mice as early as 4 weeks of HFD and remained 
statistically significant at later time points. Although % EF and %FS are slightly higher in 
HFD mice in both genotypes compared to NCD controls, cardiac function was essentially 
remained within the normal range in HFD and NCD mice. The echocardiographic data 
suggest that HFD induces mild compensatory changes in LV-dimension without affecting 
contractile function. Moreover, Beclin1 heterozygosity did not impact cardiac dimension 






Table 5.3. Echocardiographic measurements in WT and Bec1+/- mice fed with NCD or HFD. IVSd, interventricular septum thickness 
in diastole; IVSs, interventricular septum thickness in systole; LVIDd, left-ventricular internal diameter in diastole; LVIDs, left-
ventricular internal diameter in systole; LVPWd, left-ventricular posterior wall thickness in diastole; LVPWs, left-ventricular posterior 
wall thickness in systole; EF, ejection fraction; FS, fractional shortening; HR, heart rate; SV, stroke volume. Effect of diet (p<0.005), 
effect of genotype (p<0.05), and $interaction of diet and genotype (p<0.05) (n=10-12).  
 
Genotype WT Bec1+/- WT Bec1+/- 
Diet NCD HFD NCD HFD NCD HFD NCD HFD 
Weeks on diet                                                    0 4 
IVSd (cm) 
0.07 ± 0.002 0.08 ± 0.002  0.08 ± 0.003  0.07 ± 0.002  0.077 ± 0.002 0.082 ± 0.002* 0.077 ± 0.002 0.085 ± 0.002* 
IVSs (cm) 
0.10 ± 0.003 0.11 ± 0.003 0.11 ± 0.003 0.10 ± 0.005 0.106 ± 0.004 0.120 ± 0.004* 0.108 ± 0.004 0.121 ± 0.003* 
LVIDd (cm) 
0.40 ± 0.009 0.40 ± 0.008 0.40 ± 0.007 0.39 ± 0.004 0.407 ± 0.010 0.406 ± 0.006 0.396 ± 0.005 0.400 ± 0.005 
LVIDs (cm) 
0.30 ± 0.012 0.28 ± 0.010 0.29 ± 0.008 0.29 ± 0.005 0.294 ± 0.012 0.282 ± 0.007 0.281 ± 0.008 0.280 ± 0.005 
LVPWd (cm) 
0.06 ± 0.002 0.07 ± 0.002 0.06 ± 0.002 0.07 ± 0.002 0.0645 ± 0.003 0.070 ± 0.002 0.065 ± 0.003 0.067 ± 0.002 
LVPWs (cm) 
0.09 ± 0.003 0.10 ± 0.004 0.09± 0.003 0.09  ± 0.004 0.090 ± 0.004 0.101 ± 0.002* 0.092 ± 0.004 0.098 ± 0.003* 
% EF 
59.1 ± 2.804 63.2 ± 2.178 60.3 ± 1.405 60.1  ± 1.954  62.432 ± 2.16 66.355 ± 1.57 64.254 ± 1.78 65.42 ± 1.71 
% FS 
26.1 ± 1.722 28.7 ± 1.457 26.6 ± 0.867 26.5 ± 1.240 28.08 ± 1.384 30.63 ± 1.078 29.23 ± 1.273 29.99 ± 1.183 
HR (bpm) 
532 ± 16.43 540 ± 10.93 511 ± 15.84 534 ± 11.40 499 ± 11.85 524 ± 15.79* 511 ± 20.17 547 ± 11.22* 
SV(ml) 






Table 5.3. (continued) 
 
Genotype WT Bec1+/- WT Bec1+/- 
Diet NCD HFD NCD HFD NCD HFD NCD HFD 
Weeks on diet                                                    8 12 
IVSd (cm) 
0.075 ± 0.001 0.084 ± 0.002* 0.078 ± 0.002 0.081 ± 0.002* 0.076 ± 0.003 0.084 ± 0.003* 0.080 ± 0.001 0.0853 ± 0.003* 
IVSs (cm) 
0.109 ± 0.003 0.120 ± 0.004* 0.109 ± 0.004 0.116 ± 0.004* 0.109 ± 0.003 0.117 ± 0.004* 0.112 ± 0.003 0.121 ± 0.004* 
LVIDd (cm) 
0.414 ± 0.009 0.407 ± 0.007 0.392 ± 0.007# 0.388 ± 0.005
#
 0.406 ± 0.014 0.412 ± 0.011 0.406 ± 0.009 0.401 ± 0.005 
LVIDs (cm) 
0.291 ± 0.010  0.283 ± 0.007 0.272 ± 0.009# 0.264 ± 0.007
#
 0.283 ± 0.015 0.283 ± 0.011 0.277 ± 0.010 0.272 ± 0.009 
LVPWd (cm) 
0.068 ± 0.001 0.074 ± 0.002* 0.068 ± 0.001 0.074 ± 0.001* 0.070 ± 0.002 0.076 ± 0.002* 0.068 ± 0.003 0.075 ± 0.001* 
LVPWs (cm) 
0.098 ± 0.002 0.105 ± 0.003* 0.095 ± 0.003 0.103 ± 0.002* 0.097 ± 0.005 0.105 ± 0.004* 0.096 ± 0.004 0.106 ± 0.004* 
% EF 
65.15 ± 1.728 66.14 ± 1.243 66.45 ± 1.586 68.34 ± 1.608 65.84 ± 2.897 67.57 ± 1.623 68.15 ± 1.518 68.602 ± 2.341 
% FS 
29.82 ± 1.203 30.40 ± 0.834 30.67 ± 1.099 32.02 ± 1.138 30.38 ± 1.982 31.45 ± 1.150 31.813 ± 1.087 32.230 ± 1.643  
HR (bpm) 
519 ± 10.14 536 ± 17.01 549 ± 14.89 561 ± 16.36 512 ± 6.31 554 ± 10.65 538 ± 18.76 536 ± 19.23 
SV(ml) 







Table 5.4. Echocardiographic measurements in WT and Bec1-Tg mice fed with NCD or HFD. IVSd, interventricular septum 
thickness in diastole; IVSs, interventricular septum thickness in systole; LVIDd, left-ventricular internal diameter in diastole; LVIDs, 
left-ventricular internal diameter in systole; LVPWd, left-ventricular posterior wall thickness in diastole; LVPWs, left-ventricular 
posterior wall thickness in systole; EF, ejection fraction; FS, fractional shortening; HR, heart rate; SV, stroke volume. Effect of diet 
(p<0.005), effect of genotype (p<0.05), and $interaction of diet and genotype (p<0.05) (n=13-14).  
 
Genotype WT Bec1-Tg WT Bec1-Tg 
Diet NCD HFD NCD HFD NCD HFD NCD HFD 
Weeks on diet 0 4 
IVSd (cm) 0.08 ± 0.002 0.08 ± 0.002 0.76 ± 0.004 0.08 ± 0.0024 0.07 ± 0.002 0.08 ± 0.002* 0.07 ± 0.003 0.08 ± 0.003* 
IVSs (cm) 0.11 ± 0.002 0.11 ± 0.003 0.10 ± 0.003 0.11 ± 0.004 0.10 ± 0.002 0.11 ± 0.004 0.11 ± 0.005 0.11 ± 0.005 
LVIDd (cm) 0.39 ± .006 0.40 ± 0.010 0.40 ± 0.005 0.39 ± 0.005 0.41 ± 0.011 0.40 ± 0.006 0.41 ± 0.008 0.40 ± 0.007 
LVIDs (cm) 0.27 ± 0.003 0.29 ± 0.013 0.30 ± 0.003 0.28 ± 0.007
$
 0.29 ± 0.011 0.28 ± 0.007 0.29 ± 0.009 0.29 ± 0.008 
LVPWd (cm) 0.07 ± 0.004 0.06 ± 0.001 0.06 ± 0.002 0.07 ± 0.003 0.07 ± 0.003 0.07 ± 0.002 0.07 ± 0.002 0.07 ± 0.002 
LVPWs (cm) 0.10 ± 0.005 0.09 ± 0.003 0.09 ± 0.004 0.09 ± 0.004 0.09 ± 0.002 0.10 ± 0.004 0.09 ± 0.003 0.10 ± 0.003 
% EF 67.8 ± 1.709 62.4 ± 2.577 59.5 ± 1.556 63.9 ± 2.070 63.6 ± 1.846 66.1 ± 1.621 62.9 ± 2.678 62.3 ± 1.818 
% FS 31.6 ± 1.206 28.0 ± 1.647 26.0 ± 0.942 28.9 ± 1.391 28.8 ± 1.223 30.4 ± 1.119 28.4 ± 1.755 27.9 ± 1.160 
HR (bpm) 532 ± 6.073 536 ± 12.155 516 ± 8.519 532 ± 21.207 525 ± 22.482 540 ± 15.123 484 ± 16.644
#
 504 ± 13.712
#
 






Table 5.4. (continued) 
 
Genotype WT Bec1-Tg WT Bec1-Tg 
Diet NCD HFD NCD HFD NCD HFD NCD HFD 
Weeks on diet 8 12 
IVSd (cm) 0.08 ± 0.002 0.08 ± 0.003* 0.08 ± 0.002 0.09 ± 0.003* 0.08 ± 0.001 0.08 ± 0.001* 0.08 ± 0.002 0.08 ± 0.001* 
IVSs (cm) 0.11 ± 0.003 0.11 ± 0.005* 0.11 ± 0.004 0.12 ± 0.006* 0.11 ± 0.002 0.12 ± 0.002* 0.11 ± 0.002 0.12 ± 0.003* 
LVIDd (cm) 0.42 ± 0.008 0.41 ± 0.009 0.41 ± 0.004 0.40 ± 0.008 0.42 ± 0.007 0.41 ± 0.009 0.42 ± 0.007   0.40 ± 0.009 
LVIDs (cm) 0.29 ± 0.008 0.28 ± 0.013 0.29 ± 0.005 0.27 ± 0.011 0.29 ± 0.007 0.28 ± 0.010* 0.29 ± 0.008 0.28 ± 0.009* 
LVPWd (cm) 0.06 ± 0.002 0.07 ± 0.002* 0.06 ± 0.002 0.07 ± 0.003* 0.06 ± 0.004 0.07 ± 0.003* 0.06 ± 0.002 0.08 ± 0.001* 
LVPWs (cm) 0.09 ± 0.002 0.10 ± 0.004* 0.09 ± 0.003 0.10 ± 0.004* 0.09 ± 0.004 0.10 ± 0.003* 0.09 ± 0.002 0.10 ± 0.003* 
% EF 65.0 ± 0.990 66.6 ± 2.590 67.1 ± 0.856 69.5 ± 1.902 65.6 ± 1.538 68.3 ± 1.608* 64.8 ± 1.536 67.1 ± 1.876* 
% FS 29.6 ± 0.654 31.0 ± 1.617* 31.0 ± 0.611 32.9 ± 1.488* 30.0 ± 1.061 32.1 ± 1.277* 29.5 ± 1.109 31.2 ± 1.292* 
HR (bpm) 506 ± 19.908 518 ± 8.458 518 ± 20.295 554 ± 29.613 521 ± 19.833 531 ± 14.836 515 ± 28.005 544 ± 19.569 





5.3.5. LV hemodynamic functions are preserved in Bec1+/- mice  
and partially improved in Bec1-Tg mice on HFD 
Following 12 weeks of HFF, LV hemodynamic function was measured in WT and 
Beclin1+/- mice by terminal LV-catheterization. The data show that both WT and 
Beclin1+/- mice have similar LV hemodynamic profiles regardless of diet (Table 5.5). 
These results indicate that HFF and Beclin1 heterozygosity have no effect on 
hemodynamic outcomes of the heart following short-term HFF. This is consistent with 
echocardiographic data which indicate that both WT and Beclin1+/- have normal cardiac 
contractile function.  
 LV hemodynamic function was also measured in Bec1-Tg and control mice 
following 12 weeks of NCD or HFD. HFF resulted in mild hypertension as evidenced by 
significant increases in systolic and diastolic arterial pressure and left ventricular systolic 
pressure in HFD mice (Table 5.6). Interestingly, these changes are slightly attenuated in 
Bec1-Tg HFD mice compared to WT-HFD mice.  
   
 
5.3.6. Bec1+/- mice show impaired glucose tolerance but  
maintain insulin sensitivity upon high-fat feeding 
DIO is often accompanied by systemic insulin resistance and impaired glucose 
tolerance. To determine if HFF impaired systemic glucose disposal and insulin 
sensitivity, GTT and ITT were performed on WT and Bec1+/- mice fed with NCD or 
HFD. As shown in Figure 5.4.A, mice on HFD developed significant glucose intolerance 
compared to NCD mice.  However, glucose intolerance was remarkably higher in Bec1+/- 






Table 5.5. Hemodynamic parameters obtained after LV catheterization of WT and Bec1+/- mice fed with NCD or HFD. LVSP, left-
ventricular systolic pressure; LVMP, left-ventricular mean pressure; LVDevP, left-ventricular developed pressure; +dP/dt, peak rate 
left-ventricular pressure increase; -dP/dt, peak rate of left-ventricular pressure decrease; LVEDP, left-ventricular end diastolic 
pressure; Tau weiss, the time constant for left-ventricular isovolumic relaxation. Effect of diet (p<0.005), effect of genotype 
(p<0.05), and $interaction of diet and genotype (p<0.05) (n=4-6).  
 
Group WT Bec1+/- 
Diet NCD HFD NCD HFD 
LVSP (mmHg) 94.70 ± 3.8 109.16 ± 7.148 101.01 ± 2.467 101.65 ± 5.034 
LVMP (mmHg) 0.204 ± 0.9 -0.966 ± 0.369 -0.477± 0.635 -1.028 ± 0.470 
LVDevP (mmHg) 94.49 ± 4.2 110.13 ± 7.271 101.48 ± 2.606 102.68 ± 5.258 
HR (min-1) 417.3 ± 10.1 408.4 ± 31.208 468.5 ± 24.919 468.6 ± 17.598 
+dP/dt  (mm Hg/sec) 6433 ± 647.0 8134 ± 711.93 8000 ± 786.40 7931 ± 566.33 
-dP/dt  (mm Hg/sec) -6769 ± 1012.4 -8048.3 ± 1108.0 -7562 ± 1177.1 -8218 ± 421.0 
LVEDP (mm Hg) 9.745 ± 2.6 8.238 ± 1.627 10.568 ± 1.926 7.924 ± 1.000 








Table 5.6. Hemodynamic parameters obtained after LV catheterization of WT and Bec1-Tg mice fed with NCD or HFD. APsys, 
systolic arterial pressure; APdia, diastolic arterial pressure; LVSP, left-ventricular systolic pressure; LVDevP, left-ventricular 
developed pressure; HR, heart rate; +dP/dt, peak rate left-ventricular pressure increase; -dP/dt, peak rate of left-ventricular pressure 
decrease; LVEDP, left-ventricular end diastolic pressure; Tau weiss, the time constant for left-ventricular isovolumic relaxation. 
Effect of diet (p<0.005), effect of genotype (p<0.05), and $interaction of diet and genotype (p<0.05) (n=5-8).  
 
Genotype WT Bec1-Tg 
Diet NCD HFD NCD HFD 
APsys (mmHg)$ 95.35 ± 2.907 110.28 ± 2.319 98.31 ± 1.157 100.47 ± 2.842 
APdia (mmHg) 64.01 ± 1.843 74.52 ± 1.913 63.66 ± 1.837 68.62 ± 1.221 
LVSP (mmHg)$ 97.96 ± 4.061 111.2 ± 2.691 99.39 ± 1.661 100.53 ± 2.779 
LV Dev P (mmHg) 96.90 ± 5.406 110.18 ± 3.390 100.61 ± 2.083 98.94 ± 3.150 
HR (min-1) 454.2 ± 28.318 478.5 ± 7.991 475.3 ± 17.268 451.1 ± 23.847 
+dP/dt  (mm Hg/sec) 7325 ± 1019 8543 ± 801.8 8914 ± 597.9 7406 ± 542 
-dP/dt  (mm Hg/sec)   -7433 ± 1385.6 -7959 ± 904.2 -8586 ± 977.8 -6240 ± 735.1 
LVEDP (mm Hg) 15.691 ± 4.223 15.398 ± 3.420 9.259 ± 1.797 16.366 ± 1.029 
















Figure 5.4. Glucose and insulin tolerance tests in NCD or HFD fed WT and Bec1+/- mice. 
(A) Glucose tolerance tests (GTTs) performed in WT and Bec1+/- mice following 12 
weeks of NCD or HFD. The graphs represent levels of blood glucose at indicated time 
points following a single ip glucose injection. All mice were fasted for 6 h prior to GTTs. 
Effect of diet (p<0.005), effect of genotype (p<0.05), and $interaction of diet and 
genotype (p<0.05), same time point (n=6-9). (B) Insulin tolerance tests (ITTs) performed 
in WT and Beclin1+/- mice fed ad libitum with NCD or HFD for 12 weeks. The graphs 
represent blood glucose levels at indicated time points following a single ip insulin 








impairment in systemic glucose disposal in HFD animals. Despite impaired glucose 
tolerance, Bec1+/--HFD mice showed normal insulin sensitivity in ITTs (Figure 5.4.B). 
The WT-HFD mice also maintained normal insulin sensitivity. 
 
 
                                              5.4. Discussion 
Altered autophagic activity has been observed under various conditions affecting 
cardiac function such as IR, hypertension, cardiac hypertrophy and heart failure. The 
induction of autophagy could be both beneficial as in ischemia and compensatory cardiac 
hypertrophy and detrimental as in reperfusion and heart failure. Mouse models of altered 
Beclin1expression have been used to modulate autophagy and to define its role in 
response to hemodynamic stress in the heart (Gottlieb and Mentzer, 2012; Zhu et al., 
2007). In this study, we utilized the same genetic models to understand if the increased 
autophagic abundance in the murine heart is an adaptive or maladaptive response to HFF.   
We initially tested whether Beclin1 plays a role in autophagy in presence of a known 
stressor such a starvation to validate the use of Bec1+/- and Bec1-Tg mouse models for 
the regulation of autophagy initiation. As expected, Bec1+/- mice have blunted response to 
starvation-induced autophagy. Intriguingly, we did not observe induction of autophagy in 
Bec1-Tg mice in both fed and fasted states. Of note, Beclin1 expression was similar in 
Bec1+/- mice and WT mice but significantly upregulated in Bec1-Tg mice in both fed and 
fasted states. 
Modulation of autophagic response by altering gene expression is a means to 
understand the mechanism and function of autophagy. In this study, utilizing mouse 
models of differential Beclin1 expression, we sought to understand the role of increased 
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autophagic abundance in response to HFF. HFD significantly elevated autophagosomal 
abundance in WT murine hearts. However, autophagy was not suppressed in HFD-fed 
Bec1+/- mice. Moreover, overexpression of Beclin1 did not augment HFD-induced 
autophagosomal abundance in Bec1-Tg hearts. These data suggest that Beclin1-
dependent autophagic regulation plays no major role in HFD-induced autophagy.  
Examination of cardiac function in the heart revealed that 12 weeks of HFD induced 
mild cardiac hypertrophy with increased LV wall thickness but preserved contractile 
function. The HFD induced changes in cardiac hypertrophy are not corrected by 
heterozygous deletion of Beclin1 or by CM-specific Beclin1 overexpression. Moreover, 
we observed minor changes in LV systolic and diastolic functions in HFD animals, which 
are unaffected by Beclin1 knockdown. Although, Bec1-Tg mice exhibit slightly better 
hemodynamic function (higher %EF and %FS) than WT mice on HFD, it is difficult to 
interpret it as an improvement since WT HFD mice did not have impaired hemodynamic 
function. It seems reasonable from these observations to assume that the HFF protocol 
used in this study did not present sufficient or appropriate stress to invoke marked 
changes in cardiac and hemodynamic functions. Previous studies showed that Beclin1 
plays a role in autophagy only in presence of severe stress but not under basal conditions 
(He et al., 2012; Zhu et al., 2007). Our HFD regimen might not reach the threshold of 
stress necessary to induce Beclin1 signaling. Thus alterations in Beclin1 gene expression 
in either direction had no obvious impact on contractile and hemodynamic function of the 
heart in our model of DIO. However, it is important to note that Bec1+/- and Bec1-Tg 
mice used in this study have previously been shown to regulate autophagy in heart failure 
induced by sTAB as well as in response to 48-h fasting (Zhu et al., 2007).  
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Although alteration of Beclin1 expression showed no impairment in cardiac function, 
at the systemic level heterozygous Beclin1 worsens glucose intolerance induced by HFF. 
However, Bec1+/- mice fed with NCD showed normal glucose tolerance. This is 
consistent with a previous study showing that Beclin1 signaling is required to maintain 
normal glucose tolerance  only when presented with a stress such as exercise and HFF 
but not under basal conditions (He et al., 2012).  Since Beclin1+/- mice used in our study 
are heterozygous for the whole body, it is likely that HFD induced glucose intolerance is 
worsened in these mice due to lack of adequate Beclin1 signaling in tissues maintaining 
blood glucose such as liver, skeletal muscles and pancreatic beta cells. Since ITT profiles 
of both WT and Bec1+/- mice were normal on NCD or HFD, glucose intolerance in 
Bec1+/- HFD mice implies a defect pancreatic β cells in these mice upon HFF.   
In summary, this study demonstrates that HFD-induced autophagy may be 
independent of autophagic initiation and particularly Beclin1 expression or activity. The 
differential effect of Beclin1 on autophagy induced by starvation versus HFD suggests 
that the regulation of autophagy by Beclin1 may depend on factors other than its protein 
level alone. In fact, recent studies showed that Beclin1 activity is regulated by PTMs such 
as phosphorylation and K-63 linked ubiquitination (Kang et al., 2011). It might be 
possible that Beclin1 undergoes different degrees or types of PTMs in response to 
starvation compared to HFF. Further study is required to define which aspects of these 


























6.1. Restoration of autophagic turnover  
Obesity is a complex metabolic condition that adversely affects proper sensing and 
utilization of nutrients at cellular and organismic levels. Derangement of the metabolic 
and energetic homeostatic apparatus leads to the emergence of insulin resistance, 
lipotoxicity and other metabolic disturbances in obese and diabetic hearts (Boudina and 
Abel, 2007). Autophagy has emerged as a prosurvival pathway protecting the heart 
against various metabolic and mechanical stressors (Nishida et al., 2009). Conceivably, 
deregulation of autophagic activity is associated with several cardiac pathologies 
including I/R, MI, hypertension, and heart failure (Chiong et al., 2011). Relevant to 
obesity and diabetes, an animal model of DIO has shown  impaired autophagic turnover 
in the heart (Xu et al., 2012). However, whether defective turnover was due to impaired 
autolysosome formation or impaired lysosomal enzyme activity was unclear. In this 
study, we showed that HFF increased autophagic abundance in the murine heart, and, 
using an in vitro model of lipid overload, provided evidence for a pH-dependent 
impairment in lysosomal enzyme activity as a primary mechanism of defective 
autophagic turnover leading to increased autophagosome abundance.  
ROS mediated oxidative stress plays a central role in several metabolic diseases such 
as CVD, atherosclerosis, and diabetes. However, antioxidant therapy to treat such 
diseases has produced limited success, which warrants the need for targeting pathways 
that have evolved to eliminate the sources of ROS and limit ROS-induced cellular 
damage. Strong evidence suggests the role of autophagy in mitigating ROS-induced 
oxidative injury and improving cell survival. Conversely, impaired autophagic activity 
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sensitizes cells to oxidative injury (Dutta et al., 2013; Kiffin et al., 2006; Lee et al., 
2012).          
Mitochondrial ROS has long been known as a primary contributor of oxidative 
stress. However, in a more clinically relevant model of DIO and diabetes, membrane 
bound Noxs seemed to be an important determinant of oxidative stress (Feillet-Coudray 
et al., 2009; Jiang et al., 2011; Roberts et al., 2006; Wong et al., 2011). In the heart, Nox-
derived ROS has been implicated in I/R injury, MI, cardiac hypertrophy and heart failure 
(Bedard and Krause, 2007). Here, we have identified a novel role for Nox2-derived 
superoxide anion in the impairment of lysosomal enzyme activity that blunted  
autophagosome turnover. The Nox2 activation was directly regulated by classical PKCs 
in response to lipid overload. Nox2 has previously been shown to regulate autophagy in 
phagocytes and endothelial cells (Buroker et al., 2012; Teng et al., 2012). Several studies 
showed that Nox2 is directly activated by various PKCs (Raad et al., 2009; Serpillon et 
al., 2009). However, the role of the PKC-Nox2 pathway in the regulation of autophagy is 
unknown. Despite the activation of this pathway in experimental models of obesity and 
diabetes, little is known about its role in the important homeostatic process of autophagy.  
For strategies focusing on the “reactivation of autophagy as a therapeutic solution to 
obesity and metabolic syndrome” (Sciarretta et al., 2012a), our study provides a 
promising target. Given the role of Nox-derived ROS in multiple cardiac pathologies, it is 
not unreasonable to assume that Nox-induced inhibition of autophagic turnover may 
contribute to the pathogenesis of these diseases. Therefore, pharmacological inhibition of 
Nox carries the prospect of not only restoring the normal autophagic turnover but also 
having beneficial effect on pathologies associated with Nox activation. In fact, the 
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interest for the identification and development of small molecule Nox inhibitors has 
greatly increased in the past decade (Jaquet et al., 2009). However, the generation of a 
Nox inhibitor may be particularly challenging for its specificity. There are multiple 
isoforms of Nox which are highly tissue-specific and which possess different tissue-
specific physiological functions (Streeter et al., 2013). A specific inhibitor should act on 
only its intended target without affecting other isoform-specific functions.  At present 
relatively few Nox-inhibitors have been successfully used in experimental models, and 
the next challenge is to translate this success into developing a drug-like, specific Nox 
inhibitor for in vivo and clinical uses.     
 
 
                                           6.2 Future directions 
The major finding of the present study is that the impairments in lysosomal 
acidification and pH-dependent lysosomal enzyme activity led to increased 
autophagosome accumulation in H9C2 CMs in response to palmitate. The impaired 
autophagic turnover was also observed in high-fat fed mouse hearts, suggesting it to be a 
common phenomenon in response to lipid overload. We identified PKC-induced Nox2 
activation the key mechanism mediating the effect of lipid overload on lysosomal 
acidification and enzyme activity. Together with a previously reported role in oxidative 
stress and its implication in various cardiac pathologies, the findings of the present study 
suggest that Nox2 may play a key role in the activation of multiple pathophysiological 
pathways by impairing normal autophagic flux in CMs and possibly in other tissues.    
   The present study raises several questions that require further investigation. First, 
we explored the role of Nox2 in lipid-induced autophagy. However, Nox4 is another Nox 
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isoform highly expressed in the heart. It has been shown to mediate oxidative stress in 
multiple cardiac pathologies (Kuroda et al., 2010; Matsushima et al., 2013). A recent 
report has implicated Nox4 in starvation-induced autophagy in CMs (Sciarretta et al., 
2012c). Whether Nox4 also plays a role in lipid-induced autophagic regulation needs 
further study.  
Second, we showed that palmitate-induced activation of Nox2 was mediated by 
classical PKCs. However, how palmitate activates PKC was not explored in our study. 
This is particularly important since coincubation with oleate normalized palmitate-
induced autophagic abundance. Recent studies have shown that palmitate but not oleate 
impairs mitochondrial function, induces apoptosis, and activates pathways generating 
toxic lipid intermediates which collectively contribute to insulin resistance (Hu et al., 
2011; Yuzefovych et al., 2010). Long-chain acyl-CoA, ceramide, and diacylglycerol have 
constantly been cited as major toxic lipid intermediates linked to lipotoxic 
cardiomyopathy (Wende and Abel, 2010). In our study, ceramide did not seem to play a 
role in palmitate-induced autophagy. Instead, a recent study has found increased DAG 
accumulation in parallel with increased autophagic induction in palmitate-treated 
hepatocytes (Tan et al., 2012). Given the role of DAG in PKC activation and our own 
observation of the PKC-dependent effect of palmiate on autophagy, it is likely that 
palmitate treatment resulted in DAG accumulation in H9C2 CMs which leads to PKC 
activation. Additional experiments are required to test this hypothesis and to examine if 
oleate prevents palmitate-induced accumulation of DAG and of autophagosomes.  
Third, most of our experiments exploring the mechanism of lipid overload-induced 
autophagy were performed in vitro in cell culture. Therefore, to validate the 
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pathophysiological relevance of this mechanism, additional experiments need to be 
performed in our animal model of DIO.  It is important to realize that observations made 
with acute palmitate-treatment may not be the representative of the effect of relatively 
long HFD feeding.  
Fourth and most important, our in vivo data did not show any deleterious effect of 
reduced autophagosome turnover in HFD mice on cardiac function at baseline or in 
response to TAC. It is be possible that our HFD regimen and TAC-induced pressure 
overload do not present sufficient stress to induce cardiac dysfunction. Future 
experiments should focus on introducing sufficient, appropriate, and relevant stress to 
invoke cardiac dysfunction in mouse model of DIO. One such stress could be subjecting 
HFD mice to ischemia and reperfusion. In fact, studies suggest that HFD increases 
susceptibility to I/R injury but the role of autophagy in this process is not well understood 
(Liu and Lloyd, 2013; Mozaffari and Schaffer, 2008). Prolonging the duration of HFF or 
increasing the fat content in the diet have been used previously to study effect of obesity 
in animal models of DIO (Bagnol et al., 2012; Buettner et al., 2007). Once a cardiac 
dysfunction phenotype is established in DIO model, additional experiments are required 
to determine the role impaired autophagosome turnover in cardiac dysfunction. The 
presence of an appropriate stress may also allow us to re-evaluate the effect of altering 
autophagic initiation on HFD-induced autophagy and on cardiac function using Bec1+/- 
and Becl-Tg mouse models described in Chapter 5.             
Finally, we have not assessed Nox2 expression and activity in the hearts of DIO 
mice. A cardiac-specific Nox2 knockout mouse would be an ideal model in which to test 
the relevancy of the enzyme in the regulation of autophagic turnover in DIO and diabetes. 
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With the availability of global Nox2 knockout mice (Pollock et al., 1995), it is now 
possible to examine the role of Nox2 in cardiac autophagic turnover in animal models of 
obesity with cardiac dysfunction.  
 
 
                                           6.3. Final conclusions 
Our studies have identified a novel role for PKC-Nox signaling pathway in linking 
lipid overload to impairment in autophagic turnover. To our knowledge, this is the first 
report demonstrating that Nox2-borne superoxide anion directly impairs lysosomal 
acidification and consequently lysosomal enzyme activity leading to the accumulation of 
autophagic substrates. Together with its role as an important mediator of oxidative stress, 
our current findings suggest that Nox2 may exert its pathological effect in part by 
inhibiting normal autophagic flux. Our study provides a platform for future research in 
which to test the role of Nox2 in autophagic regulation in animal models of obesity and 
associated pathologies and to examine if restoring autophagic flux by targeted inhibition 
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